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Pharmaceutical care involves identifying, solving and preventing drug-related 
problems (DRPs), such as drug-drug interactions (DDIs) or adverse drug reactions 
(ADRs), so as to help patients make the best use of their medications. Patients 
undergoing cancer chemotherapy are at risk for DDIs and ADRs such as chemotherapy-
induced nausea and vomiting (CINV). Pharmacoinformatics can be used to improve 
pharmaceutical care; however, little has been done to leverage on its technologies in 
oncology practice. This project aims to address the research question of whether the 
pharmaceutical care of patients with cancer can be enhanced through the application of 
pharmacoinformatics in oncology practice.  
The main thrust of this project revolved around the creation and development of 
an oncology-specific database to detect DDIs of anticancer drugs (ACDs) and 
chemotherapy regimens (CRegs). The opinions of oncology practitioners regarding 
whether the availability of an oncology-specific DDI database would be useful, and the 
quality of online ACD interaction information, were assessed in 2 other studies. The 
feedback from these 2 studies formed the basis for the creation of OncoRx – a web-based 
search engine for DDIs – where drug-, regimen- and interaction-related data were 
compiled from hardcopy and softcopy resources, and published literature. Its structure 
was designed around 117 ACDs and 256 CRegs, and it focused on pharmacokinetic and 
pharmacodynamic interactions. It can detect DDIs with 51 psychotropic agents and 166 
complementary and alternative medicines, and users can select from 15 categories of 
CRegs. OncoRx hosts web documents that are uploaded onto a third-party domain and 
server-side scripting is used to handle DDI search enquiries. User feedback on the quality 
Summary 
xi 
and utility of OncoRx was sought. This feedback was generally positive, with accuracy of 
DDI content and clinical usefulness being highly regarded by the users.  
In addition, principal component analysis (PCA) was employed to explore the 
identification of the clinical predictors of CINV in a prospective, observational study 
involving patients receiving emetogenic cancer chemotherapies. CINV events were 
identified from patient diaries, while demographics and risk factors were collected 
through patient interviews. Five risk factors (histories of alcohol drinking, chemotherapy-
induced nausea, chemotherapy-induced vomiting, fatigue, gender) and 7 anxiety 
symptoms (fear of dying, fear of the worst, unable to relax, hot/cold sweats, nervousness, 
faintness, numbness) were identified as potential predictors that could be useful to 
practitioners who provide oncology supportive care.  
This project has demonstrated how the upcoming field of pharmacoinformatics 
can be used to target 2 specific DRPs in oncology. OncoRx is the first database of its kind 
that is catered towards ACD and CReg interactions, and it demonstrates the usefulness of 
using a pharmacoinformatics platform to target DDIs in patients with cancer. The 
utilisation of PCA to identify clinical CINV predictors in patients receiving emetogenic 
chemotherapies also demonstrates the usefulness of pharmacoinformatics tools in 
oncology practice. The application of pharmacoinformatics can definitely enhance the 
pharmaceutical care of patients with cancer, through the reduction of DRPs, such as DDIs 
and ADRs.  
 
Keywords: Chemotherapy-induced nausea and vomiting, drug interaction database, 
pharmaceutical care, pharmacoinformatics, principal component analysis 
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The practice of pharmaceutical care forms the cornerstone of any health 
science discipline which concerns itself with the rational use of drugs. Its concept 
combines a careful blend of caring orientation with specialised therapeutic 
knowledge, experiences and judgements, so as to ensure optimal medication-related 
outcomes.
1,2
 These outcomes include prevention or cure of diseases, elimination or 
reduction of symptoms, and slowing or arresting disease processes.
2
 Healthcare 
professionals, particularly clinical pharmacists, apply their knowledge and 
understanding of evidence-based therapeutic guidelines, evolving sciences and 
relevant ethical, social and economic principles so as to provide optimal medication 
therapy management in direct patient care settings. Clinical researchers, on the other 
hand, aim to contribute to new knowledge which improves the patient‟s health and 
quality of life (QOL).
1
 
Pharmaceutical care is essential in helping patients make the best use of their 
medications, and is applicable and achievable in any practice setting.
2
 It involves 
identifying, solving and preventing potential or actual drug-related problems (DRPs) 
with regards to a patient‟s drug therapy.2,3 There are a number of definitions to DRPs, 
but in essence, they can be easily understood as events or circumstances involving 
drug therapies that can actually or potentially interfere with the desired health 
outcome for patients.
2,4
  The Pharmaceutical Care Network Europe (PCNE) 
Foundation classifies DRPs in terms of problems and causes (Table 1.1),
5
 and these 
include adverse reactions (classification P1), dosing problems (P3), or potential drug-
drug, drug-food or drug-herb interactions (P5). A lack of knowledge or 
misinterpretation of information about the drug and its use (C2 and C3) can contribute 
 Chapter 1 
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to such DRPs, leading to patient non-compliance, and the patients‟ safety and quality 
of life can be significantly compromised if they are not treated effectively and 
appropriately. 
 
Table 1.1. Classification of drug-related problems (DRPs). Adapted with 








Meaning of classification 
Classification by Problems 
P1 Adverse reaction(s) Patient suffers from an adverse drug event. 
P2 Drug choice problem 
Patient gets or is going to get a wrong or no 
drug for his/her disease and/or condition.  
P3 Dosing problem 
Patient gets more or less than the amount of 
drug he/she requires. 
P4 Drug use problem Wrong or no drug taken/administered. 
P5 Interactions 
There is a manifest or potential drug-drug or 
drug-food interaction. 
P6 Other Other types of DRPs.  
Classification by Causes 
C1 Drug/dose selection 
Cause of DRP related to selection of drug 
and/or dosage schedule. 
C2 Drug use process 
Cause of DRP related to the way patient 
uses the drug, in spite of proper dosage 
instructions (on the label). 
C3 Information 
Cause of DRP related to an absence or 
misinterpretation of information. 
C4 Patient (psychological) 
Cause of DRP related to personality or 
behaviour of patient. 
C5 Logistics (pharmacy) 
Cause of DRP related to the logistics of the 
prescribing or dispensing mechanism. 
C6 Other Other causes of DRPs. 
 
Currently, in the provision of pharmaceutical care, healthcare professionals 
work in tandem to make judgements on medication use and evaluate the patients‟ 
potential or actual DRPs based on their perspective and knowledge of medication 
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therapy. This requires access to clinical information of individual patients. Certain 
therapeutic decisions, such as dosing adjustments, are made based on experience and 
through trials and errors. This is not only subjective but a very time consuming 
process as well. As an accountable member of the healthcare team, the clinician must 
ensure that his professional actions are in the best interests of the patient, and he is 
responsible for the patient‟s outcomes that result from his actions and decisions. It is 
therefore an essential requirement for the clinician to make accurate, timely, safe and 
effective decisions with regards to drug use in a patient. 
 
1.1. The roles of e-Health and the internet for health-related information 
Generally, the application of information technology (IT) in healthcare has 
been slow. When a patient visits the doctor, his medical and health information are 
stored in many different forms such as electrocardiographs, radiographs, discharge 
summaries, operative reports, laboratory results and prescription records. This 
information can be likened to multiple separate “trees” of patient data which can be 
potentially useful for patient profiling.
6
 Over the years, as the patient visits multiple 
doctors and institutions, these “trees” become a diverse “forest” (Figure 1.1). With a 
global trend towards an increasing elderly population, this forest is expected to grow 
denser with time. There is a need to combine this diverse array of data so as to 
improve on the quality of healthcare services for patients. 
 




Figure 1.1. Diagram showing separate “trees” of patient data becoming a diverse 
“forest” of health information with time, which can be combined into one “canopy” 
through the internet. 
 
The niche role of IT has increasingly gained acceptance among practising 
healthcare professionals since the beginning of the 21
st
 century, defining a concept 
known as “e-Health”. This term encompasses a broad meaning, and can refer to the 
combined use of any electronic information and communication technology in the 
healthcare sector for clinical, educational, research or administrative purposes.
7
 In 
essence, e-Health can be used in any situation which involves the electronic exchange 
of health-related data for the purpose of increasing the effectiveness of health care 
delivery. The main aims of e-Health are to provide an improvement in the quality of 
patient care, increase the healthcare practitioner‟s commitment to evidence-based 
medicine, as well as empower patients and consumers with the knowledge of their 




The internet is rapidly gaining importance not just for healthcare 
professionals, but for patients as well. The emergence of the World Wide Web 
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(WWW) is one of the most significant developments in the history of the internet,
8
 
and has affected the way in which health-related information is distributed and 
accessed over cyberspace. Nowadays, healthcare professionals can access information 
on the internet to help them make decisions regarding patient care. On the other hand, 
many people also frequent the internet to search for drug-related and other health-
related information. As such, patients are becoming more well-informed about health-
related issues through the information which they can get over the internet. In 2006, 
the Pew Internet and American Life Project 
9
 reported that about 80% of internet users 
in the United Sates (US) (more than 113 million people) have searched for health-
related information online. Factors contributing to this growth include an increased 
health literacy of the population and perceived importance of the internet as a health 
information resource, especially for chronic diseases such as cancer.
10
 Convergence of 
information platforms has also led to the use of internet-enabled mobile phones, 
creating a greater opportunity for web access. In January 2008, approximately 12.6% 
of China‟s mobile phone users (50.4 million people) were reported to have used their 
phones to access the WWW.
11
 Newer handheld technologies, an increasing support 
for hypertext and multimedia applications, and various inexpensive browsers, such as 
Internet Explorer, Mozilla Firefox, Safari, Opera, Netscape, and Google Chrome, 
have enabled health-related and drug-related information to reach the public in a more 
convenient and hassle-free manner.  
Although the advancement of technology has provided a great improvement in 
the safety, quality and efficacy aspects of healthcare, implementation of these systems 
have been slow in clinical practice. Healthcare professionals need tools that can 
combine various sources of clinical information into one “canopy” so that they can 
access the information as and when they need. The internet or the WWW provides 
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tools for this purpose (Figure 1.1). With a web browser and an internet connection, 
healthcare professionals can virtually access all kinds of information anywhere in the 
world, as long as they have the access rights. 
 
1.1.1. The evolving roles of informatics and the internet for cancer care 
In the early 20
th
 century, interactive technologies in healthcare mostly 
involved the use of audio and video programmes in the public health education of 
chronic diseases, such as cancer. In fact, some cancers were more “favourably” 
portrayed in films during the 1930s to 1970s, since they were more photogenic and 
less offensive.
12
 Organizations, such as the American Cancer Society, realized the 
impact of interactive media technologies on public health education, and thus began 
releasing several cancer-education films to the general public in the 1920s.
13
 The 
usefulness of digital media in improving the knowledge and awareness of prostate-




Since then, the ubiquitous nature of the internet and the WWW has allowed 
for easy dissemination of health-related information, not only to healthcare 
professionals, but to patients too. The first version of the WWW, known as Web 1.0, 
replaced hardcopy information from books, CD roms, and disks, with online versions, 
the so-called electronic books. This online information gained popularity because it 
provided a faster and easier solution for information searches.
15
 Web 1.0 was rapidly 
replaced by Web 2.0 due to the latter‟s ability to allow creation and compilation of 
content, as well as sharing and discussion between many users. The main aim of Web 
2.0 is to allow users to interact with online information and knowledge repositories, of 
which popular examples include blogs, wikis and podcasts.
16
 The next generation of 
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the web, also known as Web 3.0 or the semantic web, is an upcoming web that will 
provide better ways for the retrieval and cognitive processing of information.
17
 
Labelled as “the next big thing”, the feature that distinguishes Web 3.0 from its 
predecessors is its use of metadata – that is, data about data.17  
The proliferation of online health information has encouraged patients to be 
more well-informed. Freely accessible evidence-based information on cancer and its 
treatment strategies empowers patients with the appropriate knowledge to better 
participate in the management of their own conditions. Therefore, drug information 
that is not only easily accessible, but also complete and factually correct, is essential 
for the provision of optimal pharmaceutical care. Several studies that assessed online 
drug information databases,
18,19
 personal digital assistant (PDA) databases,
20,21
 and 
even the popular Wikipedia resource,
22
 have shown differences in terms of the scope, 
completeness and accuracy of these resources. The challenge for both healthcare 
professionals and patients is to critically assess the vast amounts of available 
information, and healthcare professionals should use the results of evidence-based 
studies, such as those mentioned above, in a way that is suitable to their specific 
practices and needs, so that they can provide the best care for their patients‟ well-
being. 
 
1.2. Pharmacoinformatics as a bridging aid to enhance the pharmaceutical care 
of patients with cancer 
Medical informatics is a basic biomedical science that spans a wide variety of 
application areas, and hence is interdisciplinary.
23
 It studies and applies theories, 
methods and techniques to solve pertinent fundamental problems in clinical 
research.
24
 Its applications involve improvements in the management of any 
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information relevant to patient care and community health, such as patient and 
population data, and clinical knowledge.
25
 Contrary to the impression of the common 
layman who mistakes this term for the provision of computer and technical network 
support to the medicine domain, medical informatics focuses on the management of 
information with its core in patient care, rather than the technology used for this 
purpose.
23
 Inherently, medical informatics is defined as having 2 main objectives: to 
search for new knowledge and to utilise this knowledge to improve practice in the 
healthcare setting (i.e. application research).
23
 Its ultimate goal is to improve health 
itself, which when broadly described, encompasses many factors such as genetics, 
social, economic and environmental issues, as well as the cognitive, emotional and 
behavioural domains.
23
 In this aspect, no profession can address all these factors 
thoroughly, even though they all contribute to health improvement to some degree.
23
  
 Medical informatics draws on both the informatics arena and health services 
arena to develop studies and instruments to solve clinical issues in the practical 
setting.
24
 Pharmacoinformatics is an application science which is a branch under the 
broad field of medical informatics. Other branches include public and consumer 
health informatics, imaging informatics and bioinformatics, among others, which refer 
to their respective applied domains.
23-25
 The pharmacoinformatics discipline intersects 
the practice of pharmacy with technology and information science,
26
 and is focused 
on the acquisition, dissemination, storage, analysis and use of medication-related 
knowledge and data within the continuum of healthcare systems.
27
 This discipline 
includes all healthcare systems and pharmacy technologies related to medications and 
clinical decision support, such as bar-coding, smart pump delivery systems, robotic 
tools for the preparation and dispensing of medicines, and e-prescribing applications. 
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Pharmacoinformatics is, therefore, an appropriate discipline for improving 
pharmaceutical care through the reduction of DRPs in the clinical setting.  
In recent years, translational research has been an area of discussion within the 
scientific community. Although this field of inquiry is more commonly understood as 
the application of science that “translates” discoveries from the laboratory bench to 
the patient‟s bedside or from mouse to man,28 an important view that is missing in the 
concept of translational research is the bidirectional interplay between laboratory 
research and clinical practice.
29
 Visualising this idea as a two-way traffic on a bridge, 
newer agents (such as newly developed drugs) flow from academic and industrial 
laboratories to the clinics for disease prevention and therapy, while patient-oriented 
research in the clinical setting provides ideas and biological data for the laboratory to 
search for newer targets for drug discovery and development.
30
 With regards to 
oncology, the Translational Research Working Group at the National Cancer Institute 
(NCI) relates translational research to scientific discoveries from laboratory, clinical 
or population studies which lead to clinical applications that can reduce cancer 
incidence, morbidity and mortality.
31
 However, there is a further need to link basic 
biomolecular research to the clinical sciences with more effective informatics and 
protocol management. Various individuals and organisations have taken great courage 
to step onto this bridge. They include cancer biologists, clinician-scientists based in 
the laboratory, and clinician-investigators who base themselves in the clinics.
30
 The 
integration of healthcare with pharmacoinformatics has enabled computational tools 
to play an important role in the management of clinical knowledge and information, 
particularly in the field of oncology, but there is a need for a new generation of 
clinician-scientists who are willing to embrace the computer and informatics 
revolutions to make these protocols become a reality. The computing power in the 
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year 2030 is postulated to be powerful enough to enable each individual to have his 
own computer chip describing his genetic makeup, probability of developing a disease 
and the most appropriate therapy that will work for him.
30
 The focus for healthcare 
professionals is thus to be able to produce new knowledge in medicine and locate 
trusted clinical information efficiently to cater towards patients‟ needs. This is 
definitely an area which requires the expertise of the various health professions, 
including clinicians, nurses and pharmacists. 
 
1.3. Pharmacoinformatics for oncology healthcare professionals and patients 
with cancer 
Pharmacoinformatics has changed the way in which healthcare is practised. 
The advancement of IT in recent years has led to the development of various 
software, tools, and internet applications that can be used as aids by healthcare 
professionals in the oncology sector for delivering optimum pharmaceutical care and 
health-related outcomes. Furthermore, patients with cancer are often overwhelmed by 
concerns regarding their treatment options or the disease itself. Patients on new 
medications want to know more about their drug therapies, whereas those on chronic 
medications want reassurance about the effectiveness and the need for the 
medications.
32
 It is therefore important that both healthcare professionals and patients 
are able to locate detailed and appropriate information regarding drug therapies and 
the consequences of non-adherence to treatment plans. The following sub-sections 
provide a non-exhaustive review of all the available informatics technologies for 
healthcare professionals and patients. A summary list of online resources is also 
provided in Appendix 1. The aim of this section is to highlight the different 
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pharmacoinformatics channels that have been used in the provision of pharmaceutical 
care, and which are relevant to both oncology practitioners and patients with cancer.  
 
1.3.1. Health information technology systems 
 Many applications of pharmacoinformatics currently exist within the 
healthcare sector. These applications have important roles in helping to reduce DRPs 
in the oncology setting. Support systems for clinical decisions, e-prescribing and 
drug-order entry have shown benefits in reducing medication errors 
33,34
 and in the 
prevention and management of chronic diseases.
35,36
 For example, bar-coded inpatient 
drug orders can minimise the probability of medication and dispensing errors,
37
 while 
electronic medical records (EMRs) can decrease the risk of DRPs, such as errors of 
omission, which can result in failure to provide the required medications to the 
patient.
38
 Hospital e-prescribing systems also remind clinicians about potential drug-
drug interactions (DDIs) or a patient‟s drug allergies through pop-up windows.39 
These systems are particularly useful in the oncology setting, since many drugs and 
complicated dosage regimens are involved in chemotherapy treatments. Interestingly, 
in a study aimed at establishing the rates and types of medication errors in outpatients 
with cancer, a site which had a complete EMR and computerised order-entry system 




To maximise the use of these new technologies, oncology practitioners should 
understand the importance of the designs and operations of IT systems that can affect 
their daily work flow. Practitioners who design, manage, and work within these 
systems might find it useful to be adequately trained in both pharmacotherapeutics 
and systems theory, even though these are different disciplines.
41
 The recently passed 
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American Recovery and Reinvestment Act of 2009, signed by President Barack 
Obama, shows the support of the US federal government in broadening the effect of 
health IT in its healthcare delivery system, by providing over US$19 billion for health 
IT systems as part of the economic stimulus package.
42
 Grants will also be provided 
to ensure that providers and healthcare professionals are appropriately trained in 
informatics and health IT systems.
42
 In this regard, medical and allied health 
education should include courses in health IT and medication systems as essential 
components in their curricula.
41
 For practitioners, distance-learning and internet-based 
webinars offered by various organisations, such as the Healthcare Information and 
Management Systems Society (www.himss.org), allow them to learn about health IT 
at their own pace. Furthermore, professional certification exams are also available for 
oncology health practitioners who are interested in attaining a “Certified Professional” 
status.
43,44
 These certification programmes can be broadly divided into certified 
professionals for healthcare information and management systems (CPHIMS), 
electronic health records (CPEHR), health information technology (CPHIT) and 
health information exchange systems (CPHIE), and they cater towards subsets of 
individuals who are stakeholders or practice administrators of health IT systems 
within their organisations. This wide range of programmes allow current practitioners 
to gain better insights in adopting and familiarising themselves with electronic 
medical-management systems, so as to provide better pharmaceutical care for their 
patients.  
Despite the potential benefits of health IT systems, resistance to these 
technologies still exists, possibly as a result of the inconsistency and inconclusiveness 
of the available studies, which might not have focused on the overall effect of these 
systems.
45
 Some of these issues include high costs, an absence of uniform standards 
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between institutions, software problems leading to a reduced productivity of 
clinicians‟ time, and security issues with the confidentiality of patient records.45-48 
Nevertheless, with the rapid development of informatics and IT, the potential of such 
health information systems are indeed attractive in the pharmaceutical care of patients 
with cancer.  
 
1.3.2. Oncology information warehouses 
Many websites provide their readers, mainly healthcare practitioners, with 
drug-related information, and information on clinical practice guidelines, practice-
related issues, and management and treatment updates (Appendix 1). The Clinical 
Care Options (CCO) Oncology 
49
 and American Society of Clinical Oncology 
(ASCO) 
50
 websites have also made use of interactive tools, such as webcasts and 
podcasts, to provide oncology healthcare teams with the latest presentations, news and 
commentary updates in cancer management. Additionally, some sites provide 
programmes that estimate the risks of negative outcomes, such as death and relapse on 
the basis of patient and tumour-related data.
51
 Online resources that provide e-
monographs and compendia, compiled by various organisations, have provided in-
depth anticancer drug (ACD) information to oncology practitioners.
52-58
 Many of the 
drug information resources that are traditionally available in print, such as the 
American Hospital Formulary Service Drug Information, British National Formulary 
and Lexi-comp‟s Drug Information Handbook, have also developed their own 
electronic versions as well.
54,59,60
  
Nowadays, technology has further advanced and encouraged the use of PDAs 





 Facts and Comparisons eAnswers,
58
 




 and Micromedex 
55
) offer downloadable PDA versions for 
convenient use. Although these technological tools have positively affected many 
aspects of patient care, such as medication prescribing and disease-state management, 
users need to be aware of the limitations regarding the information obtained from 
these sources. PDA versions of drug information databases tend to be less 
comprehensive in terms of scope and completeness than their online counterparts.
20,21
 
Furthermore, information provided by online databases can also be prone to errors, 
some of which can potentially affect patient safety and treatment efficacy.
19
 
The proficiency of search engines, such as Google, Yahoo and Bing, for mass 
compiling of similar content-related data has gained increasing popularity with 
internet users. Recently, a dedicated search engine, whose content is filtered by a 
physician editorial board and medical editors, has been developed for oncologists and 
haematologists by SearchMedica.com (http://www.searchmedica.com/?c=on). 
Although its search results are not as broad as those from mainstream engines, its 
content includes relevant clinical information from peer-reviewed research and 
evidence-based articles for oncology practitioners.
61
 
All these electronic warehouses of oncology information, which are rich in 
drug-related and cancer-related information, enable oncologists and other allied health 
professionals to keep abreast of the latest developments in the field and the most up-
to-date practices, so as to enhance their therapeutic management strategies. This 
information will lead to improvements in the pharmaceutical care of patients with 
cancer through the reduction of DRPs.  
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1.3.3. Cancer-related information on the World Wide Web for patients with 
cancer 
Many internet websites and databases are currently available for patients with 
cancer and their families and caregivers (Appendix 1). An example is the US NCI 
website,
62
 which provides information on cancer research, education, and patient care 
for both healthcare professionals and the general public. In addition to incorporating 
information on the different cancer types, treatments and management options, the 
website also provides a dictionary of cancer-related terms for the layman to refer to, 
as well as stories and experiences shared by cancer survivors. By making cancer-
related information easy to understand, the public can learn more about the condition, 
available treatment strategies, and how to manage or cope with the situation, thereby 




The OncoLife and OncoPilot sections of the OncoLink drug information 
website is another pharmacoinformatics application that is catered towards patients 
with cancer.
66
 This website helps patients with cancer learn more about their disease 
and record their management plans, so that they can discuss these plans with their 
healthcare providers. This situation promotes a closer relationship between patients 
and practitioners, by allowing patients greater participation in their own cancer 
management. For patients who are interested in oncology-related research, the 
American Association for Cancer Research website provides opportunities for 
collaborations with other research organisations, the public and the media industry.
67
 
Their magazine “Collaborations  Results” is targeted at cancer survivors and their 
families, other patient advocates and scientists in cancer-related fields.  
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Good patient-practitioner communication is also essential for the provision of 
pharmaceutical care. Oncology practitioners need to know that patients with cancer 
have profound existential suffering, and should therefore provide empathy and 
support so that patients can find healing within themselves.
68
 A more patient-centred 
treatment approach can lead to improved communication, patients‟ level of 
satisfaction with care, their compliance with treatment, and ultimately a better patient-
practitioner relationship and better pharmaceutical care.
69
 However, patients are often 
in need of something more, perhaps a form of social support, to complement their 
relationship with their primary healthcare team. The social network provides a good 
avenue for this purpose, with various virtual communities and online social support 
(e.g. email groups, discussion forums, chat rooms, newsgroups and blogs) being 
formed in recent years to address this need.
70
 Patients with cancer not only share a 
large amount of information via these portals, but also find forms of peer support that 
might not otherwise be available to them through conventional healthcare systems.
71
  
These forms of online social support enable patients to communicate and share 
their experiences of their illness in an intimate, emotional and personal manner,
72,73
 
which can be important for patients who suffer from certain cancers that carry specific 
cultural connotations, such as losing a breast.
74
 These patients not only share their 
physical pain, but also their cultural experiences attached to their womanhood. 
OncoChat is an online chat room specifically developed to offer such online peer 
support for cancer survivors, families and friends.
75
 Autobiographies of diagnoses and 
treatments by patients with breast cancer 
76
 also offer therapeutic benefits by helping 
to alleviate the stigma and embarrassment associated with this condition,
77
 
functioning perhaps as an alternative form of therapy for these patients. 
 Chapter 1 
17 
Blogs (otherwise known as “web-logs”) have been gaining popularity in recent 
years. Being analogous to online diaries, the entries or posts that are updated by users 
are filed in reverse chronological order with the most recent entry at the top of the 
page.
15,78,79
 Blogs that are networked among several users usually focus on thoughts 
of common themes,
16
 and a feature of this web-based application is its ability for 
users to provide immediate feedback and comments on a post. This allows 
communication in a lighter and less formal way. Thus, blogs are a useful way for 
dissemination and sharing of medical information with the public, including patients 
with cancer (Appendix 1). While some medical bloggers relate their experiences 
online, others use their blogs to provide updates from medical conferences which they 
have attended.
80
 The entries by such bloggers can be a “double-edged sword”. If the 
entries are objectively updated, the information can be clinically useful for the reader.  
However, blogs are largely subjective since bloggers usually pen their thoughts in 
their entries. Thus, a conference update can potentially be biased towards the view of 
the blogger if its entry is not sufficiently substantiated with facts. As such, readers 
should always interpret blog entries with caution, bearing in mind the possibility of 
bias. Nonetheless, blogs can serve as a platform for information about cancer 
treatments, management strategies, experiences, advances, and advice to patients and 
healthcare professionals. A blogger‟s point of view can also provide useful insights to 
practical issues pertaining to oncology practice. 
Podcasts are also an emerging tool for patients and clinicians in the world of 
digital media and cybermedicine, and several papers describing this channel have 
been published.
79,81
 The advantages of podcasts are their portability, flexibility and 
convenience,
81
 making them suitable for use by clinicians who are always on-the-go. 
Since its inception, various international organisations have adopted podcasting as a 
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way to provide cancer-related information to their audiences. In the United Kingdom 
(UK), the Cancer Research UK Podcasts offer monthly thematic information based on 
the latest advances in cancer research and news.
82
 The Cancer.Net Podcasts by ASCO 




All these portals provide an invaluable source of cancer-related information to 
both patients and practitioners, and the interactive format of these portals is important, 
as it provides rapid and valuable feedback on moral, ethical and legal concerns not 
available through traditional resources. The knowledge gained by patients about the 
disease and treatment options, as well as the sharing of experiences, will not only 
improve their quality of life, but can also indirectly impact pharmaceutical care, since 
they can better participate in the management of their conditions. 
 
1.4. Drug-related problems associated with pharmacoinformatics 
The roles of informatics and the internet have been critical in transforming the 
public‟s attitudes towards healthcare and medicine. However, several issues have also 
surfaced from the use of cyberspace technologies, which can ultimately affect the 
quality of pharmaceutical care in patients with cancer. Three factors are proposed that 
can potentially lead to DRPs in cybermedicine. The key is to weigh the benefits and 
risks of these new technologies so as to reduce the potential risks of these DRPs, and 
hence provide the appropriate level of pharmaceutical care for patients.   
 
1.4.1. Digital dehumanisation in the patient-practitioner relationship   
The advent of e-Health has brought about universal access of healthcare 
information and greater contact between patients through digital networks.
84
 E-Health 
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information systems have many potential benefits in terms of patient-care 
management. These benefits include increased accessibility to healthcare providers, 
access to shared knowledge resources, increased convenience for patients in terms of 
scheduling their appointments and participating in their care, the ability for patients to 
view their own health-related data, and increased social support.
85,86
 However, the 
relationship between patient and practitioner through cyberspace can interfere with 
the development of patient trust and practitioner compassion.
87
 This issue could lead 
to a decrease in the rapport between the patient and practitioner, and might also raise 
ethical issues because it would hinder the advancement of patient health and well-
being, which forms the core goal of medical care.
87
  
Although cybermedicine can possibly enhance and strengthen the relationship 
for patients who continue to obtain most of their medical care through face-to-face 
encounters with their healthcare practitioner, the ethical implications in the absence of 
such a patient-practitioner relationship in cybermedicine becomes more complex.
87
 
The interaction between a patient and practitioner differs when the communication 
process is mediated by digital means (e.g. email, online chatrooms, or forums), 
compared with face-to-face contact. For example, emails might work well for 
communicating impersonal or abstract information to patients, but because of the 
absence of an emotional connection, this becomes an inadequate way for 
communicating personal and sensitive information (e.g. results of a blood test or 
examination, or revealing a diagnosis of a certain cancer, such as prostate or breast 
cancer). The distortion or obscuring of non-verbal cues exchanged within these 
“virtual relationships” makes it difficult for practitioners and patients to understand 
each other‟s characters and motives. This issue can result in a breakdown in 
communication and in the patient-practitioner relationship.
88
 Furthermore, a situation 
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where the practitioner is unable to see the circumstances under which a patient agrees 
to something can be a source of much frustration. Miscommunication can result, 
leading to non-compliance to treatment by the patient and the occurrence of DRPs. 
The seeming lack of compassion in the communication process can also lead to 
adverse outcomes as a result of the psychological distress experienced by the patient. 
In the management of chronic diseases such as cancer, these technologies should 
therefore be used to complement (rather than replace) the patient-practitioner 
relationship, so that the quality of pharmaceutical care in the management of patients 
with cancer can be enhanced. 
 
1.4.2. Virtual conflicts of recommendations 
 Another major concern of cyberspace health technology is the conflict which 
may exist between information obtained from the internet by patients with cancer and 
the recommendations made by the healthcare team. This conflict can arise due to 
misinterpretation of generalized information that is not applicable or tailored towards 
the patient‟s personal needs, or the patient retrieving erroneous information on the 
internet, which can cause a sense of uncertainty and confusion in the patient, resulting 
in delaying his treatment or turning to other inappropriate forms of therapy. Some 
patients may also challenge the authority of their healthcare providers with the 
knowledge they obtain from the internet. Furthermore, with online consultations 
gaining popularity over the internet, misunderstandings leading to DRPs can result, 
due to patients relying on the advice of these “virtual consultants”, who do not always 
have a full appreciation of the patient‟s health status. The legality aspects of such 
virtual consultations, including whether the “virtual consultant” has met or examined 
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the patient, or seen their medical records and test results, are questionable and have 
yet to be resolved.  
Conversely, virtual consultations can be promising if there are systems in 
place for providing transparency between the patient, his primary healthcare provider, 
and the virtual consultant. For example, online “second opinions” provide a way for 
patients to gain access to expert opinion on their diagnosis and treatment plans.
89-91
 
These “e-consultations” allow patients and healthcare professionals to consult with 
medical experts of various specialties via the WWW, regardless of their location. This 
service can be especially beneficial for people who live in rural areas or overseas, and 
for local physicians who may encounter patients with complex medical conditions, for 
which they would prefer to seek the expertise of a specialist.
92
 Online second opinions 
usually have strict requirements for complete medical records, primary imaging and 
pathology data to be sent for consultation purposes.
92
 Due to licensure restrictions, 
these services may also require referrals from the patient‟s primary physician, and 
some providers also exclude patients from certain US states or territories.
93
  
Nevertheless, when this service is used in tandem with face-to-face 
consultations with a patient‟s primary healthcare provider, the patient-practitioner 
relationship can be strengthened because the practitioner feels more confident in his 
treatment plans for the patient, and the patient is also reassured that they are getting 
the appropriate treatment.
94
 Virtual second opinions offer technical knowledge and 
expertise, but do not replace the “caring part of medicine”.93 By working together in a 
complementary triad, the patient, health professional, and the virtual consultant can 
minimise the possibility of a DRP and cater towards the patient‟s treatment goals. 
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1.4.3. Online self-prescribing 
Anticancer drugs represent a subset of specialty drugs that are traditionally 
administered by intravenous (IV) means, often in the physician‟s office or by home 
health companies. There has been a shift in paradigm towards oral chemotherapy use 
due to its advantages of greater patient convenience, flexibility in time and place of 
administration, and improvement in the patient‟s QOL. However, in the management 
of cancer, many of these oral anticancer agents are expensive and unaffordable.
95
 
Anticancer agents prescribed for off-label uses are not covered by the US Medicare 
prescription drug benefit (Part D) because these drugs are used for a non-US Food and 
Drug Administration (FDA)-approved indication or an indication that is not supported 
by specific medical compendia.
96,97
 In an attempt to find the best deals for their 
chemotherapy, patients often turn to other sources, such as the internet, for cheaper 
alternatives to their anticancer drugs. Oncology healthcare professionals can help by 
discussing the various options available for patients with financial constraints on the 
affordability of their cancer treatments. For example, pharmacy benefit management 
companies may help provide a lower unit cost of drugs by obtaining discounts and 
rebates from pharmacies and drug companies.
98
 Selected national organisations, 
pharmaceutical and patient assistance organisations, and patient advocacy foundations 




The WWW has opened up many channels – so-called online pharmacies – for 
internet-based promotions of various drugs, which claim to improve our health and 
lifestyles. Although we are all familiar with this occurrence, such as the promotion of 
Viagra online,
101
 such advertising has also caught up with chronic diseases such as 
cancer. Patients who learn about ACD therapies, such as bevacizumab and erlotinib 
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for the treatment of advanced colorectal and non-small-cell lung cancers respectively, 
tend to self-prescribe by shopping online to get the best treatments at cheaper 
prices.
102
 However, many patients do not realize that such actions increase the risk of 
them suffering from a DRP. A case report of a patient whose congestive heart failure 
deteriorated after long-term self-prescribing of drugs obtained from the internet 
highlights the serious consequences that can result from this situation.
103
 Hence, 
widespread safety fears have emerged from both oncology health professionals and 
government agencies because anticancer drugs can interfere and compromise the 
patients‟ ongoing therapies.104 Concerns exist of online suppliers not having the 
appropriate professional qualifications or healthcare expertise, and the paucity of 
quality and efficacy controls resulting in substandard or fake medicines.
105
 Various 
national organisations have since taken steps to ensure the quality and safety 
standards of the products and services offered by online pharmacies. The General 
Pharmaceutical Council, in its attempt to educate the public about the dangers of 
illegal online drug sales, has introduced the use of an approved internet pharmacy 
logo, which helps consumers and pharmacists identify legitimate online registered 
pharmacies in the UK.
106
 The Verified Internet Pharmacy Practice Sites
TM
 (VIPPS) 
programme, developed and administered by the US National Association of Boards of 
Pharmacy (NABP) and supported by the Canadian National Association of Pharmacy 
Regulatory Authorities, is the equivalent accreditation for online pharmacies in the 
US and Canada.
107,108
 VIPPS-accredited online pharmacies can display the VIPPS 
seal on their homepage, which is linked to the NABP‟s VIPPS website, so that visitors 
are able to obtain information about their dispensing practices, quality of products and 




 Chapter 1 
24 
1.5. The role of pharmacoinformatics in addressing drug-related problems faced 
by patients with cancer 
Cancer is a highly prevalent health problem with increasing incidence 
worldwide. In 2007, one in 8 deaths was due to cancer.
109
 The global burden of cancer 
is also estimated to grow to 27 million new cancer cases and 17.5 million cancer 
deaths by 2050.
109
 The application of pharmacoinformatics has led to an increasing 
acceptance of IT among healthcare professionals in their clinical practice. In addition, 
the rapid growth of the WWW in the last decade has enabled the development of 
many internet applications which can assist clinicians in delivering optimum 
pharmaceutical care and health-related outcomes. Healthcare professionals can now 
keep themselves updated in the latest developments in oncology, as well as proper 
therapeutic management strategies through the use of online databases and software 
tools.
110
 The proliferation of freely accessible online health information has also 
enabled patients with cancer to become more well-informed, and empowered with the 
appropriate knowledge, to better participate in the management of their own 
conditions. However, despite the advancement of informatics and IT, little has been 
done in clinical oncology practice to leverage on the use of these technologies to 
improve the pharmaceutical care of patients with cancer. Thus, a key issue exists – 
can the pharmaceutical care of patients with cancer be enhanced by leveraging on the 
role of pharmacoinformatics to reduce DRPs in clinical practice? This project 
attempts to address this “gap” or key issue by using cancer chemotherapy as its focus. 
Two prevention strategies have been identified. These are the early recognition of 
DDIs, especially in patients concomitantly treated with ACDs or chemotherapy 
regimens (CRegs) and other non-ACDs, and adverse effects from emetogenic 
chemotherapy. The sections that follow describe these “gaps” in further details and 
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the rationale of developing this project into 2 major parts, so as to show how 
pharmacoinformatics can fill these “gaps” by reducing specifically these 2 DRPs. 
 
1.5.1. Targeting drug interactions in patients receiving chemotherapy  
Drug interactions are known to commonly occur in patients with cancer, as 
many of them receive multiple medications to treat their co-morbid conditions and 
toxicities that are associated with anticancer treatments and cancer-related syndromes. 
A drug interaction is defined as a change in the way a drug acts in the body when 
taken with certain other drugs, herbs, foods, or when taken with certain medical 
conditions.
62
 They may cause the drug to be more or less effective, or cause a unique 
response that does not occur when either agent is given alone. Approximately 20-30% 
of all adverse drug reactions (ADRs) are due to drug interactions.
111,112
 The potential 
for an interaction is about 6% when 2 drugs are prescribed together for a patient, and 
the risk increases markedly to 84% when the number of concomitant medications is 
increased to 6.
111,113
 A study done by Riechelmann and colleagues estimated that at 
least one potential DDI occurs in 27% of patients with cancer, of which 13% involves 
an ACD, and 86% are classified as being of moderate or major severity.
114
 The 
complex pharmacological profiles of ACDs, their narrow therapeutic indices and 
steep dose-toxicity curves, predispose patients with cancer to high incidences of DDI-
related adverse events. Patient-related factors, such as age-related renal and/or hepatic 
insufficiencies, malnutrition and malabsorption, and patients‟ pharmacogenetic 
characteristics, can also alter the metabolism and elimination of ACDs, thus causing 
elderly patients with cancer to become more susceptible to DDI effects.
115,116
 Such 
effects are relevant clinically in up to 80% of the elderly,
112
 and can be a problem, 
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particularly in Singapore, because the percentage of elderly is expected to increase 
from 7.2% to 18.4% in the year 2030.
117
  
Patients manifesting certain cancer types, such as brain tumours and 
metastases, are often at higher risks of DDI events, since these patients are likely to 
receive long-term antiepileptic drugs (AEDs), which are highly prone to interactions 
with ACDs. The incidence of seizures occurring in patients with brain tumours and 
metastases ranges from 20-70%, depending on the tumour type.
118
 A further 10-20% 
of patients are affected as the tumours progress, while the severity and frequency of 
seizure activity may also increase with tumour size.
118
 A meta-analysis done by 
Sirven et al.
119
 found high risks for new-onset seizures and epilepsy in patients with 
various types of brain tumours, with the highest rates found in those with 
oligodendrogliomas (92%), astrocytomas and meningiomas (both 70%). Metastasis to 
the central nervous system (CNS) is another major concern in a number of primary 
cancers, such as lung and breast cancers, among others. The number of cases of CNS 
metastases varies by primary cancer type in the literature. Lassman and De Angelis 
reviewed 9 studies and found that the reported percentages of patients in whom brain 
metastases developed varied among specific primary tumors.
120
 Patients with CNS 
metastasis may also experience seizure episodes and need long-term antiepileptic 
therapy.  
The efficacy of AEDs in the treatment of epilepsy is well-established.
121,122
 It 
is undisputed in clinical practice that AED therapy is appropriate in patients who 
experience seizures. However, its use in seizures due to brain tumours or brain 
metastases has not been well-established. The prophylactic use of AED therapy is 
common in treating patients with brain tumours, regardless of whether these patients 
have had episodes of seizures in the past.
123,124
 In general, AED monotherapy has 
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been shown to be effective in ~60-70% of newly diagnosed patients,
121,122,125
 while up 
to 50% of patients who fail initial antiepileptic treatment can be managed by a switch 
to an alternative AED.
121,122
 Furthermore, epileptic patients who do not respond to 
monotherapy are typically administered a combination of AEDs to optimise seizure 
control at the expense of an increased risk of adverse effects.
121,122,125,126
 
On the other hand, the issue of AED prophylaxis in patients with brain 
tumours without documented seizures has been controversial. The American 
Academy of Neurology has advised in its practice parameter against the use of AED 
prophylaxis in such patients based on a meta-analysis of 12 studies, none of which 
found efficacy of prophylactic AEDs in preventing first seizures in patients with brain 
tumors.
123
 Yet a large majority of neurosurgeons (82%), neurologists (53%), and 
medical (50%) and radiation (33%) oncologists have reported prescribing AED 
prophylaxis,
123
 presumably based on personal preference, training, and experience, 
despite a lack of clinically available evidence on its efficacy. AED prophylaxis may 
also be prescribed in a clinician‟s effort to avoid malpractice claims brought by 
patients or family members of patients who might experience seizures.
124
 
Patients with cancer also experience physiological changes and emotional 
upheavals, which often lead to psychological distress and predispose them to 
psychiatric illnesses or exacerbated pre-existing psychiatric conditions.
127
 Previous 
studies have shown high prevalence rates of psychological distress in patients with 
cancer (30-43%), and this can range from conditions, such as anxiety and post-
traumatic stress (25-48%), to psychological disorders, such as major depressive 
disorder (5-42%), schizophrenia (0.5-1.5%) and bipolar disorder (0.4-1.6%).
128-130
 
Psychotropic drugs are often prescribed for these patients. Psychotropics are 
medications capable of altering the mind, emotions and behavior,
131
 and these drugs 
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include the antidepressants, antipsychotics, and sedatives and/or hypnotics.
132
 Patients 
with cancer are more likely to receive psychotropic agents than patients in general 
hospitals. In a study examining psychotropic drug prescribing patterns of physicians, 
over 80% of 200 hospitalised patients with cancer were prescribed with at least one 
psychotropic, among which 36% were prescribed with 3 or more psychotropics.
133
  
Among the psychological disorders, depression is a condition that is often 
experienced by patients with cancer, and its incidence is 3 to 5 times more than the 
general population.
134-136
 Several reasons are associated with the increased risk of 
depression in these patients. These include the emotional impact of the diagnosis of a 
terminal illness,
137
 the knowledge of one‟s deteriorating condition,137,138 biological 
stresses such as pain, the effects of treatment from chemotherapeutic agents, surgical 
procedures, radiotherapy, and side effects of such therapies.
134,135
 Having a history of 
depression and socioeconomic pressures are also precipitating factors of depression in 
patients with cancer.
139-141
 Untreated depression in these patients may lead to 
increased rates of cancer progression, worsened medical outcomes, and longer 
duration of hospital stays,
134
 which may in turn lead to poorer QOL and higher 
mortality rates.
136
 Therefore, it is important that patients with cancer who suffer from 
depression are treated appropriately in order to improve their QOL. However, 
concomitant use of ACDs and psychotropic drugs, such as the antidepressants, might 
result in potential DDIs that are harmful and of concern in clinical practice.  
In the course of cancer therapy, an increasing number of patients with cancer 
are also consuming complementary and alternative medicines (CAMs), including 
traditional Chinese medicines (TCMs).
142,143
 CAM usage in the general US population 
has increased over the past 20 years, reaching 36% in 2002,
143
 and a similar trend is 
seen in the cancer population. A study conducted on women with breast cancer 
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showed an increase in CAM usage from 66.7% in 1998 to 81.9% in 2005.
142
 A 
particularly large proportion of Asian patients also use CAMs concurrently with their 
cancer therapies, ranging from 45% of Japanese,
144
 61% of Taiwanese,
145
 and 76% 
and 67% of Singaporean adult and paediatric patients respectively.
146,147
 
Patients with cancer use CAMs for a variety of reasons. These include having 
a more holistic approach for the treatment of their cancer, as well as relieving the 
associated side effects of chemotherapy (e.g. immunosuppression, cancer pain, nausea 
and emesis).
148,149
 In addition, some patients also use CAMs for their anticancer 
properties as replacements for, rather than adjuncts to, mainstream therapy; some of 
which have limited evidence.
150-152
 These CAMs are usually taken without the 
physician‟s knowledge, and patients tend to be resistant to discussions of their CAM 
use with their physicians, possibly due to clinician indifference or opposition to CAM 
use, their clinician‟s emphasis on scientific evidence, or their anticipation of a 
negative response from the clinician.
153
 Furthermore, the effects of many CAMs are 
not well-documented due to the lack of well-designed safety and efficacy studies.
154
 
As a result, DRPs such as herb-drug interactions (HDIs) between ACDs and CAMs 
may occur, which can lead to a compromise in the safety and efficacy of the 
chemotherapy treatment. 
Interactions with ACDs may potentially be harmful to patients due to the 
narrow therapeutic indices of ACDs and the interacting non-ACDs. In addition, some 
CAM products may contain multiple pharmacologically-active constituents, which 
may further increase the risk of ACD-CAM interactions.
155
 Although the term “drug 
interaction” typically refers to drug-drug interactions,156 other interactions (e.g. food-
drug and herb-drug) also exist, and are important considerations in the pharmaceutical 
care of patients with cancer. As such, this term (also abbreviated as DDIs) shall be 
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referred to as the whole range of interactions described above. In general, DDIs can 
be classified into 3 main categories: pharmacokinetic, pharmacodynamic and 
pharmaceutical.
157
 Pharmacokinetic interactions involve alterations in the absorption, 
distribution, metabolism, or elimination properties of a drug, which can be due to 
enzyme induction or inhibition, or protein displacement; while pharmacodynamic 
interactions can be due to antagonistic, additive, or synergistic effects of the 
individual drugs. On the other hand, pharmaceutical interactions occur when 
chemically incompatible drugs are co-administered, which lead to precipitation and 
inactivation of the therapeutic effects of the drugs.
157,158
 Albeit the fact that 
pharmacodynamic interactions form the basis of the combination CReg cocktails used 
in improving the clinical responses of patients with cancer, other undesirable clinical 
consequences can also occur in these patients.
158,159
  In clinical practice, there are 3 
scenarios in which DDIs can potentially affect the therapy of patients with cancer: (a) 
addition of an interacting drug to a patient‟s existing chemotherapy treatment; (b) 
administering chemotherapy treatment to a patient who is concurrently on an 
interacting drug; and (c) removal of an interacting drug from a patient‟s chronic 
chemotherapy.
158
 Clinicians must be vigilant when treating patients with cancer who 
are concurrently on both chemotherapy and non-ACDs, in this case, the psychotropics 
and CAMs; so as to avoid unwanted toxicities and inadequate drug exposures due to 
the interactions. Although there are more than 2000 DDIs that have been identified, 
only a limited number are of interest from a clinical standpoint.
160
 By knowing the 
magnitude of the DDIs, clinicians can better manage their patients‟ drug therapies. 
Clinicians currently use a variety of resources for information on ACD 
interactions, which include primary literature, textbooks, compendia, conventional 
drug information texts, online databases, and websites. With the vast amounts of drug 
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information sources that are available, they require accurate and effective methods for 
identifying relevant DDIs, so that they can make a better informed decision when 
confronted with such DDIs in their daily practice. The use of DDI databases is 
advantageous, since clinicians do not have to sieve through the sheer volume of 
information from various sources to determine any suspected DDIs.
161
 Furthermore, 
the use of such databases can also raise an alert to any potentially harmful drug 
combinations, and provide useful information about the detected DDI.
162
 A number of 





provide detailed DDI information, including the onset, severities, effects, and 
mechanisms of interaction, are available electronically. In contrast, there are also 
websites that only alert users to potential DDIs without giving other supporting 
details.
163
 Databases that provide information about CAMs have limited information 
on ACD-CAM interactions, especially for TCM herbs. Additionally, major conflicts 
on DDI information exist among various commercial resources and compendia, 
especially with combination listings, consistency of interaction severities, and 
strengths of scientific evidences.
164
 There is currently no oncology-specific drug 
database that is dedicated to ACD interactions based on single-agent and multiple-
agent CReg searches. Most of the available drug databases require the input of 
individual drugs in a patient‟s prescription in order to search for DDIs. 
Pharmacoinformatics can play a role here to improve the detection of clinically-
relevant DDIs in oncology practice. A pharmacoinformatics platform can be created 
to house an oncology-specific drug database, so that DDI searches with ACDs and 
CRegs can be carried out. This database will be relevant to clinicians who deal with 
patients with cancer in their daily practices.    
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1.5.2. Targeting adverse drug reactions in patients on emetogenic chemotherapy  
Patients who are on certain chemotherapies tend to suffer from certain ADRs, 
of which chemotherapy-induced nausea and vomiting (CINV) is one of the most 
distressing.
165,166
 The prevalence of CINV ranges from 13-58% for acute nausea and 
vomiting (NV lasting up to 24 hours after chemotherapy), and 15-75% for delayed 
nausea and vomiting (NV occurring after 24 hours and lasting up to 5 to 7 days).
167-172
 
CINV causes extreme discomfort in patients with cancer and also impairs their QOL, 
despite preventive therapies with antiemetics.
173-176
 Uncontrolled CINV can 
negatively affect the patients‟ nutritional status leading to metabolic imbalances, 
nutrient depletion and injury to the oesophageal tract;
169,177,178
 as well as their 
motivation to follow recommended cancer treatment regimens,
179
 due to their fear of 
developing nausea and vomiting.
180,181
 This uncontrolled CINV results in increased 
total direct and indirect costs of cancer treatments because of the use of additional 
antiemetics, hospitalisations and loss of productivity.
182,183
 Studies have shown that 
effective management of CINV can prevent patients from unnecessary hospitalisation 
and expenditures.
184
 Therefore, it is important that healthcare professionals manage 
CINV appropriately to prevent other complications such as those mentioned above. 
Research has shown that multiple risk factors for CINV exist. These include 
the emetogenicity of CRegs and patient-related factors, such as young age, female 
gender, prior CINV experiences, histories of morning and motion sickness, low 
alcohol use, and presence of anxiety, fatigue and labyrinthitis, among others.
174,181,185-
189
 Some risk factors, such as anxiety and fatigue, are subjective in nature and difficult 
to quantify. Furthermore, the methodologies of assessing certain risk factors and their 
evidence as clinical predictors for CINV have been inconsistent. For example, studies 
that suggested a positive relationship between alcohol intake and improvement in 
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CINV have used different kinds of parameters for analysis, such as the quantities of 
alcohol consumed (more than 100g of ethanol per day or 5 mixed drinks per week) 
190,191
 and the use of alcohol-drinking categories (current versus non-current 
drinkers).
192
 In contrast, other studies have also suggested no significant association 
between alcohol consumption and control of CINV.
193-195
 In addition, various 
methods have been employed in studies evaluating anxiety as a clinical predictor of 
CINV. These ranged from a simple query addressed to patients,
186
 to semi-structured 
interviews 
180
 and a combination of self-administered questionnaires consisting of 
several study scales and interviews.
185
 State anxiety was reported to increase the 
intensity of nausea and vomiting, as well as the duration of delayed nausea, in a 
prospective, longitudinal study of 71 chemo-naïve Chinese patients with breast cancer 
receiving moderately emetogenic chemotherapy (MEC) consisting of IV doxorubicin 
60 mg/m
2




 However, in another recent 
prospective, observational study done in 91 Asian patients with breast cancer 
receiving the same regimen, the authors suggested that patients who reported anxiety 
were less likely to experience acute nausea.
186
 
Currently in Singapore, medical oncologists prescribe the appropriate classes 
of antiemetics based on established clinical guidelines,
189,196-198
 along with their 
clinical experience and professional judgement. Adherence to these guidelines, 
however, is completely voluntary. In the clinical setting, objective instruments for 




 are not 
commonly used for the purpose of prescribing antiemetics, possibly due to time 
constraints in clinic visits, as well as the inconvenience of using the instruments. 
Clinicians need appropriate measures so as to better assess their patients‟ risks of 
CINV in daily practice. In such cases, it will be good to have a pharmacoinformatics 
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tool that can systematically assess a patient‟s susceptibility to CINV so that 
appropriate antiemetics may be prescribed accordingly.  
 
1.6. Research question and objective 
The key research question that this project aims to answer is whether the 
pharmaceutical care of patients can be better improved by leveraging on the 
application of pharmacoinformatics in healthcare practice, by focusing on how it can 
reduce drug-related problems associated with cancer chemotherapy. To this end, the 
objective of this project is to apply pharmacoinformatics in relation to 2 DRPs 
commonly observed in clinical oncology practice – (a) DDIs with ACDs and CRegs, 
and (b) chemotherapy ADRs. Therefore, this project was developed in 2 major parts: 
a) To design a platform for healthcare professionals that will facilitate the 
identification of DDIs between chemotherapeutic agents and adjuvant drug 
therapy. This platform will incorporate clinically-relevant information related to 
the properties of the chemotherapeutic agents and other medications, including 
complementary medicines, that are frequently used in combination by patients 
with cancer; and 
b) To explore the use of a computational tool to identify predictors that will 
contribute towards a patient‟s susceptibility to CINV, which is a common and 
distressing side effect experienced by patients on cancer chemotherapy. This 
method will allow oncology practitioners to identify the risk factors that may lead 
to the occurrence of adverse reactions, particularly CINV, in patients who are 
treated with chemotherapy.  
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1.7. Scope 
This project was initiated with the intention of providing healthcare 
professionals in the oncology setting with a platform that comprises a DDI database, 
and a method that utilises a computational tool for prediction of CINV, which will be 
relevant to their daily practice. Currently, there is no oncology-specific database that 
allows clinicians to search for DDIs with CRegs. There is also no 
pharmacoinformatics tool that is based on computational techniques, which can be 
used to help predict drug therapy outcomes of patients with cancer. In order to show 
that pharmacoinformatics can be a useful tool for improving DRPs in oncology 
practice, the platform that will be created in this project will focus on DDIs of both 
single-agent and multiple-agent CRegs. In addition, a method incorporating a machine 
learning technique that can predict health-related outcomes will be used. This 
methodology will be applied specifically for the prediction of CINV based on 
patients‟ profiles and clinical responses. 
 
 Chapter 2 
36 
Chapter 2 
Establishing the need for an oncology-specific database on anticancer drug 
interactions 
2.1. Determining the opinions on drug interaction sources in anticancer 
treatments from pharmacy practitioners in Asia 
Oncology clinicians may not have the time or necessary skills to constantly 
update, critically evaluate and apply the enormous amount of published literature 
available to their clinical practice.
203
 Studies done on information sources used by 
oncology practitioners have concentrated on general cancer information instead of 
oncology DDIs.
203,204
 A higher proportion of practitioners in the US has been reported 
to use electronic databases (51-79%) as sources for DDI information rather than 
printed references (9-24%);
205
 and approximately 53% and 25% of prescribers and 
pharmacists rely on a colleague for such DDI information.
205
 This phenomenon is 
worrying since healthcare professionals may lack the ability to identify potential 
DDIs.
206-210
 The practitioners‟ ability to identify DDIs is inversely affected by the 
number of drugs on patients‟ medication profiles.206 Thus, it is essential that clinicians 
find appropriate sources of ACD interaction information at the point of patient care. 
The practitioner‟s ability to keep abreast with the latest ACD-related information is 
likely to be hindered by inherent delays in traditional literature publication 
processes.
211
 Online drug databases can be useful for obtaining up-to-date DDI 
information in a timely, efficient and accessible manner.
19
 Therefore, the objectives of 
this study were to investigate the current sources of DDI information among 
practitioners, the usefulness of an oncology-specific database which targets ACD 
interactions, and the parameters that are essential if such a database was available for 
clinical practice. 
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2.1.1. Methodology and study design 
A qualitative, cross-sectional research design was employed. A structured 
questionnaire consisting of 10 questions collected information regarding the 
respondents‟ practice characteristics, frequency of encountering ACD interactions in 
their daily practice, and their current sources of DDI information. Their opinions on 
the usefulness of an online ACD interaction database were also asked together with 
the features that they deemed important for such a database. These included the 
accuracy of DDI content, usefulness in clinical practice and user-friendliness. In 
addition, they had to rate the importance of several DDI parameters as “absolutely 
essential”, “essential”, “not essential, but good to have” or “not essential at all”. The 
“neutral” option was also provided. The DDI parameters were pharmacokinetics of 
the chemotherapy and interacting drugs, mechanism of interaction, severity, 
substantiation, and presence of a management plan. 
The self-administered questionnaire was distributed to the participants of The 
2nd Asia-Pacific Oncology Pharmacy Congress held in Bangkok, Thailand, from 11-
13 September 2008. Participants were healthcare professionals from the Asia-Pacific 
region, US and Australia. Returned questionnaires were coded with an identification 
number to ensure confidentiality. Survey implementation was approved by the 
congress organizing committee, and replies from the individual participants were 
considered as consent to the questionnaire. 
Returned questionnaires were included for analysis if the questions regarding 
respondents‟ sources of ACD interaction information, or useful features in an online 
database were answered, and at least half (5/10) of the questions were answered. 
Responses with minor missing data, such as practice demographics and frequency of 
encountering DDIs were also included. 
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Data were analysed using SPSS 17.0 (Chicago, IL, USA). Descriptive 
statistics were used to describe the categorical variables. Kruskal-Wallis test was 
performed to detect for statistical significant differences in sources of interaction 
information and parameters related to the usefulness of an ACD database among 4 
groups of respondents (inpatient practice only, outpatient practice only, both inpatient 
and outpatient practices, other practice settings). Mann-Whitney rank sum test was 
used for comparisons between any 2 groups. All tests were two-tailed and p-values 
below 0.05 were considered as statistically significant. 
 
2.1.2. Respondent characteristics 
Of the 209 distributed questionnaires, 105 (50%) were returned and analysed. 
Three (1%) were excluded from analysis because majority of the questions were not 
answered. Of the remaining questionnaires that were usable, only those that were 
completed by pharmacists working in Asia were included for analysis, since majority 
of the respondents were pharmacists by profession (96%) and practising in Asia 
(93%). The results would then represent a clearer picture on the opinions of 
pharmacists in this part of the world regarding DDIs and the usefulness of an 
oncology-specific database that targets ACD interactions. As a result, a total of 91 
completed questionnaires were used for the analyses. Table 2.1 shows the practice 
characteristics of the respondents. Approximately half practiced in inpatient and 
outpatient settings, out of which 31 (34%) and 21 (23%) were solely in either 
inpatient or outpatient practices respectively. Fifty-two respondents (57%) had 5 to 20 
years of practice experience, and a quarter frequently encountered DDIs with ACDs 
(more than 25% of their time) in their daily practice. 
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Table 2.1. Practice characteristics of the survey respondents (n=91). 
 
Practice characteristics Number of respondents (%)
+
 
Area of specialisation 
Community / Retail 2 (2%) 
Hospice / Home care 5 (6%) 
Hospital inpatient 54 (59%) 
Outpatient practice 44 (48%) 
Private practice 1 (1%) 
Other 17 (19%) 
Length in healthcare practice 
Less than 5 years 36 (40%) 
5-10 years 28 (31%) 
11-20 years 24 (26%) 
21-30 years 3 (3%) 
Frequency of encountering anticancer drug interactions in practice 
0-24% 66 (73%) 
25-49% 14 (15%) 
50-74% 5 (6%) 
75-100% 4 (4%) 
+
 Percentages may not add to 100% due to missing values and rounding 
of data. 
 
2.1.3. Practitioner sources of anticancer drug interaction information 
Electronic databases (70%), drug interaction textbooks (69%) and drug 
compendia (64%) were most commonly used by the pharmacy practitioners to check 
for ACD interactions (Table 2.2). On the other hand, medication package inserts 
(41%) and standard textbooks (42%) were seldom used. Sixteen respondents (18%) 
did not utilise any computerized forms of information sources, such as electronic 
databases or specific softwares, to check for ACD interactions. Among those who did, 
electronic databases seemed to be more frequently used (Tables 2.2 and 2.3). The 
proportion of pharmacists who consulted with their colleagues was a little less than 
half (44%), edging the use of standard textbooks (42%) and product information 
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(41%). Inpatient pharmacists were more likely to utilise standard textbooks as DDI 
sources for ACDs than outpatient pharmacists (52% versus 14% respectively, 
p=0.007). 
 
Table 2.2. Healthcare professionals‟ sources of anticancer drug interaction 
information (n=91). 
 






Compendia of drug products 
(e.g. AHFS Drug Information, British National Formulary, Drug 
Facts & Comparisons, Lexi-Comp’s Drug Information Handbook, 
Martindale, Physician’s Desk Reference, etc) 
58 (64%) 
Consultations with other colleagues / healthcare professionals 40 (44%) 
Drug interaction textbooks 
(e.g. Drug Interaction Facts, Stockley’s Drug Interactions, etc) 
63 (69%) 
Electronic databases 
(e.g. PubMed, Medline, Scirus, Scopus, ScienceDirect, etc) 
64 (70%) 
Medication package inserts / product information 37 (41%) 
Specific softwares 
(e.g. Clinical Pharmacology, Drugdex / Micromedex, Epocrates, 
Facts & Comparisons, Lexi-Comp, Martindale, etc) 
44 (48%) 
Standard medical, pharmacology and pharmacotherapy textbooks 
(e.g. Applied Therapeutics: the Clinical Use of Drugs by Mary 
Anne Koda-Kimble, Basic & Clinical Pharmacology by Bertram 
G. Katzung, Goodman & Gilman’s the Pharmacological Basis of 
Therapeutics by Laurence Brunton, Pharmacotherapy: a 
Pathophysiologic Approach by Joseph T. DiPiro, etc) 
38 (42%) 
+
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Table 2.3. Sources of drug interaction information based on the practice settings of 
healthcare professionals.  
 
Sources of anticancer 
drug interaction 
information 




























Compendia of drug 
products 
24 (77%) 14 (67%) 13 (57%) 7 (44%) 0.121 
Consultations with other 
colleagues / healthcare 
professionals 
12 (39%) 8 (38%) 14 (61%) 6 (38%) 0.315 
Drug interaction 
textbooks 
19 (61%) 14 (67%) 16 (70%) 14 (88%) 0.327 
Electronic databases and 
specific softwares 
    0.625 
Electronic databases 
only 
10 (32%) 7 (33%) 7 (30%) 7 (44%)  
Specific softwares 
only 






























16 (52%)* 3 (14%)* 13 (57%) 6 (38%) 0.020 
+
 Percentages may be over 100% due to multiple selections. 
* p<0.05 between the 2 groups indicated by asterisks (*). 
 
An important finding in this study was that there were lower percentages of 
inpatient and outpatient practitioners who used drug information softwares (45-57%) 
than DDI textbooks (61-67%) or compendia (67-77%) for ACD interaction 
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information. A similar trend was seen with inpatient practitioners when comparing 
electronic databases (58%) with DDI textbooks (61%) and compendia (77%). This 
could be due to the existence of certain environmental barriers in hospitals:
203
 (a) 
connection or firewall issues which impede access to the internet/intranet; (b) 
restricted access to the internet/intranet in clinical areas; (c) limited number of 
computers available in the wards or treatment areas for clinical purposes; (d) old or 
slow computers, and (e) economic reasons such as costs of online journal 
subscriptions. These barriers might not have been as prominent in other non-clinical 
settings. 
Despite these environmental barriers, a large proportion of pharmacy 
practitioners in this study still used electronic references such as e-databases (e.g. 
PubMed) and softwares (e.g. Micromedex) as ACD interaction resources. This is not 
surprising since clinicians tend to perceive these sources as being readily available 
and time-efficient at the point of patient care.
203
 The advent of the internet and 
portable electronic devices such as PDAs have allowed clinicians to access online 
databases and drug information programmes for evidence-based oncology 
information.
203
 The advantage of these resources over hardcopy books is their 
currency of information.
203
 In general, larger proportions of pharmacy practitioners 
from all practice groups in this study consulted electronic resources for DDI 
information compared to standard textbooks. However, a lower proportion of 
practitioners used drug information softwares (48%) compared to drug compendia 
(64%) and other drug interaction textbooks (69%). This proportion was also lower 
than that reported in a study on US practitioners (79%).
205
 The results in this study 
were expected since it was specifically targeted at ACD interactions, in contrast to the 
US study, which assessed sources of general DDI information used by prescribers in a 




 Drug information softwares used in clinical practice, such as 
Micromedex, Lexi-Comp, and Facts and Comparisons, among others, are not specific 
to ACD interactions. The low proportion of practitioners who use these softwares to 
check for ACD interaction information is consistent with the high percentage of 
respondents (93%) who indicated a need for an online ACD interaction database. In 
this aspect, an oncology-specific database which caters towards ACD interactions 
would definitely be a useful tool for pharmacy clinicians in Asia. 
 
2.1.4. Interaction parameters for an oncology-specific database of anticancer 
drug interactions  
The most important DDI parameters for an oncology-specific database, 
indicated by ratings of “essential” and “absolutely essential”, were the mechanism and 
severity of the detected interaction, as well as the presence of a management plan 
(98% each). The high ratings of these parameters were probably because they were 
directly related to the interaction effects and how the interactions could be managed at 
the point of patient care. However, the respondents in this study considered the 
presence of a proposed management plan to be more crucial than the other 
parameters. This was reflected by the presence of “not essential, but good to have” 
ratings for the mechanism and severity of the DDI, in contrast to those for the 
proposed management plan, which were “essential” and “absolutely essential” (Table 
2.4). In addition, more outpatient (76%) than inpatient (42%) pharmacists considered 
the interaction mechanism as an “absolutely essential” component in the database 
(p=0.014), probably due to their difficulty of consulting DDI resources at the point of 
patient care; unlike inpatient practitioners who could still refer to other DDI resources 
for supporting evidences of the interaction mechanisms. One inpatient pharmacist also 
 Chapter 2 
44 
felt that the mechanism was not essential but a value-added component in the 
database. 
 
Table 2.4. Drug interaction parameters that are important in an oncology-specific 
drug interaction database. 
 
Drug interaction 
parameters (% of total 
respondents who 
considered the 
parameter as being 
essential and absolutely 
essential) 




























Pharmacokinetics of chemotherapy and interacting drugs (95%) 0.169 
Absolutely essential 14 (45%) 13 (62%) 12 (52%) 13 (81%)  
Essential 17 (55%) 4 (19%) 10 (44%) 3 (19%)  
Not essential, but good 
to have  
0 (0%) 2 (10%) 0 (0%) 0 (0%)  
Not essential at all 0 (0%) 2 (10%) 0 (0%) 0 (0%)  
Mechanism of interaction (98%) 0.019 
Absolutely essential 13 (42%)* 16 (76%)* 14 (61%) 13 (81%)  
Essential 17 (55%) 5 (24%) 8 (35%) 3 (19%)  
Not essential, but good 
to have  
1 (3%) 0 (0%) 0 (0%) 0 (0%)  
Severity of interaction (98%) 0.709 
Absolutely essential 26 (84%) 16 (76%) 19 (83%) 12 (75%)  
Essential 5 (16%) 5 (24%) 3 (13%) 3 (19%)  
Not essential, but good 
to have  
0 (0%) 0 (0%) 0 (0%) 1 (6%)  
Substantiation of interaction (85%) 0.324 
Absolutely essential 10 (32%) 11 (52%) 8 (35%) 5 (31%)  
Essential 15 (48%) 9 (43%) 10 (44%) 9 (56%)  
Not essential, but good 
to have  
5 (16%) 1 (5%) 4 (17%) 2 (13%)  
Not essential at all 1 (3%) 0 (0%) 0 (0%) 0 (0%)  
Proposed management plan (98%) 0.446 
Absolutely essential 19 (61%) 15 (71%) 18 (78%) 11 (69%)  
Essential 12 (39%) 6 (29%) 4 (17%) 4 (25%)  
References sources (90%) 0.872 
Absolutely essential 14 (45%) 10 (48%) 10 (44%) 7 (44%)  
Essential 13 (42%) 10 (48%) 10 (44%) 8 (50%)  
Not essential, but good 
to have  
4 (13%) 0 (0%) 2 (9%) 0 (0%)  
+
 Percentages may not add to 100% due to missing values and rounding of data. 
* p<0.05 between the 2 groups indicated by asterisks (*).  
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Interestingly, the pharmacokinetic profiles of the drugs were viewed to be less 
important (95%) than the mechanism and severity of interaction, or the management 
plan (98% each). Substantiating studies (85%) and reference sources (90%) fared the 
most poorly. In fact, some pharmacists felt that the pharmacokinetic profiles (2%) and 
substantiating studies (1%) were not needed at all. On the other hand, all the 
pharmacy practitioners agreed that the other 4 parameters would be “good to have” as 
DDI information. Some respondents also gave useful feedback with regards to other 
DDI parameters that could be considered for inclusion in the database. These 
additional parameters were the risk or incidence of interaction; interactions with 
combination CRegs; interactions with TCMs, CAMs, parenteral and enteral 
nutritional products; and non-interacting alternative drugs.  
A consistently higher percentage of outpatient practitioners rated the DDI 
parameters as “absolutely essential” compared to inpatient practitioners, except for 
the severity of interaction. More inpatient than outpatient practitioners considered 
severity as “absolutely essential”, even though the percentages were not statistically 
different (p=0.495). A high probability exists for inpatient pharmacists to identify 
interactions when they screen the drug orders for patients. A study by Ducharme and 
Boothby had identified a substantially higher number of DDIs occurring in the 
outpatient setting compared to hospitalised inpatients.
212
 Severity could have played a 
higher weightage in the clinical practices of inpatient pharmacists, probably because 
they viewed DDIs as being a preventable drug-related problem, and severity would 
play a more important role in their decisions to dispense or not dispense the affected 
drug combination. Moreover, recent studies have shown the existence of inconsistent 
severity ratings among different drug compendia.
164,213-215
 Hence, it is imperative that 
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the severity data that is provided by such a database has to be accurate and reliable for 
clinical practice. 
 
2.1.5. Accuracy, clinical usefulness and usability of the oncology-specific 
database 
The majority of the pharmacy practitioners who completed the questionnaire 
(93%) indicated that it would be useful to have an online ACD database catering 
towards DDIs. Only 2% disagreed. The rest felt that it was not essential, but a bonus, 
to have such a database. 
The pharmacy practitioners seemed to be more concerned about the accuracy 
of DDI content and clinical usefulness of the database than its user-friendliness, as 
shown by the higher overall ratings for DDI information accuracy (98%) and 
usefulness in clinical practice (97%) than user-friendliness of the database (88%). One 
respondent in other practice settings also indicated that clinical usefulness was “not 
essential, but good to have” (Table 2.5).  
Almost all the pharmacy practitioners considered DDI content accuracy as an 
important factor for the database. A larger proportion of outpatient pharmacists (91%) 
indicated this as “absolutely essential”, in contrast to only 65% of inpatient 
pharmacists (p=0.013). The trend was similar for clinical usefulness of the database, 
where a higher proportion of outpatient pharmacists (76%) rated as “absolutely 
essential” compared to 52% of inpatient pharmacists (p=0.043). An assumption that 
respondents who rated the factors as “absolutely essential” would consider them of 
higher priority than “essential” was made. Thus, it was hypothesised that these 2 
factors played more important roles for outpatient practitioners and could be related to 
the ease-of-access to the various DDI resources in the inpatient and outpatient 
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settings. Pharmacists working in outpatient settings could be subjected to time 
constraints and greater difficulty in accessing drug information resources because of 
their contact with patients at the point of dispensing. Studies conducted by 
pharmacists have suggested that the outpatient setting may be suitable for improving 
the quality of patient care.
216-218
 The outpatient practitioners in this study could have 
viewed the database as their main source of ACD interactions at the point of 
dispensing, and therefore considered these factors to be of higher priority, while those 
in inpatient practice probably viewed the database as being complementary to other 
available resources.  
 






























Accuracy of drug interaction information 0.101 
Absolutely essential 20 (65%)* 19 (91%)* 16 (70%) 11 (69%)  
Essential 11 (36%) 1 (5%) 6 (26%) 5 (31%)  
Usefulness in clinical practice 0.245 
Absolutely essential 16 (52%)* 16 (76%)* 14 (61%) 11 (69%)  
Essential 15 (48%) 4 (19%) 8 (35%) 4 (25%)  
Not essential, but 
good to have 
0 (0%) 0 (0%) 0 (0%) 1 (6%)  
User-friendliness 0.032 
Absolutely essential 11 (36%) 11 (52%) 3 (13%) 8 (50%)  
Essential 18 (58%) 6 (29%) 15 (65%) 8 (50%)  
Not essential, but 
good to have  
1 (3%) 3 (14%) 4 (17%)* 0 (0%)*  
Neutral  1 (3%) 0 (0%) 0 (0%) 0 (0%)  
+
 Percentages may not add to 100% due to missing values and rounding of data. 
* p<0.05 between the 2 groups indicated by asterisks (*). 
 
 Chapter 2 
48 
On the other hand, user-friendliness of the database was considered to be less 
important by pharmacists working in both inpatient and outpatient practices than 
those who were in other practice settings (p=0.006). All the pharmacists in the latter 
group agreed that user-friendliness was important for such a database, but there were 
4 pharmacists in the former group (17%) who indicated that this factor was only 
“good to have”. In fact, among all the respondents, 9 pharmacists working in inpatient 
and outpatient settings (10%) were either neutral or considered this factor to only be 
of added value to the database, compared to pharmacists practising in other settings, 
who deemed this factor as an essential or absolutely essential component for the 
database. Granted the fact that user-friendliness is subjective and depends on the 
practitioner‟s familiarity with the database, approximately 80 respondents (88%) still 
considered this as an important factor. User-friendliness was more highly desirable 
among pharmacy practitioners who were working in other settings (e.g. academia, 
retail, home care, and private practice), probably because they relied heavily on 
electronic databases (81%) and softwares (44%) as resources for DDI information, but 
had to work independently in their workplace. A user-friendly database could have 
possibly enabled them be more efficient in terms of time-management when checking 
for DDIs. Desirable features of a good online database include ease-of-use and good 
navigation features.
18
 Database usability has also become increasingly important in 
clinical practice with the availability of software programmes for handheld devices 
such as PDAs, which could be a reason for current software programmes to also offer 
alternative versions for handheld devices. In fact, one respondent indicated that a 
software programme was preferred over an online DDI database. However, ease-of-
use comes at a price which may compromise the scope and completeness of drug 




 thus it was an expected result that content accuracy and clinical 
usefulness was still viewed as being more important than user-friendliness. 
 
2.1.6. Limitations of study 
The respondents in this study were pharmacists practising in Asia, thus the 
results may not reflect the views of other healthcare professionals, and may also differ 
from practitioners in other parts of the world. However, these results are still useful 
since majority of patients are seen by pharmacists as the last line of practitioners 
during their consultations with the healthcare team for the dispensing and counselling 
of their medicines. The opinions of this subgroup of healthcare professionals can 
provide an insight to the development of future drug information systems which will 
hopefully provide a “slice” to the Swiss cheese model of safety incidents,219 so that 
patient safety can be improved. 
Despite distributing the surveys before the commencement of a plenary lecture 
at the conference, where most of the practitioners would be expected to attend, and 
thus be captured, only half were completed, possibly introducing non-response bias to 
the study. It was postulated that those who responded were more interested in 
oncology DDIs, probably because of their lack of experience in this area. Tan et al. 
had previously identified that when less experienced cancer clinicians were exposed 
to unfamiliar situations, they tended to refer to their more experienced colleagues for 
guidance and quick information.
203
 Thus, the relatively high percentages of 
respondents in this study who had a limited duration of clinical practice (71% 
practiced for 10 or less years, of which 40% had less than 5 years of experience) 
could have also biased the results to a higher than expected proportion (44%, range 
38-61%) who relied on consultations with other colleagues as information sources for 
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ACD interactions, compared to other studies done on US prescribers (14-53%).
205,220
 
Furthermore, even though the majority encountered DDIs less than one-quarter of the 
time, the idea of having an ACD interaction database could have attracted their 
attention, and prompted them to do the survey. Nevertheless, the results of this study 
would still apply to the cohorts of pharmacy practitioners who enter oncology 
practice, either fresh from graduation or from another specialisation.  
Certain conclusions in this study, particularly those regarding the usefulness of 
the oncology-specific database, as well as the importance of the various DDI 
parameters, were made based on the assumption that respondents who rated 
“absolutely essential” would consider that component to be of higher importance than 
“essential”. Due to the nature of the Likert-scaled questions in the study survey, and 
the different practice settings of the surveyed population, the interpretations of these 2 
anchor points (“absolutely essential” versus “essential”) could vary among the 
respondents, leading to subtle differences in their responses. However, there was an 
attempt to control for this difference in the designing of the questionnaire by 
arranging the parameters for each of those sections as separate parts of a single 
question. For example, participants would be asked to rate the importance of the 3 
different factors of the database (information accuracy, usefulness in clinical practice, 
and user-friendliness) as one full question with the same set of Likert scales. This 
design would inevitably allow them to compare the factors in terms of importance. An 
“essential” rating for both clinical usefulness and user-friendliness would imply that 
these factors were equally important, while an “absolutely essential” rating for 
information accuracy would imply that this factor was considered to be more crucial 
than the other 2 factors. Thus, it could be assumed in this study that a rating of 
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“absolutely essential” would consistently be a notch higher than “essential” in terms 
of importance in all the survey responses. 
In addition, a “ceiling effect” might have occurred since this study was carried 
out in an oncology congress meeting, whereby majority of the responses from the 
surveyed population could have skewed towards the higher priority end of the 
spectrum, thus masking the actual differences in opinions of the pharmacy 
practitioners. Various statistical techniques have been published in literature to 
control for this “ceiling effect”, such as ordinary least squares regression, Tobit 
models, censored least absolute deviation approach, two-part models, latent class 
models, and the likelihood ratio test; among which the latter 3 approaches seemed to 
be more robust in accounting for ceiling effects.
221,222
 These approaches could be 
considered in future studies when this survey is administered to a larger group of 
healthcare professionals from a wider international audience (e.g. physicians and 
nurses practising outside Asia). Although the aim of this study was to obtain the 
opinions regarding ACD interaction sources and the usefulness of an oncology-
specific DDI database from the core group of healthcare professionals practising in 
the oncology setting, another way to minimise the ceiling effect would be to target 
healthcare professionals from other specialisations who encounter patients with 
cancer in their daily practice. Patients with cancer tend to suffer from depression due 
to the emotional impact of the diagnosis of this terminal illness, biological stressors 
and side effects of chemotherapy,
134,135,137
 while those with brain tumours or 
metastases may be predisposed to suffering from seizures,
118,120
 thus requiring other 
medications such as antidepressants or anticonvulsants. In these cases, suitable groups 
of healthcare professionals in which the survey could be targeted would include 
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psychiatrists and neurologists. Their opinions would be valuable since they might 
hold different points of view from the oncology practitioners surveyed in this study. 
Lastly, this survey was administered in English and not translated to other 
Asian languages such as Chinese, Malay or Thai. Since this conference was held in 
Thailand, many of the practitioners who attended the conference could be from the 
host country, and their English language abilities could differ. An assumption made in 
this study was that the attendees of the conference would have a certain level of 
understanding in the English language since all the sessions were carried out in 
English. However, a conscious effort was taken to ensure that there were no difficult 
phrases in the survey, and technical terms were not included. It can only be postulated 
that those who did not understand the survey would not have completed it, which 
could possibly have contributed to the low response rate of the study. 
 
2.1.7. Study summary 
This study has contributed to the understanding on the usefulness of various 
information sources for ACD interactions among healthcare professionals, especially 
pharmacists, working in Asia. In addition, this study has demonstrated the need for an 
oncology-specific database which caters towards ACD interactions. From the author‟s 
knowledge, this is the first and only known study that has identified the need for such 
a database in clinical practice, as well as determined the DDI parameters which 
pharmacy practitioners deem as being clinically-relevant. The potential of a DDI 
database for clinical practice is definitely attractive to improve the awareness of ACD 
interactions among healthcare professionals, and can ultimately improve the 
pharmaceutical care of patients with cancer by targeting oncology drug interactions. 
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2.2. Determining the quality of online anticancer drug interactions 
Healthcare professionals need to keep themselves informed with the most 
current DDI information, particularly involving newer ACDs. However, their ability 
to keep abreast with the latest ACD-related information is likely to be hindered by 
inherent delays in traditional literature publication processes.
211
 The use of clinical 
decision support tools, such as online drug databases, can be useful to obtain up-to-
date interaction information in a timely, efficient and accessible manner.
19
 Physicians 
tend to utilise the internet to access the latest information on specific health-related 
topics.
223
 Although drug databases can provide relevant and current DDI information 
in a convenient manner, there is much concern regarding the wide variation in the 
quality of such online health-related information.
223,224
 Several tools have been 
developed to evaluate the quality of online health information and guide healthcare 
professionals and patients to the best sources.
225
 Some manifest as codes of conduct 
for voluntary compliance, whereas others provide guidance to users in the form of a 
questionnaire or checklist. Five currently available assessment tools are described in 
Table 2.6 with a summary of their evaluation criteria.  
Although these tools are useful in appraising online drug databases, they also 
possess limitations in terms of utility. Tools such as Netscoring 
226
 are more 
comprehensive than others (e.g. eEurope 
227
 and DARTS 
228
), but are time-consuming 
to use. On the other hand, tools with fewer questions provide a fast and user-friendly 
way to evaluate health information websites. These tools also differ in terms of their 
quality assessment criteria. For example, DISCERN 
229
 and eEurope 
227
 do not include 
the presence of disclaimers and biasness as part of their evaluation criteria. In 
contrast, the Health on the Net code (HONcode) 
230
 and DARTS 
228
 do not consider 
editorial review and target audiences as part of their quality assessment. Some tools 
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like HONcode, eEurope and DARTS also do not provide a scoring system, which 
makes objective comparisons among databases difficult. 
More importantly, a common limitation among these tools is the absence of 
assessment criteria for evaluating the accuracy of health-related content. Furthermore, 
these tools do not cater toward any specific clinical specialty and can only be used to 
evaluate general health information websites. Despite the potential of DDIs occurring 
in cancer patients, from the author‟s knowledge, there is currently no quality rating 
instrument that evaluates drug databases for information on ACD interactions. 
Therefore, an assessment tool, called OncoRx-IQ, was created to evaluate the overall 
quality of drug information databases and the content accuracy of online ACD 
interaction information. The utility of this tool was then tested in a pilot feasibility 
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Table 2.6. Comparison of the characteristics and evaluation criteria of 5 currently 
available quality assessment tools. 
 





















To provide a 
set of criteria 






















Specific to a 
clinical speciality 




X   X X 
Content accuracy 
evaluation 
X X X X X 
Evaluation Criteria 
Authorship      
Disclaimer  X  X X 
Editorial review X X   X 
Financial 
disclosure 
 X    
Presence of bias  X  X X 
User privacy  X   X 
Purpose of 
database 
     
Referencing      
Target audience X    X 
Navigation tools  X    
Links to other 
databases 
   X X 
User support 
features 
X X   X 
Loading speed X X   X 
 The assessment tool contains the characteristic or criteria. 
X The assessment tool does not contain the characteristic or criteria. 
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2.2.1. Methodology and pilot testing 
2.2.1.1. Definition of quality 
Akin to the operationalised quality definition for health-related websites put 
forth by Provost et al.,
224
 the quality of online drug databases in this study is defined 
as the level of excellence which characterises an online drug database in terms of its 
ability to satisfy DDI information needs. 
 
2.2.1.2. Creation of the quality assessment tool 
The development of OncoRx-IQ was based on the review of the rating 
instruments described previously. Its criteria for assessing the overall quality of a drug 
database are similar to the criteria detailed in the second half of Table 2.6, with 
additional criteria for assessing ACD interaction content. The evaluation criteria of 
each section of OncoRx-IQ, together with explanations on what users should look out 
for in each criterion, are shown in Table 2.7. OncoRx-IQ is created in the form of a 
questionnaire which consists of 25 questions separated into 2 sections. Section A 
assesses the accuracy and comprehensiveness of the interaction content of a drug 
database (27 points), and section B evaluates its overall quality (40 points). Questions 
in section B are further subdivided into 2 domains – ease-of-use (12 points) and 
reliability (28 points). The questions in section A (Q1-12) specifically assess the 
interaction parameters between a combination chemotherapy regimen EP (consisting 
of the ACDs etoposide and cisplatin) and vorinostat (an ACD) with valproic acid (an 
AED). Summaries of the studies and reference citations are provided for verification 
of the interaction evidences. These include in-vitro and animal studies, case reports 
and human studies, as well as product information of the interacting drugs.  
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Table 2.7. Evaluation criteria in the OncoRx-IQ tool with explanations on what each 
criterion entails.  
 





Provision of the drug interaction effects 
and/or clinical manifestations 
Mechanism of 
interaction 




Provision of evidences which substantiate the 
drug interaction  (e.g. case reports, in-vitro / 
animal / human studies, package inserts) 
Management 
strategies 
Provision of appropriate recommendations to 




Presence of the names and credentials of 
authors 
Disclaimer 
Presence of a statement indicating that 
information should not replace a healthcare 
professional's advice 
Editorial review 
Explanation of the database's content 
verification procedure 
Financial disclosure Indication of the database's sources of funding 
Presence of bias Presence of advertisements and/or affiliations 
User privacy 
Presence of a privacy policy statement 
pertaining to users 
Purpose of database Indication of the database's objectives 
Referencing Presence of citations for the editorial content 
Target audience Indication of who the database is intended for 
Navigation tools Presence of a site map, index or menu system 
Links to other 
databases 
Presence of hyperlinks to other drug 
databases for verification of drug information 
User support 
features 
Presence of a help feature or frequently-asked 
questions (FAQ) section 
Loading speed 
Acceptability of the time taken for the 
database to load 
Drug interaction risk 
information 
Indication of the likelihood of a drug 
interaction occurring  
Drug interaction 
severity information 
Indication of the severity of a drug interaction 
 
The rationale of selecting the regimen EP was to assess whether the databases 
could identify the pharmacokinetic interactions based on CReg acronyms. Vorinostat, 
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a relatively new ACD, was also selected because it manifests a pharmacodynamic 
interaction with valproic acid. Furthermore, this interaction could be used to assess 
how updated the drug databases are. An AED was chosen because of its indication in 
patients with brain tumours and brain metastases who often manifest seizures.
158
 
These interactions would be clinically relevant to the large majority of healthcare 
professionals (e.g. neurosurgeons, neurologists, medical and radiation oncologists) 
who prescribe antiepileptic drugs as prophylaxis to patients with cancer.
123
 
On the other hand, questions in section B (Q13-25) are based on the 15 criteria 
shown in the second part of Table 2.7. Database usability is assessed according to 
whether it has certain tools and features which allows easy navigation, such as a help 
function, site map or menu system, and the loading speed of the database. Conversely, 
database reliability is determined through quality aspects such as its credibility (e.g. 
authorship, presence of bias), the types of drug-related information and resources it 
provides, its target audiences, user privacy policy and how its drug-related content 
should be interpreted by users (e.g. disclaimers). Further details of the OncoRx-IQ 
tool are provided in Appendix 2. 
 
2.2.1.3. Database selection and pilot testing 
OncoRx-IQ was reviewed by 4 male undergraduate students (21-23 years old) 
from the Department of Pharmacy, National University of Singapore, to ensure its 
user-friendliness. Alterations were made according to their feedback, and their 
responses were not considered for evaluation. The tool was then distributed to a panel 
of 6 pre-registration pharmacists (4 females and 2 males, 24-26 years old) after 
modification as a pilot study to evaluate the drug databases. A search was conducted 
in Google in February 2009 with the following keywords: drug interactions, drug 
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interaction checkers, drug interaction databases, chemotherapy interaction databases, 
chemotherapy regimen interactions, oncology interaction databases, oncology drug 
interaction databases, anticancer drug interaction databases and antineoplastic drug 
interaction databases. From each search, the top 5 hits that provided direct links to 
freely accessible drug databases were considered for evaluation. Links to journal 
articles and other drug databases targeted for patient use were excluded. Some 
databases appeared within the top 5 hits on more than one occasion. The top 3 
databases which appeared most frequently in the searches were selected for 
evaluation. These were Drugs.com, Medscape and Drug Digest. Micromedex 
Healthcare Series was also included for evaluation as it was a commonly used 
database by healthcare professionals.
18
 Table 2.8 provides the publisher details and 
the uniform resource locators (URLs) of the evaluated databases. 
 
Table 2.8. Publisher details and uniform resource locators (URLs) of the drug 
databases evaluated with the OncoRx-IQ tool.  
 
No. Drug Database Publisher URL 











2 Medscape®  WebMD 
 
http://www.medscape.com 
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2.2.1.4. Statistical analyses 
Statistical analysis of the pilot study results was done using SPSS version 16.0 
(Chicago, IL, USA). Descriptive statistics for each database were computed based on 
their domain and composite scores. Spearman‟s correlation coefficient was used to 
correlate the domain scores to the composite scores, and the Friedman and Wilcoxon 
signed-rank tests were carried out to check for variance in scores for each quality 
domain. Kendall‟s coefficient of concordance was used to evaluate the level of 
agreement among the evaluators for each domain, as well as the composite scores. All 
tests were two-tailed and p-values below 0.05 were considered statistically significant. 
 
2.2.2. Quality of drug databases from the pilot study 
From the pilot study results, the composite scores were largely affected by 
scores in both the content accuracy and reliability domains. Among all the databases, 
Micromedex was rated as the best in terms of overall quality with the highest 
composite score of 66.9% (Table 2.9). Drugs.com obtained the second highest score 
(50.5%), followed by Medscape (42.3%). Drug Digest had the lowest composite score 
at 35.8%, and this was also reflected by its low scores in content accuracy (8.0%) and 
reliability (48.2%). In contrast, Micromedex scored the highest in all the 3 domains of 
content accuracy (56.3%), ease-of-use (75.0%) and reliability (73.6%), and it was the 
only database which was rated above 50% with regard to its accuracy of drug 
interaction content. The scores in 2 of the domains, content accuracy (p=0.008) and 
reliability (p=0.046), were statistically different among the databases, which also led 
to a statistical variance in their composite scores (p=0.007). 
Content accuracy in OncoRx-IQ was evaluated based on the interactions 
between the chemotherapy regimen EP and valproic acid causing increased risks of 
 Chapter 2 
61 
ACD and haematological toxicities, and loss of seizure control,
231-233
 as well as 
between vorinostat and valproic acid leading to increased risks of severe 
thrombocytopenia and gastrointestinal bleeding.
234-237
 Although these 2 parameters 
were allocated almost equivalent weights, for the databases in which content accuracy 
played a major role in correlating to their overall quality, such as Drugs.com 
(r
2
=0.89), its reliability played a secondary role. As for the other databases which did 
not score as well in content accuracy, such as Medscape and Drug Digest, the 





=0.82 for Drug Digest). Consequently, these 2 databases also had lower 
composite scores due to their lower ratings in both of these domains. In contrast, 













Table 2.9. Mean and percentage scores of the evaluated drug databases in each quality domain, and the correlation of each domain to 














Drugs.com Medscape Drug Digest Micromedex 
Scores 


























9.2 ± 3.8 
(34.0) 
0.89* 
4.8 ± 3.4 
(17.9) 
0.60 
2.2 ± 1.2 
(8.0) 
0.78 
15.2 ± 4.3 
(56.3) 




8.2 ± 1.9 
(68.1) 
0.44 
8.0 ± 1.5 
(66.7) 
0.62 
8.3 ± 2.1 
(69.4) 
0.49 
9.0 ± 1.2 
(75.0) 
<0.01 p=0.631 W=0.12 
Reliability 
(28 points) 
16.5 ± 4.2 
(58.9) 
0.49 
15.5 ± 5.1 
(55.4) 
0.89* 
13.5 ± 2.7 
(48.2) 
0.82* 
20.6 ± 4.8 
(73.6) 




33.8 ± 7.1 
(50.5) 
-- 
28.3 ± 7.8 
(42.3) 
-- 
24.0 ± 4.1 
(35.8) 
-- 
44.8 ± 5.4 
(66.9) 
-- p=0.007* W=0.81* 
*p<0.05 
+Level of agreement among evaluators was evaluated using Kendall‟s coefficient of concordance (W). 
 
 








Interestingly, all the evaluated databases fared poorly in terms of content 
accuracy, with Micromedex as the only database which scored higher than 50%. 
Although both Micromedex and Drugs.com managed to identify 2 interacting pairs 
(valproic acid with cisplatin and vorinostat), the information in Micromedex was 
more detailed and specific, and thus could possibly explain its higher scores in this 
domain. However, closer inspection of the DDI content in the databases showed that 
there were deficiencies in the DDI information provided for users. For example, 
Micromedex, Drugs.com and Drug Digest only managed to identify one of the 
interaction effects stated in the interaction profile in Appendix 2, between cisplatin 
(one of the ACDs in the regimen EP) and valproic acid. The interaction between 
cisplatin and valproic acid could lead to decreased plasma valproic acid 
concentrations resulting in loss of seizure control, as well as an increased risk of 
haematological toxicity due to inhibition of cytochrome P450 (CYP450) 2C9-
mediated metabolism of cisplatin.
231-233
 The databases previously described did not 
manage to identify the latter interaction effect, which necessitates monitoring of signs 
and symptoms of bleeding as a management plan.
231,238,239
 Furthermore, despite 
providing suggestions to monitor for seizure control, none of the databases indicated 
alternative non-interacting AEDs, such as gabapentin or levetiracetam, as part of 
managing the drug interaction.
239
 
Remarkably, the interaction between etoposide and valproic acid due to 
inhibition of CYP3A4-mediated etoposide metabolism 
231,238
 was not identified in any 
of the online databases assessed. However, an evaluator who used the CD-ROM 
version of Micromedex indicated that he managed to identify this interaction pair. 
Medscape (17.9%) and Drug Digest (8.0%) were the lowest scorers for content 
accuracy, obtaining less than one-third the score of Micromedex (56.3%). These low 








scores could be explained by the fact that Medscape only managed to identify one out 
of the 3 DDI pairs (vorinostat and valproic acid), whereas Drug Digest did not 
manage to identify any of the interactions. Moreover, a quick search also showed that 
vorinostat was not in the list of drugs in Drug Digest. 
Not surprisingly, results of this study showed that all evaluators agreed that 
content accuracy was an important component of determining quality of a DDI 
database. In fact, the inter-rater agreement for this domain was the highest (W=0.79), 
which was much more than that for reliability (W=0.54). Although Micromedex 
seemed to fare the best among all the databases in terms of content accuracy, there is 
still room for improvement in the comprehensiveness of interaction information 
provided for users. Nevertheless, an average of 56.3% for the content accuracy of a 
professional subscription database has to be considered nothing more than modest, 
given its popularity and extensive use among healthcare professionals. 
Database reliability was differentiated from content accuracy in that this 
domain ascertained the level of trustworthiness of the drug databases through criteria 
such as authorship information, editorial review processes and the possible presence 
of bias. Interestingly, even though Micromedex was deemed to be the most reliable 
database based on their domain scores (73.6%), there were, in fact, 2 evaluators who 
rated Drugs.com as being more reliable than Micromedex. Their ratings could have 
been attributed to the presence of the HONcode approval seal in combination with a 
sentence which stated that the Drugs.com website “compl(ied) with the HONcode 
standard for trustworthy health information”. The reliability score of Drug Digest, 
however, was not as high as that of Drugs.com, even though it was also HONcode 
certified. The reason could probably have been due to Drugs.com displaying an 
additional “TRUSTe certified privacy” logo on its homepage in addition to its 








HONcode certification. TRUSTe is an independent organisation that ensures online 
privacy and protection of confidential user information on certified websites so as to 
instil the trust and confidence in visitors and users of these websites, such as 
Drugs.com.
240
 These auxiliary features could have served to demonstrate Drugs.com‟s 
commitment to user privacy, which was also an indicator of the reliability of a drug 
database in OncoRx-IQ, and thus could have played a role in influencing the 
responses of the evaluators. 
As part of assessing reliability, a question was also posed in OncoRx-IQ on 
whether the databases contained a disclaimer that specified that the drug information 
provided was not meant to replace the advice of a healthcare professional (Appendix 
2, Q25). Although all but one of the evaluators agreed that Drugs.com clearly 
displayed such a disclaimer, only half of them agreed that this disclaimer was clearly 
displayed in Medscape to users. The discrepancy could be attributed to the manner in 
which the databases displayed this piece of vital information to their users. Users of 
Drugs.com were required to read and agree to a set of terms and conditions, which 
includes a disclaimer, before being allowed to access the interaction checker. 
However, this disclaimer would only be shown to users if they had clicked the link on 
“Terms of Use” in Medscape. Granted that the presence of such a disclaimer may not 
be as important in institutional subscription databases (e.g. Micromedex), which are 
predominantly used by healthcare professionals, its presence in freely accessible 
online databases assumes a far greater significance. Unlike the former type of 
databases that are mainly accessed by healthcare professionals who complement their 
interpretation of the DDI content with their professional judgement, the latter online 
databases that offer free access can also be used by patients, who may alter their 








dosing regimens themselves based on the information that they find in these 
databases. 
Usability of the databases was assessed with questions on various aspects of 
user-friendliness, such as a help feature or frequently asked questions section, website 
navigation tools, as well as questions indicative of the evaluators‟ expectations on 
loading times and overall expediencies of the drug databases. This domain was 
allocated the lowest weightage in OncoRx-IQ because its scores could be affected by 
users‟ prior experiences and familiarity with the databases. One of the questions 
(Appendix 2, Q15) asked whether the databases could detect interactions with 
combination CRegs based on their acronyms, since such combination regimens are 
frequently administered in patients with cancer. Certain CRegs may consist of as 
many as 7-8 drugs, and it is not only time-consuming to search for DDIs of each 
individual drug within the regimen, but also inconvenient for clinicians who, in 
oncology practice, may have time constraints in clinic visits. If they are in a rush for 
time, they may be prone to accidental omissions of an interaction search with a 
particular ACD within the regimen when searching for multiple drug-pair interactions 
in a combination regimen, which may lead to a possibility of DRPs and adverse 
outcomes in patients. Examples of such regimens include BEACOPP (bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) 
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 and the double-delayed intensification regimen for paediatrics (vincristine, 
dexamethasone, doxorubicin, L-asparaginase, cyclophosphamide, cytarabine, 
thioguanine and methotrexate).
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 The ability of a database to detect DDIs based on 
the acronyms of the combination regimens would thereby eliminate the need to enter 
each individual drug in the regimen as an interaction search strategy. However, none 
of the databases that were evaluated in this study had such a feature, suggesting that 








this feature could potentially be useful for drug databases which cater toward clinical 
oncology practice. Nevertheless, the scores for ease-of-use were similar among the 
databases, with Micromedex achieving the highest score of 75.0% (Table 2.9). The 
high score obtained with Micromedex could have been attributed to the familiarity of 
the evaluators with this database given its prevalent use as a drug information 
resource in local hospitals, even though statistical variance was not observed 
(p=0.631). Medscape, on the other hand, obtained the lowest score (66.7%), possibly 
because the evaluators were required to register for a free account and log into 
Medscape as an additional step before being able to access the interaction checker. 
This step, however, was not a prerequisite to use the interaction checkers from 
Drugs.com and Drug Digest; hence, the hassle of spending time to register for an 
account was avoided. 
Inter-rater agreement of the overall quality of the drug databases was high 
among the evaluators (W=0.81). This was also reflected in the level of agreement for 
content accuracy (W=0.79), which was the highest among the 3 domains. In contrast, 
usability of the databases had the lowest inter-rater score (W=0.12), suggesting an 
element of subjectivity in determination of this quality component. The scores in this 
domain could have been affected by the familiarity and prior experiences of the 
evaluators with these databases, and thus they could have placed a lower emphasis for 
ease-of-use of the databases that they were already familiar with during their 
assessments. Nonetheless, the evaluation of this domain was still necessary as part of 
overall quality of a drug database, since users who are unfamiliar with the drug 
database and using it for the first time would probably place a higher emphasis in 
navigating the website and how to carry out searches for particular DDIs. 
 








2.2.3. Limitations of pilot study 
The major limitation of this study was the length of time required for each 
evaluator to assess the 4 drug databases. Evaluation of the databases was a laborious 
task, and feedback from the evaluators indicated that each person took an approximate 
45 minutes to an hour to fully complete the evaluations. This long duration could have 
caused them to be more fatigued and less meticulous in their evaluations, thus 
explaining the subtle differences in the results. It was for this same reason that this 
tool was not distributed to clinicians, since evaluating these databases would require 
them to devote almost an hour of their time and concentration on top of their busy 
schedules. Pre-registration pharmacists were recruited into the study since they were 
already practising in the clinical setting and would somewhat be also familiar with the 
area of DDIs. Nevertheless, the overall results were not adversely affected by these 
slight inaccuracies as shown from the high level of agreement observed in the 
composite scores (W=0.81). Still, clinicians‟ views are important as their clinical 
interpretations of any DDIs are of utmost value. Hence, future OncoRx-IQ studies 
should be targeted at this population group with fewer numbers of databases being 
assigned for evaluation. 
Another limitation was the use of Likert-scaled questions in the OncoRx-IQ 
tool, which inevitably imparted subjectivity in the quality assessment of the databases. 
However, evaluating the databases without these questions would result in a less 
comprehensive assessment of quality. Certain aspects of quality, such as the 
convenience of using a database and loading within an acceptable time frame, are 
more efficiently and perhaps more exhaustively, determined by subjective 
assessments of each individual user, especially if the database is unfamiliar to the 
user. In order to cater for practical quality assessments using the OncoRx-IQ tool, a 








compromise of 3 databases was decided based on the feedback of the preliminary 
review with the undergraduate students. The top 3 databases that appeared the most 
frequently in the Google search were chosen, with the assumption that these databases 
would be the most frequently encountered and utilised by users. Nonetheless, there is 
a wide variety of online DDI databases that can be considered in larger scale studies 
involving the OncoRx-IQ tool. 
 
2.2.4. The OncoRx-IQ tool for evaluating oncology drug interactions 
In summary, OncoRx-IQ is an assessment tool developed to systematically 
assess the quality and content accuracy of drug databases for ACD interaction 
information. The inspiration behind its name is because of its specificity to assess the 
“Information Quality” of drug databases for ACD interactions in oncology CReg 
prescriptions. Although assessment tools have been developed for clinical specialties, 
such as HIV,
223
 obtaining ACD interaction information from online databases still 
remains a subjective decision influenced by the clinicians‟ familiarity and experience 
with the databases.
18
 Evaluation studies have suggested that assessment tools can be 
useful as long as they possess customized criteria for evaluating domain-specific 
information.
243,244
 Thus, this tool was created to evaluate the quality of these 
databases for oncology DDIs in relation to 3 domains. 
Besides assessing the overall quality features of a drug database, such as its 
reliability and usability, this tool additionally evaluates the databases for accuracy of 
their DDI information. Although a direct correlation between good quality online drug 
information and positive treatment outcomes has yet to be established in large-scale 
studies, it is the author‟s belief that accurate and good quality DDI information has a 
pivotal role to play in aiding healthcare professionals make sound clinical decisions 








by facilitating safe and efficacious use of anticancer agents. Thus, this tool has been 
developed in an effort to increase the awareness of healthcare professionals and 
patients alike regarding the quality of online ACD interaction information and also lay 
the groundwork for the long-term evaluation of such DDI information. Needless to 
say, the evaluation of DDI information should be time-dependent, and the interaction 
profiles should also be individualised to include the most current information based 
on published literature. Nevertheless, it is hoped that OncoRx-IQ will not only be a 
useful quality assessment tool for oncology clinicians to evaluate online ACD 
interaction information, but also an educational tool for students in the oncology, 
medical and allied-health fields on the wide-ranging quality of online DDI 
information available. 
 
2.3. Quality considerations for developers of pharmacoinformatics tools 
The results of the studies that were previously described demonstrate a need 
for accurate DDI information that is easily accessible to both healthcare professionals 
and patients. The opportunity of integrating pharmacoinformatics as an aid to solve 
DRPs in the clinical practice setting is indeed appealing. However, certain design 
aspects must be taken into consideration by developers of pharmacoinformatics tools, 
so that it is clinically-relevant in healthcare practice. Table 2.10 shows the “Four 
Pharmaco-cybernetic Maxims” that should be applied to any tool or product that is 
designed for the purpose of providing drug information.
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 Adapted from the 
principles originally identified by Weir and Heeps for designing animation tools,
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developers of pharmacoinformatics applications are encouraged to follow these 
maxims in terms of quality and quantity of drug information, relation to target 
audiences, and the manner of data presentation.  









Table 2.10. The “Four Pharmaco-cybernetic Maxims” for designing 




Explanation of principle with regards to designing tools for 
pharmacy and/or the pharmaceutical sciences 
Quality 
The content of the drug information provided by the created 
informatics or internet tool(s) should be accurate and follow the 
appropriate resources for evidence-based therapies (e.g. research 
articles, established databases or product information from package 
inserts). 
Quantity 
Adequate information about the drug or drug therapy is provided so 
that users of the tool know enough about the therapy to minimise the 
likelihood of drug-related problems (e.g. underdose, overdose, drug 
interactions). 
Relation 
Drug information provided by the tool(s) is/are relevant to what the 
target audience needs to know, and should clarify their doubts 
instead of making them more confused. 
Manner 
Drug information provided by the tool(s) is/are conveyed clearly in 
an appropriate manner which avoids ambiguity and misinterpretation 






















Designing a pharmacoinformatics platform for oncology drug interactions on the 
World Wide Web – an overview of OncoRx 
The author designed OncoRx, an online oncology database, with the aim of 
reducing the incidence and harmful effects of DDIs that are relevant to ACDs. It was 
set up on the 8
th
 July 2007 and is accessible through the website www.onco-
informatics.com. OncoRx is developed in modular format, and is currently able to 
detect interactions with psychotropic agents (PSYs) and CAMs.  
 
3.1. Methodology of creating the OncoRx database 
In order to understand how a DDI search query is handled by OncoRx, a 
summary of how the data flows through server side technology when a user searches 
for a drug interaction is described below (Figure 3.1).  
 
 
Figure 3.1. Steps of a server round trip, showing how data flows through server side 
technology when a drug interaction (DDI) search query is performed. 
 








When a browser is launched and the user sends a request for a URL, such as 
the Onco-informatics website (www.onco-informatics.com), the gateway passes the 
request to the web server via the standard http-protocol, and the request is handled by 
the server as it would a normal request for a web page. However, if the URL refers to 
an action (e.g. searching for a DDI), the scripts, such as the hypertext preprocessor 
(PHP) in this case, will first be processed by the server side page. The DDI search 
query will then be handled, the output formatted, and the result returned to the 
gateway as a new hypertext markup language (HTML) web page, which is passed 
back to the browser. The processing logic resides in the internet server, and the whole 
process involving this request (i.e. DDI search) and response (i.e. results of the 
detected DDI) is known as a server round trip. 
The creation of OncoRx involves 3 main steps: (a) collation and compilation 
of drug, CReg and interaction information from published literature sources, (b) 
creation of the database and graphical user interface, and (c) mounting of the database 
and web documents on the internet cloud. The next few sections describe these steps 
in detail. A flowchart illustrating the process of creating OncoRx is also shown in 
Figure 3.2.  










Figure 3.2. Flowchart showing the process of creating the OncoRx database. 
 
 
3.1.1. Collation and compilation of information on anticancer drugs, 
chemotherapy regimens, psychotropic agents, and complementary and 
alternative medicines 
Drug information on ACDs, psychotropic agents, and DDIs were collated 
from a variety of hardcopy and online resources, which included drug manuals, 
textbooks, monographs and databases. Manuals, textbooks and monographs that were 
utilised were the American Hospital Formulary Service (AHFS) Drug Information 
(2007 ed.) 
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, British Columbia Cancer Agency (BCCA) Cancer Drug Manual,
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 Drug Interaction Facts (2008 ed.),
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 Hansten 
and Horn‟s Drug Interactions Analysis and Management (3rd ed.),250 Lexi-Comp‟s 






















Micromedex Healthcare Series (v5.1),
255
 and Up To Date (v16.2).
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 Interaction 














 Physician‟s Desktop Reference (PDRhealth),263 and Medscape.264 In 
addition, information was acquired from the package inserts of the various ACDs and 
psychotropics. Data on the characteristics and clinical uses of CAMs and their 























 Alternative therapies 
(e.g. Ayurveda), substances with limited documentation on their medicinal properties 
(e.g. alkaline water), vitamins and minerals, and commercial supplements (e.g. 
Centrum) were excluded. Literature searches on DDIs were carried out in PubMed, 
Scopus and Science Direct based on a combination of the keywords “anticancer 
drugs”, “antineoplastic drugs”, “chemotherapy”, “chemotherapy regimens”, 
“complementary and alternative medicines”, “drug-drug interactions”, “drug-herb 
interactions”, the generic names of the individual ACDs and psychotropic agents, 
pharmacological categories of the psychotropics, as well as common and scientific 
names of the CAMs. 
Information on single-agent and multiple-agent CRegs that are positively 
evaluated in Phase II or III trials and published in English-language journals, or 
regimens approved by the FDA, were also collated with substantiating references in 
scientific literature, using the keywords “anticancer drugs”, “chemotherapy regimens” 








and the generic names of the ACDs. Due to the varying doses and frequencies of 
administering the chemotherapy combinations among institutions, these parameters 
were not included in the database. 
Compiled drug-related information included the generic names and indexed 
terms of the drugs, their pharmacological categories, mechanisms of action, and 
pharmacokinetic properties, such as percentages of bound protein, metabolism and 
elimination routes, and enzymatic parameters. CAM-related information included 
their common and scientific names, active constituents, uses in cancer, 
pharmacokinetic properties and TCM principles (e.g. hot-cold nature, nourishing 
properties and flavours). Chemotherapy-related information included the acronyms of 
the CRegs, drugs used in the regimens, the types of cancers they treat, and 
substantiating references.  
On the other hand, interaction-related information consisted of the interaction 
effects, interaction mechanisms, substantiating evidences and references, as well as 
proposed management plans. DDI literature was collated from 1970 to 2009, and 
included in-vitro studies, animal models, human case reports, clinical studies, and 
other relevant abstracts and review articles that were published in English. When the 
DDI documented in various resources was found to be different, this information 
would be collated together with the appropriate substantiating evidences and reference 
citations. 
 
3.1.2. Creation of database and graphical user interface 
The compiled data was distributed into interrelated tables in Microsoft Excel. 
The programme structure of the search interface was designed around the generic 
names of the ACDs, as well as combination CRegs. The database could search for 








specific ACDs, or ACDs in a CReg based on its acronym. A Structured Query 
Language (SQL), known as MySQL, was then used to create a MySQL 5.0 database 
and store the data based on the structure of the Excel tables. An example of the 
scripting layer is shown in Figure 3.3. 
 
Figure 3.3. Scripts for table creation and data input into a MySQL database. 
 
 Web documents were created using Adobe Dreamweaver CS4 (Adobe 
Systems Incorporated, San Jose, California), and were associated with a combination 
of HTML, extensible HTML and javascripts. Cascading style sheets were used to 
provide a consistent look for the website. The web documents were served from a 
web server associated with a Multi-Purpose Internet Mail Extension type, so that the 
browser could determine how the file should be processed, for example, handled by a 
helper application or rendered as a HTML file. An example of the code used to create 
a HTML document is shown in Figure 3.4. 










Figure 3.4. Example of the code used to create a HTML web document. 
 
 The graphical user interfaces were created using various elements, such as 
forms, drop-down menus and lists. XAMPP (version 2.5.8, Apache Friends) and 
Filezilla (version 3.3.4.1, SourceForge.net) software programmes were used to upload 
the documents onto the server. The collated data on ACDs, psychotropics, CAMs and 
their interactions were transferred from the Microsoft Excel tables into the MySQL 
database using SQL Manager 2007 for MySQL (version 4.4, EMS Database 
Management Solutions). 
 
3.1.3. Mounting of database on the internet cloud  
The OncoRx database was programmed with the server-side scripting 
language PHP5 running as a common gateway interface application. A domain was 
bought from the DreamHost
TM
 web hosting company,
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 which used an Apache 2.0 








web server installed on a Debian Linux server. phpMyAdmin 2.11.2.1, an open source 
tool written in PHP, was used to handle MySQL administration over the web. PHP is 
a scripting language designed to be embedded in HTML, and a common gateway 
interface enables the client web browser to request data from the web server. Database 
queries were handled through SQL access to the database, and the contents of the 
database were returned to the client‟s browser. The choice of scripting language was 
somewhat arbitrary. Languages such as Active Server Pages and Perl are the more 
popular ones. However, PHP is gaining recognition due to its ease of implementation, 
thus it was used in this project. An example of a PHP script which connects to the 




Figure 3.5. Example of the code used to connect to the server and select the OncoRx 
database. 
 








3.2. User search strategies for interactions in OncoRx  
The structure of OncoRx is designed around ACDs and CRegs. Its graphical 
user interface is designed for easy navigation and searching of DDIs and instructions 
on how to search for a DDI are also provided above the search box. Users can search 
for DDIs with psychotropic agents and CAMs from 2 search interfaces – generic drug 
names of the ACDs or CRegs combinations. In the sections that follow, examples of 
various interactions will be described to illustrate how users can carry out DDI 
searches. Detailed lists of the anticancer and psychotropic drugs, regimens and CAMs 
in the OncoRx database, as well as their interactions are provided in Appendices 3 
and 4 respectively. 
 
3.2.1. Search strategy using generic anticancer drug names  
When a user searches for a DDI by the generic name of the ACD, for example 
between doxorubicin and valproic acid, the relevant data will be extracted from the 
database and the results displayed for the user. The information is presented in tabular 
format and consists of 3 parts: the pharmacokinetic parameters of the ACD and the 
psychotropic drug, which is an AED in this case, and parameters of the detected DDI 
(Figure 3.6).  
The generic names of the user choice of ACD and AED are displayed at the 
top of the results page, together with other indexed terms of the drugs. 
Pharmacokinetic data include the absorption, protein-binding information, 
metabolism and elimination routes of the drugs, as well as enzymatic parameters such 
as substrate, inducer and/or inhibitor information. In addition, the pharmacological 
category of the ACD, its indication in cancer therapy, and mechanism of action are 
also shown to users. The last section of the results page provides the DDI effects, 








severities and/or risks, mechanisms of interaction, substantiating evidences, and 
proposed management plans where appropriate. In the given example, a decrease in 
plasma valproic acid concentrations is expected, which may lead to decreased 
effectiveness of the AED and possible loss of seizure control.
232
 The clinician should 
monitor the patient for seizure control when using these 2 drugs concurrently, or 
consider an alternative AED. Other AEDs in which an interaction with the ACD is not 
identified are listed as well. 
 
 
Figure 3.6. Screenshots of the interaction search between doxorubicin and valproic 
acid. (a) Users select the anticancer and antiepileptic drugs from the scroll-down 
menu and pull-down list. (b) Results of the search, showing the pharmacokinetics of 
the drugs, as well as the parameters of the detected interaction. 
(a) 
(b) 









Additional information that is provided to users if they search for an 
interaction with a CAM include the common, scientific and pinyin names of the 
CAMs, their uses in cancer and supportive care therapies, mechanisms of actions, 
pharmacokinetic data and data on adverse reactions, unless there is no documented 
data available (Figure 3.7). Furthermore, the active constituents and other 
characteristics related to TCM principles, such as their hot-cold nature, nourishing 
properties (e.g. nourishing yin, yang, qi, or blood) and flavours (e.g. sweet, sour, 
pungent, salty, or bitter) are also shown. In this example, American ginseng, also 
known as Panax quinquefolius, is used for cancer prevention and treatment, or 
immunostimulation. It has a sweet, yet slightly bitter property, and its active 







Figure 3.7. Screenshot of the results showing the characteristics of the 
complementary and alternative medicine, with American ginseng as example. 
 









3.2.2. Search strategy using acronyms of chemotherapy regimens  
Clinician users can also search for DDIs of combination CRegs. A section 
providing information on the regimen will be displayed, showing the acronym and 
type of regimen, the type of cancer in which it can be used, the drugs in the regimen, 
as well as substantiating references for the use of the CReg for that particular cancer 
type. The example of the regimen AC, consisting of doxorubicin and 
cyclophosphamide, used for the treatment of breast cancer,
273,274
 and its interaction 
with fluvoxamine (an antidepressant) is given in Figure 3.8. The interaction details of 
each drug in the regimen are also provided together with an overall management plan 
for the DDI with the CReg. As shown, increases in plasma concentrations of 
doxorubicin and cyclophosphamide are expected due to inhibition of CYP3A4-
mediated metabolism of the ACDs.
275-277
 This DDI is substantiated with a case report 
of 2 patients who experienced three- and four-fold increases in mirtazapine 
concentrations during co-administration with fluvoxamine due to CYP450 isozyme 
inhibition.
277
 Clinical and laboratory monitoring of plasma ACD levels is advised 
during concurrent administration of AC with fluvoxamine, and dosage adjustments of 
the ACDs may also be needed. Alternative non-interacting antidepressants are also 
provided.  










Figure 3.8. Screenshots of the results of an interaction search between the regimen 
AC and fluvoxamine, showing information about the chemotherapy regimen, 
interaction details of each anticancer drug in the regimen, and an overall proposed 
management plan for the interaction. 
 
3.3. Hierarchical development of the OncoRx search engine 
The search engine of OncoRx was developed in a hierarchical format so that 
users can narrow down their searches for DDIs with ACDs or CRegs (Figure 3.9). 
When users carry out an interaction search, they will begin by either searching for an 
ACD interaction or an interaction with a CReg. This is done by clicking on the links 
of collapsible menus coded in javascript. They can then narrow their searches by 
selecting the interacting agent from either drugs used in CNS-related disorders, or 
CAMs. Although the option is provided for the user to search for DDIs based on all 
psychotropic drugs or all CAMs, OncoRx also provides a further breakdown of these 
modules by allowing users to search based on their specific indications and uses. The 








psychotropic drugs are categorised into 4 classes: CNS stimulants and attention-
deficit hyperactivity disorder (ADHD), depression, epilepsy, and substance 
dependence. Similarly, the CAMs are categorised into 8 classes: alopecia, cancer 
prevention and treatment, fatigue, immune-system-related, inflammation, nausea and 
vomiting, pain and neuropathy, and non-cancer-related. 
To allow for easy searching of regimens by oncology practitioners with 
various specialisations (e.g. breast and gynaecologic cancers, gastrointestinal and 
colorectal cancers, CNS and brain cancers), as well as other clinician users who may 
otherwise be unfamiliar with the CRegs, OncoRx provides an additional option to 
narrow the CReg searches by cancer types. There are 15 categories of CRegs that 
users can choose from (Figure 3.9). Furthermore, regimens for the treatment of 
paediatric cancers are also categorised as a separate class on its own for clinicians 
who encounter this subgroup of patients in their practices. This hierarchical structure 
of the OncoRx search engine makes the database more user-friendly, since it allows 
clinicians to narrow their regimen searches to those that are only relevant to the 
patients whom they encounter. 










Figure 3.9. Hierarchical system development of the OncoRx search engine. 
 
3.4. Database statistics  
The OncoRx database consists of 117 ACDs, which make up 256 single-agent 
and multiple-agent combination regimens. This database covers all the major ACDs 
and their frequently prescribed CReg combinations used in the treatment of patients 
with cancer, and it focuses primarily on pharmacokinetic and pharmacodynamic 
interactions. Leukaemias (16.8%), lymphomas and myelomas (16.0%) have the 
largest number of regimens, while CNS and brain cancers (5.1%) and bone and tissue 
cancers (4.7%) have the lowest numbers of regimens. Table 3.1 shows a breakdown 
of the classifications of ACDs based on their pharmacological categories and the 
CRegs based on the types of cancers they treat.  
 








Table 3.1. Statistics of anticancer drugs and chemotherapy regimens in the OncoRx 
database. 
 
Pharmacological categories of anticancer drugs 




Alkylating agents 15 (12.8) 
Antimetabolites 15 (12.8) 
Antimicrotubules 7 (6.0) 
Biological modifiers 7 (6.0) 
Corticosteroids 5 (4.3) 
Hormone agonists / antagonists 19 (16.2) 
Platinum compounds 3 (2.6) 
Topoisomerase inhibitors 9 (7.7) 
Tyrosine kinase inhibitors and monoclonal antibodies 16 (13.7) 
Other categories of anticancer drugs 21 (17.9) 
Chemotherapy regimens by types of cancers 
Number of regimens 
in the category (%)
+
 
Bone and tissue cancers 12 (4.7) 
Breast cancers 36 (14.1) 
Central nervous system and brain cancers 13 (5.1) 
Gastrointestinal, colorectal, liver and pancreatic cancers 24 (9.4) 
Genitourinary cancers 30 (11.7) 
Leukaemias 43 (16.8) 
Lung cancers 25 (9.8) 
Lymphomas and myelomas 41 (16.0) 
Other types of cancers 32 (12.5) 
+
 Percentages may not add to 100% due to rounding of data.  
 
OncoRx can currently detect DDIs with 2 different modules: the “PSY” and 
“CAM” modules. The PSY module comprises of 51 psychotropic agents classified 
into 4 categories based on their pharmacotherapeutic indications (Table 3.2). 
Antiepileptics and antidepressants make up the majority of the PSY module in the 
database (over 90%), while the CNS stimulants and drugs for ADHD, and substance 
dependence make up 3.9% and 7.8% respectively. On the other hand, the CAM 
module comprises of 166 CAMs categorised based on their uses in cancer therapy. 








Much of the focus in this module has been on TCMs, and the detailed list of 
psychotropic drugs and CAMs in the database are also provided in Appendix 3. 
CAMs for cancer treatment and prevention (39.8%), inflammation (23.5%), and 
immune-system-related (12.0%), make up the highest proportions of this module. In 
contrast, fatigue syndrome (3.0%), alopecia (1.8%), and nausea and vomiting (1.2%) 
have the lowest proportions of CAMs. In addition, over a third of the CAMs in the 
OncoRx database are for non-cancer-related purposes as well. 
 
Table 3.2. Statistics of psychotropic agents and complementary and alternative 
medicines in the OncoRx database. 
 
Pharmacotherapeutic indications of psychotropic agents 




Agents for depression 21 (41.2) 
Agents for epilepsy 26 (51.0) 
Central nervous system stimulants and agents for attention-
deficit hyperactivity disorder 
2 (3.9) 
Substance dependence agents 4 (7.8) 
Uses of CAMs 




Alopecia 3 (1.8) 
Cancer treatment and prevention 66 (39.8) 
Fatigue syndrome 5 (3.0) 
Immune-system-related 20 (12.0) 
Inflammation 39 (23.5) 
Nausea and vomiting 2 (1.2) 
Peripheral neuropathy and pain 15 (9.0) 
Non-cancer-related 64 (38.6) 
+
 Percentages may not add to 100% due to rounding of data and inclusion of agents 
into multiple categories based on their indications and uses.  












3.4.1. Interaction statistics with psychotropic agents 
A total of 737 and 4800 drug-pair interactions were identified between ACDs 
and CRegs with psychotropics respectively, which translated to over 520 interacting 
CReg-PSY pairs (Table 3.3).  
 

























24 out of 26 21 out of 21 4 out of 4 2 out of 2 49 out of 51 
Interactions with anticancer drugs 
Proportion of 
PK DDIs (%) 
82.5 37.0 16.9 25.0 60.0 
Proportion of 
PD DDIs (%) 
17.5 63.0 83.1 75.0 40.0 
Total number 
(%) of DDIs 
416 (54.6) 273 (35.8) 65 (8.5) 8 (1.0) 737 
Interactions with chemotherapy regimens 
Proportion of 
PK DDIs (%) 
88.7 49.7 22.9 6.7 69.2 
Proportion of 
PD DDIs (%) 










230 (34.2) 200 (29.8) 206 (30.7) 36 (5.4) 521 
+
 Numbers may not add up due to some psychotropics in multiple classes. 
ACD: anticancer drug, ADHD: attention-deficit hyperactivity disorder, CNS: central 
nervous system, CReg: chemotherapy regimen, DDI: drug-drug interaction, PK: 
pharmacokinetic, PD: pharmacodynamic, PSY: psychotropic agent 
 








The drugs in all the psychotropic classes had interactions with ACDs, except 
for the AEDs, where no interactions were identified for piracetam and vigabatrin. In 
general, the majority of the DDIs with ACDs and CRegs were pharmacokinetic in 
nature (60.0-69.2%), with the highest proportion occurring with AEDs (82.5-88.7%). 
Not surprisingly, the AEDs also had higher overall numbers of total interactions with 
both ACDs and CRegs. In contrast, the other psychotropics had more 
pharmacodynamic interactions, with substance dependence agents (77.1-83.1%) and 
CNS stimulants and ADHD drugs (75.0-93.3%) having higher proportions than 
antidepressants (50.3-63.0%). However, this inflation in proportions could be due to 
the lower numbers of drugs in the former 2 psychotropic classes. Nonetheless, a 
substantial amount of pharmacodynamic interactions also occur with drugs in the PSY 
class (30.8-40.0%), and caution is advised when extrapolating these interactions to 
other agents of this class. 
Among the pharmacokinetic interactions, induction of the CYP450 isoenzyme 
system was the most significant, explaining more than one-third of the interactions 
with ACDs and CRegs (Table 3.4). In contrast, enzyme inhibition only explained 
about one-fifth of the psychotropic interactions. The higher proportions of enzyme 
induction activity are probably due to the fact that over half of the DDIs occurred with 
the AEDs, which are mainly inducers, rather than inhibitors, of the CYP450 isozymes. 
In general, the AEDs have more prominent enzyme-induction effects than inhibition 
effects. The older generation AEDs such as carbamazepine, phenytoin, phenobarbital 
and primidone are strong inducers of most of the isoenzymes, while valproic acid is 
predominantly enzyme-inhibiting. On the other hand, the enzyme-inhibiting effects of 
the other psychotropic classes are more evident, with the highest proportions observed 
with antidepressants (33.7% with ACDs, 46.5% with CRegs). Lower proportions of 








other pharmacokinetic interactions that occurred between the psychotropics with 
ACDs and CRegs included altered bioavailabilities of the drugs, protein displacement 
reactions, and altered volumes of distribution and/or eliminations. 
 
Table 3.4. Types and proportions of interactions between anticancer drugs and 
chemotherapy regimens with psychotropic agents. 
 















Altered bioavailability and/or protein displacement 3.8 8.3 
Altered volume of distribution and/or elimination 1.0 6.4 
Induction of metabolism / CYP isozymes (1A2, 
2B6, 2C8/9/10, 3A4/5) 
34.3 34.5 
Inhibition of metabolism / CYP isozymes (1A2, 
2B6, 2C8/9/19, 2D6, 3A4) and/or PGP 
20.3 20.0 
Pharmacodynamic interactions 
Cardiotoxicity, QT prolongation and torsades de 
pointes 
11.4 9.5 
CNS / respiratory effects (e.g. depression, mood 
problems, sedation, seizures) 
9.0 4.5 
CNS toxicity (e.g. peripheral neuropathy) and 
serotonin syndrome 
4.7 5.7 
Haematological effects (e.g. altered platelet 
function, anaemia, leucopoenia, neutropenia, 
thrombocytopenia, gastrointestinal bleeding) 
7.2 2.3 
Hepatotoxicity 7.3 7.1 
Other pharmacodynamic effects 0.9 1.5 
+ 
Percentages may not add up to 100% due to rounding of data. 
ACD: anticancer drug, CReg: chemotherapy regimen, CNS: central nervous system, 
CYP: cytochrome P450, PGP: p-glycoprotein, PSY: psychotropic agent 
 
Pharmacodynamic interactions that were most frequently observed with the 
psychotropics were increased risks of cardiotoxicity, QT prolongation and torsades de 
pointes (9.5-11.4%). The antidepressants accounted for majority of the cardiotoxic 








effects (30.3-30.8%), while the substance dependence agents, CNS stimulants and 
ADHD drugs did not account for this effect at all. Increased risks of hepatotoxicity 
(7.1-7.3%); and CNS/respiratory effects, such as CNS/respiratory depression, mood 
disorders, sedation and occurrence of seizures (4.5-9.0%); were also observed among 
the DDIs. On the contrary, CNS toxicity and serotonin syndrome (4.7-5.7%), and 
haematological effects accounted for only a small percentage (2.3-7.2%) of the DDIs. 
CNS toxicity included increased risks for peripheral neuropathy, while 
haematological effects included the presence of altered platelet function, anaemia, 
leucopoenia, neutropenia, thrombocytopenia, as well as induction of gastrointestinal 
bleeding. 
 
3.4.2. Interaction statistics with complementary and alternative medicines  
The numbers of ACD-CAM and CReg-CAM interactions in the database were 
584 and 2750 respectively, with the latter making up a total of 4408 drug-CAM 
interacting pairs (Table 3.5). Generally, the proportion of pharmacokinetic 
interactions (75.9-79.1%) was higher than that of pharmacodynamic interactions 
(20.9-24.1%), with CAMs for nausea and vomiting (90.5-98.0%) having the highest 
proportions of pharmacokinetic HDIs among all the cancer-related CAMs. The non-
cancer-related CAMs had almost similar proportions of pharmacokinetic HDIs (88.7-
95.7%). In contrast, only one CAM for alopecia (fenugreek) had HDIs with ACDs, 
and these HDIs were fully pharmacodynamic in nature. Among all the CAMs used for 
cancer-related uses, not surprisingly, those for cancer treatment and prevention had 
the highest amounts of HDIs (38.9-39.0%), followed by those for inflammation (17.6-







































18 out of 66 1 out of 3 5 out of 5 7 out of 20 7 out of 39 2 out of 2 5 out of 15 3 out of 64  29 out of 166  
Interactions with anticancer drugs 
Proportion of PK 
HDIs (%) 
69.7 0.0 65.3 69.3 65.3 90.5 76.2 95.7 75.9 
Proportion of PD 
HDIs (%) 
30.3 100.0 34.7 30.7 34.7 9.5 23.8 4.3 24.1 
Total number (%) 
of HDIs 
356 (39.0) 4 (0.4) 62 (6.8) 101 (11.1) 163 (17.9) 42 (4.6) 103 (11.3) 82 (9.0) 584 
Interactions with chemotherapy regimens 
Proportion of PK 
HDIs (%) 
73.2 0.0 66.9 67.9 68.9 98.0 84.3 88.7 79.1 
Proportion of PD 
HDIs (%) 
26.8 100.0 33.1 32.1 31.1 2.0 15.7 11.3 20.9 
Total number (%) 
of ACD-CAM 
HDIs 
2684 (38.9) 6 (0.1) 447 (6.5) 826 (12.0) 1212 (17.6) 296 (4.3) 690 (10.0) 732 (10.6) 4408 
Total number (%) 
of interacting 
CReg-CAM pairs 
1692 (39.0) 5 (0.1) 306 (7.1) 550 (12.7) 730 (16.8) 178 (4.1) 418 (9.6) 456 (10.5) 2750 
ACD: anticancer drug, CAM: complementary and alternative medicine, CReg: chemotherapy regimen, HDI: herb-drug interaction, PK: pharmacokinetic, PD: 
pharmacodynamic 








Inhibition of CYP450-mediated metabolism was the most common interaction 
among the ACDs and CAMs, accounting for more than half of the interactions (Table 
3.6). On the other hand, the proportion of CYP450 isozymes and p-glycoprotein 
induction was approximately half of that due to CYP450 inhibition. Hepatotoxicity 
was the most commonly observed pharmacodynamic HDI among CAM interactions 
with ACDs and CRegs (8.2-10.4%), especially among those for inflammation and 
cancer treatment and prevention. Altered immunomodulatory effects accounted for 
~6.0% of the HDIs and these effects mainly occurred during co-administration with 
corticosteroids, leading to altered efficacies of the drugs. A small proportion of HDI 
effects were also due to haematological effects (1.1-3.9%), which generally resulted 
in increased risks of bleeding. Interestingly, rituximab-induced hypoglycaemia was 
also identified as a HDI that was not detected with the psychotropics. The least 
common HDIs that occurred with CAMs were increased risks of CNS effects (0.5-
0.7%), such as sedation, CNS depression, peripheral neuropathy, paraesthesias and 



















Table 3.6. Types and proportions of interactions between anticancer drugs and 
chemotherapy regimens with complementary and alternative medicines. 
 














Pharmacokinetic interactions   
Induction of metabolism / CYP isozymes (2B, 
2C9/19, 2D6, 3A4) and/or PGP 
23.4 23.9 
Inhibition of metabolism / CYP isozymes (1A2, 
2B6, 2C9/19, 2D6, 2E1, 3A4) 
52.5 55.2 
Pharmacodynamic interactions   
Altered immunomodulatory effects 6.0 6.2 
CNS effects (sedation, CNS depression, peripheral 
neuropathy, paraesthesias, serotonin syndrome) 
0.5 0.7 
Haematological effects (hypertensive crisis, anti-
platelet, anti-coagulation) 
3.9 1.1 
Hepatotoxicity 10.4 8.2 
Hypoglycaemia 1.4 0.7 
Skin reactions 0.7 0.05 
Other pharmacodynamic effects 1.4 3.9 
+ 
Percentages may not add up to 100% due to rounding of data. 
ACD: anticancer drug, CAM: complementary and alternative medicine, CReg: 
chemotherapy regimen, CNS: central nervous system, CYP: cytochrome P450, PGP: 
p-glycoprotein 
 
3.5. Version for handheld devices – the OncoRx-MI application  
The advent of 3
rd
 generation (3G) networks and mobile handheld devices (e.g. 
smartphones) has enabled numerous healthcare applications to be developed. 
Epocrates Rx 
278
 and Lexi-Comp ON-HAND 
279
 are examples of popular drug 
reference guides available as applications on smartphones, such as the iPhone and 
BlackBerry. Although drug information databases on mobile devices tend to be less 
comprehensive in terms of completeness and scope compared to their online 
counterparts 
20,21
, the use of such mobile applications among healthcare professionals 
will nevertheless continue to grow as there is a need for these applications in the 










. Many drug databases, such as those mentioned above, allow for 
DDI searches among individual drugs. However, from the author‟s knowledge, there 
is currently no application that has been designed to identify DDIs of CReg 
prescriptions. A mobile application which draws on the utility of 3G and Wireless 
Fidelity (Wi-Fi) networks will be useful to healthcare professionals in both the 
hospital and clinic settings, who may need to check for DDIs “on-the-spot” during 
patient consultations. Thus, a novel database application that allows the identification 
of interactions with CRegs, called OncoRx-MI for the “Mobile Internet”, was 
developed as an extension to the OncoRx database. The iPhone was used as a 
prototype for development, since there is a demand from clinicians for healthcare 




3.5.1. Features of OncoRx-MI  
The OncoRx-MI application is the first of its kind that allows users to search 
for DDIs of CRegs on smartphones. It is coupled to its parent online database and is 
located at www.onco-informatics.com/OncoRxMI. It can be accessed using the 
iPhone via 3G or Wi-Fi connection. Users can search for interactions from the iPhone 
Safari browser. The relevant information is extracted from the database and presented 
on the results page, which consists of 4 sections: information about the selected CReg, 
pharmacokinetic profiles of the ACDs in the CReg, information about the selected 
psychotropic agent or CAM, as well as data on the detected interaction (Figure 3.10). 










Figure 3.10. Example of an interaction search in OncoRx-MI. 
 
OncoRx-MI is different from its online parent version (OncoRx) on the WWW. 
The interface of the OncoRx database is geared towards the larger display sizes and 
resolutions of desktops, laptops and netbooks. However, OncoRx-MI caters towards 
the smaller resolutions of mobile devices and its interface has been modified to allow 
better usability for iPhone users. In essence, the data in OncoRx-MI is organised in 
longitudinal format, so that users can scroll in an up-down fashion instead of panning 
sideways to read the DDI information. In addition, users do not need to frequently 
zoom in and out of the iPhone screen to read the DDI content.  
The OncoRx-MI application is based upon the adoption of the “Four Pharmaco-
cybernetic Maxims” previously described for the development of 
pharmacoinformatics tools (quality, quantity, relation to target audiences, and manner 
of data presentation).
157,245
 This application provides adequate clinically-relevant DDI 
information to clinician users so that they have sufficient knowledge to manage the 








interaction, and is also designed to fit the usability of mobile phones. A web-clip icon 
providing a shortcut to the OncoRx-MI database has also been created to cater for 
improved usability and easy access by iPhone clinician users who are always on-the-
go (Figure 3.11). Emphasis has been placed on reducing the screen resolution of 
OncoRx-MI to one that is optimal for mobile web browsing on the iPhone (320x480 
pixels) without compromising in terms of drug- and interaction-related content. By 
leveraging on the use of 3G networks via mobile devices, the DDI content obtained 
by mobile users is exactly of the same quality as that acquired using the parent online 
version. This is because both the mobile and online versions retrieve information from 




Figure 3.11. Web-clip icon providing a shortcut to OncoRx-MI on the iPhone. 
 
 









Relevance and potential of OncoRx and OncoRx-MI in clinical practice 
4.1. Certification of the database 
As the target audiences of the OncoRx database are mainly healthcare 
professionals, it is mandatory to show its users that the Onco-informatics website, 
which includes the OncoRx database and OncoRx-MI application, is committed to 
providing trustworthy drug-related information. Hence, certification of the website‟s 
quality was obtained from the Health On the Net (HON) Foundation. Despite a few 
shortcomings with regards to the lack of certain quality indicators (previously 
described in Table 2.6), the HON Foundation and the HON Code of Conduct, 
otherwise known as the HONcode, is perhaps one of the oldest and most widely 
recognised third-party quality evaluators in the healthcare world. This non-profit 
organisation accredited to the Economic and Social Council of the United Nations 
was first launched in July 1996, and it provides a voluntary certification system that is 
based on an “active quality seal” concept to show that health-related websites comply 
with 8 HONcode principles, and that the information provided to the public is useful, 
reliable and up to the appropriate ethical standards.
230,282,283
 
The Onco-informatics website has been certified to be compliant to the 
HONcode since August 2009. The HONcode quality seal on the website indicates that 
the OncoRx database provides objective and reliable drug information to its users 
(Figure 4.1). In fact, this website is listed in MedHunt, the medical search engine of 
the HON Foundation, as one of the 13 health-related websites in Singapore that is 
HONcode certified as of July 2010.
282
 As a guide, Table 4.1 also shows a summary of 
the HONcode principles and how the Onco-informatics website complies with these 
principles. 











Figure 4.1. HONcode certification of the Onco-informatics website showing (a) the 
HONcode quality seal of approval on the website, and (b) its listing in the MedHunt 
search engine. 
 








Table 4.1. The 8 HONcode principles and how the Onco-informatics website 




Descriptions of principles How the Onco-informatics website 
complies with the principles 
Authoritative Author(s) qualifications 
are indicated 
 Authors‟ names and credentials 
are clearly listed 
 Drug information is not attributed 
to the authors but from evidence-
based sources 
Complementarity Information should 
support, not replace, the 
doctor-patient relationship 
 Disclaimer is provided to declare 
that information is not meant to 
replace a healthcare professional‟s 
advice 
 The intended objectives of the 
website and its target audiences 
are clearly stated 
Privacy Privacy and confidentiality 
of visitors‟ personal data 
should be respected 
 A privacy policy is provided as 
part of the terms and conditions of 
website use 
Attribution Source(s) of information 
and last modification date 
of the website should be 
clearly displayed  
 Drug information is referenced to 
published references with a 
hyperlink where appropriate 
 Date of last modification of all the 
webpages are provided 
 
Justifiability Claims relating to benefits 
/ performance of a 
treatment, product or 
service must be supported 
by appropriate evidence 
 Claims relating to the drugs and 
complementary and alternative 
medicines are supported by clear 
references to scientific literature 
 
Transparency Information is displayed in 
the clearest possible 
manner and an accurate 
email contact should be 
displayed clearly  
 A valid email address of the 
webmaster is provided throughout 
the site 
 A feedback form is provided and 




Funding sources should be 
clearly identified 
 Funding from a non-commercial 




Content from advertising 
should be clearly 
distinguished from 
editorial content 
 A clear statement explaining that 
the website does not host or 
accept advertisements is provided 
 









4.2. Advantages of the database 
From the author‟s knowledge, there is currently no oncology-specific database 
that allows for drug interaction searches by both individual ACDs and multiple-agent 







 and the BCCA cancer drug manual 
52
 provide useful information on ACDs 
and cancer therapies, they do not specifically target chemotherapy interactions. 
OncoRx is the first database of its kind where practitioners can search for DDIs of 
combination CRegs by their acronyms. This database not only saves time and effort 
on the part of healthcare professionals in searching for chemotherapy interactions 
“on-the-spot” as and when they encounter such DDIs in their practice, but is also 
practical since patients with cancer are often on combination CRegs in which the 
individual drugs within the CReg are usually standard. The OncoRx-MI application 
further substantiates this advantage by drawing on the popularity of mobile handheld 
devices and the widespread availability of 3G and Wi-Fi networks to deliver the DDI 
content to healthcare professionals in the clinic or in the wards. Unlike other mobile 
applications, a unique benefit of OncoRx-MI is that its drug-related information is not 
compromised from its OncoRx parent, since its content is drawn from the same SQL 
database. For example, if a clinician wants to search for a DDI with the RCHOP 
regimen for non-Hodgkin‟s lymphoma, which consists of 5 drugs (cyclophosphamide, 
doxorubicin, vincristine, prednisone and rituximab);
286
 instead of entering each 
individual drug within the regimen in his interaction search, he can just search for all 
DDIs based on the “RCHOP” acronym. A proposed plan for the overall management 
of the patient on this CReg is also provided if an interaction is detected. Healthcare 
professionals can then get an overall view of the DDIs in the CReg instead of 








collating and extracting relevant information for each individual ACD by themselves. 
If they are in a rush for time, searching for multiple drug-pair interactions in a 
combination CReg may also predispose them to a risk of accidental omissions of a 
DDI search with a particular ACD within the regimen, especially when dealing with 
the small resolutions of mobile touch-screen interfaces, which may lead to a 
possibility of DRPs and adverse outcomes in patients. OncoRx and OncoRx-MI lower 
the risk of accidental omissions by providing the interactions of all the ACDs in the 
regimen.  
Some drug information databases provide detailed information about an 
interaction (e.g. Micromedex, AHFS Drug Information). However, it is time-
consuming for the clinician to thoroughly read through the details in order to sieve out 
the relevant information in the practice setting. On the other hand, other databases 
only provide a summarised paragraph of the interaction effects and precautions to take 
(e.g. Caremark, PDRhealth). Clinicians who want to know more details regarding the 
interactions may have to do additional searches on other information resources. As 
such, the content in OncoRx and OncoRx-MI is summarised and placed under 
relevant headings so that healthcare professionals can rapidly sieve out the 
information they need. 
Some resources do not provide interactions of individual drugs, but of drug 
classes or drugs with certain common parameters instead (e.g. Lexi-comp‟s Drug 
Information Handbook, British National Formulary). This requires some specialised 
knowledge on the part of the clinicians regarding the drug, and may be time 
consuming if they need to look up additional information in the practice setting. For 
example, the increased risk of carboplatin toxicity when used concurrently with 
nephrotoxic drugs 
251
 implies that clinicians need to know whether the interacting 








drug is nephrotoxic, or otherwise look up for this piece of information on the 
interacting drug. The OncoRx database enables its users to search for interactions 
between specific drug-pairs, since it extrapolates these class effects to the individual 
drugs. This feature is especially important for interactions involving CAMs, since 
their interactions, particularly for TCMs, have not been well-documented in literature. 
Furthermore, such information may not be consistent for the less well-established 
CAMs. It is important for clinicians to gain better understanding on the interactions 
between ACDs and TCMs because TCMs are gaining increasing acceptance in the 
West as a therapeutic option, particularly for the treatment of chronic diseases such as 
cancer.
287
 Therefore, it is hoped that OncoRx and OncoRx-MI will be used as a 
resource for this purpose, since the database combines information from CAM- and 
TCM-specific sources in addition to the typical DDI resources used by clinicians. 
Lastly, the OncoRx database compiles DDI information from various drug 
information and interaction sources, as well as published literature. This makes the 
database a comprehensive one. As a result, the database is able to provide clinicians 
with any contradictory information regarding a detected interaction. For example, 
corticosteroids such as dexamethasone, which are commonly used as antiemetic 
agents in treating CINV,
188
 have been reported to cause both increases and decreases 
in plasma phenytoin concentrations. The OncoRx database is able to provide this 
piece of information as a summary of the evidence with substantiating references 
(Figure 4.2), so that clinicians have the flexibility of deciding how to manage their 
patients based on their clinical judgement.  










Figure 4.2. Interaction results between dexamethasone and phenytoin in the OncoRx 
database.  
 
4.3. Potential of the database in clinical practice  
4.3.1. Drug interaction prevalence study resulting from use of the database 
In the global setting, there have been few studies that were designed to 
determine the occurrence of DDIs for ACDs and CRegs. Although a number of case 
reports suggesting potentially interacting combinations between ACDs and non-ACDs 
have been published in literature, the prevalence of DDIs in the local setting has not 
been determined. A recent, retrospective study conducted by Cheung et al.
288
 at a 
local ambulatory cancer centre in Singapore (National Cancer Centre) determined the 
prevalence and prescribing patterns of ACDs and AEDs in the local setting. In this 
study, the authors identified a prescription pool of “co-prescribed medications” 
(defined as an ACD and AED jointly prescribed by the same prescriber and dispensed 
on the same day) and “concomitant medications” (concurrent use of an ACD and 








AED prescribed by one or more prescribers, but not necessarily dispensed on the 
same day) from their institutional electronic prescription database, for a period of 3 
years. The study utilised the interaction information from the OncoRx database to 
identify potentially interacting ACD-AED pairs in their institution. Of the 42,810 
prescriptions that were identified with at least one ACD, 274 (0.64%) prescriptions 
were combined with an AED, with majority (82.8%) of the drug pairs being co-
prescribed, and the remaining 17.2% were concomitant prescriptions. Among the 274 
prescriptions that had ACD-AED pairs, 51 (18.6%) were identified by the authors as 
potentially interacting, in a total of 22 patients. More than one potentially interacting 
pair was observed in 2 patients. Surprisingly, these DDIs only occurred with 4 AEDs 
– carbamazepine, clonazepam, phenytoin and valproic acid. The most common DDIs 
were associated with lomustine and valproic acid (7 patients), and with capecitabine 
and phenytoin (5 patients). The authors of this study postulated from the high 
proportion of co-prescribed medications that most ACD-AED pairs prescribed by 
clinicians were given intentionally because they might have been unaware of the 
potential for DDIs. Furthermore, another study suggested that specialists were less 
likely to identify DDIs than clinicians in general practice.
289
 Thus, the results of the 
retrospective study show that there is a tremendous potential for the OncoRx database 
to aid clinicians, particularly oncology practitioners, in reducing DRPs such as DDIs 
in the clinical practice setting.  
 
4.3.2. User statistics and feedback on the database 
Since its launch in September 2009 till August 2010, the OncoRx database has 
reached out to a total of 90 users. Their demographics are shown in Table 4.2. Most 
of the users were from the US and Canada (38%), followed by Australia (19%). 








Surprisingly, large proportions were also from Germany and France (9%), as well as 
Italy, the UK and Ireland (7% each). Our local Singaporean population made up 6%, 
while other users included those from Europe, such as Spain (2%), Belgium, Sweden 
and Switzerland (1% each); the Asia-Pacific region (China, Hong Kong, India, Japan, 
Korea and New Zealand, 1% each); as well as the Middle East (Israel and Turkey, 1% 
each).  
Approximately 40% of the users were from academia or affiliated with an 
academic institution, and nearly half were working in hospitals, cancer/medical 
centres and health service provider organisations. One user (1%) was in private 
practice, and a small minority was from non-profit governmental organisations (2%) 
(e.g. BC Cancer Agency and the Western Australia Cancer and Palliative Care 
Network), as well as pharmacies and the pharmaceutical industry (3%) (e.g. 
AstraZeneca and medac GmbH).  
Approximately 60% of users were healthcare professionals. These included 
pharmacists (24%), physicians (20%), nurses (13%) and other allied health 
professionals (2%). The latter comprised of a clinical social worker and a 
psychologist. Among the first 3 groups of healthcare professionals, a large percentage 
specialised in oncology (41% pharmacists, 50% physicians and 75% nurses). The 
proportion of naturopaths was also high (16%), edging over that of nurses. 
Researchers and trainees/students made up one-fifth of the users, with the latter 













Table 4.2. Demographics of OncoRx users. 
 
Demographics Number of users (%)+ 
Countries  
Australia 17 (19) 
France and Germany 8 (9) 
Italy 6 (7) 
Singapore 5 (6) 
Spain 2 (2) 
UK and Ireland 6 (7) 
US and Canada 34 (38) 
Others 12 (13) 
Organizations  
Academic institutions 29 (32) 
Academic-affiliated / teaching hospitals 7 (8) 
Cancer / medical centres 6 (7) 
Governmental organisations 2 (2) 
Hospitals 12 (13) 
Natural medicine clinics 2 (2) 
Network hospitals / health service providers 25 (28) 
Pharmacies / pharmaceutical industries 3 (3) 
Others 4 (4) 
Occupations  
Naturopaths 14 (16) 
Nurses 12 (13) 
Pharmacists 22 (24) 
Physicians 18 (20) 
Other allied health professionals 2 (2) 
Researchers 8 (9) 
Trainees / students 10 (11) 
Other non-healthcare professionals 4 (4) 
Knowledge of the OncoRx database  
Published articles on OncoRx 28 (31) 
Citations of other published articles 4 (4) 
Searches from PubMed and institutional libraries 10 (11) 
Internet, search engines and listserves 8 (9) 
Word-of-mouth 23 (26) 
+ Percentages may not add up to 100% due to missing values and rounding of data. 
UK: United Kingdom, US: United States 









Users were asked to indicate how they got to know about OncoRx when they 
signed up for an account. Surprisingly, over a quarter of them found out about the 
database through word-of-mouth from their colleagues. This finding could probably 
explain the large numbers of users who were from network hospitals and health 
service providers (28%), which included the Cancer Treatment Centers of America 
and the Greater Western Area Health Service in Australia. Other major sources of 
knowledge about the database included the published articles on OncoRx (31%), as 
well as through searches in PubMed or through institutional libraries (11%). Among 
those who indicated that they knew OncoRx through its published articles, ~75% of 
them had read about its ability to identify oncology interactions with CAMs.
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Therefore, it was not surprising that many of the users were naturopaths (16%). 
A specific online form was created and put at a prominent location on the 
login page of the Onco-informatics.com website to seek feedback from users 
regarding the OncoRx database. Its hyperlink was open for a period from 21
st
 July to 
24
th
 August 2010. In addition, emails were sent to the users to inform them about this 
online form. The completion of this feedback form was completely voluntary. In order 
to encourage their honest feedback, a disclaimer was put in the instructions for 
accessing the form. The disclaimer stated that no personal information would be 
collected, except their IP addresses which would only be used for statistical purposes.  
Specifically, this form asked the users to comment about the usefulness of 
OncoRx in relation to their current sources of oncology DDI information, as well as 
its relevance to their clinical practice. For usefulness, they were asked to rate the 
database in terms of information on the drugs, CRegs and CAMs, interaction-related 
content, management plans, non-interacting alternatives, and usability with 5 scale 








points (a lot better, a little better, makes no difference, a little worse, a lot worse). For 
clinical relevance, they were asked whether OncoRx increased their knowledge on 
managing oncology DDIs, improved their drug-related decision making, and if it was 
a useful tool in practice. Users could agree, disagree or remain neutral to these 
questions. Users were also encouraged to provide suggestions for improvement of the 
database.  
A total of 16 users completed the feedback form. On the whole, majority of 
them agreed that the OncoRx database was better than their current sources of 
oncology DDI information (Table 4.3), with 13 of them (81%) indicating that the 
content on drugs, regimens and CAMs were better than their current sources of 
information. The same number of users also felt that the interaction-related data 
provided by OncoRx was better. However, one user indicated that the content in 
OncoRx was “a lot worse” because he could not find interactions with a curcumin 
product, but curcumin was indexed under a different name (turmeric) in the database. 
In his comments, he stated that he would like to see more CAMs in the database so 
that more HDIs could be identified, but nevertheless, he agreed that this database 
would be useful in the future if the list of interactions could be further expanded.  
Nearly 70% of the users (11 users) indicated that the management plans 
provided by OncoRx were better than their current information sources, but only a 
little more than half (9 users) indicated the same for the non-interacting alternatives. 
This could be because the non-interacting alternatives were provided in the same 
paragraph as the management plans, and if the users did not read the management 
plans in detail, they could have missed out on these alternatives, especially at the 
point of patient consultations. An improvement would be to provide a separate section 
for non-interacting drugs/CAMs that is distinct from the rest of the management plan, 








so that users can see it even when they are in a rush for time.  Although majority of 
the users (11 users) indicated that OncoRx‟s ease-of-use was better, one user also 
indicated that its usability was “a little worse”. This user felt confused due to the 
many drug and CAM categories that he could choose from. He said that he would 
have preferred to just select the ACD and the interacting drug/CAM instead. In fact, 
this option is provided for users of the OncoRx database as the default search 
interface. A statement describing this default search interface as part of the 
instructions might clarify users‟ doubts on how to carry out a search in OncoRx. 
  
Table 4.3. Ratings of OncoRx parameters based on user feedback. 
 
OncoRx parameters 













Content on drugs, 
regimens and CAMs 
5 (31) 8 (50) 2 (13) 0 (0) 1 (6) 
Interaction-related 
content 
7 (44) 6 (38) 2 (13) 0 (0) 1 (6) 
Management plans 5 (31) 6 (38) 5 (31) 0 (0) 0 (0) 
Non-interacting 
alternatives 
2 (13) 7 (44) 7 (44) 0 (0) 0 (0) 
Ease-of-use 5 (31) 6 (38) 4 (25) 1 (6) 0 (0) 
+ 
Percentages may not add up to 100% due to rounding of data. 
CAMs: complementary and alternative medicines 
 
In terms of clinical relevance, 12 users (75%) indicated that OncoRx was a 
useful tool in their practices, and that it helped increase their knowledge on managing 
oncology DDIs. Fourteen of them (88%) also indicated that the database helped to 
improve their drug-related decision making. One user, who was an oncology 
practitioner, had found this database useful when handling a patient query about 
DDIs. Despite several neutral ratings and some discontent regarding the amount of 
drugs that OncoRx can identify interactions with, many of the users still gave positive 








comments regarding the database, saying that OncoRx was an “awesome resource” 
and it was “much more complete for oncology regimens and CAMs”. Some users 
stated that this database was “very good as it is, as long as the current information can 
be maintained”. In fact, one user said that “more practitioners should know about it”, 
while another complimented on OncoRx‟s ability to suggest alternative medications 
and wished that “all patients had clear instructions on drugs to take and drugs to 
avoid”. A limitation of the feedback results was the small number of users who 
responded to the online survey, thus their results might not be representative of all 
users of the database. Feedback from users should be obtained on a regular basis to 
keep the database current and up to date. Nevertheless, the following comment by a 
user clearly summarised how those who responded to the survey felt about the 
OncoRx database and its usefulness to healthcare professionals: 
 
“I have found the level of detail with regard to the interaction to surpass that in most 
other databases. In fact, there are a couple interactions identified in your database 
that are completely lacking in other databases. As well, the referencing is excellent. 
When searching for drug interaction information I usually check more than a single 
database and I have added OncoRx to my list of routinely searched databases. Good 
job!” – Feedback comment by an OncoRx user 
 
The users also provided detailed suggestions on what they would like to see as 
improvements to OncoRx. Many of the suggestions were in relation to expanding the 
database to include other natural remedies (e.g. amino acids, vitamins and minerals, 
other natural supplements such as melatonin, co-enzyme Q10, slippery elm, cranberry 
and Huachansu), and other drug classes (e.g. over-the-counter medications, 








analgesics, antimicrobials, antifungals, antihypertensives and diuretics). Some users 
suggested inclusions of more specific monitoring plans, DDI identifications based on 
the pharmacological classes of the ACDs, as well as DDIs among the ACDs 
themselves. Others wanted ways to carry out multiple DDI searches, and also a list of 
non-interacting ACDs when a DDI is identified with a CAM or non-ACD. Lastly, one 
user suggested a short summary of updates to be copied to other OncoRx users in the 
form of letters or newsletters. These feedbacks are definitely important for OncoRx to 
be successful and accepted among clinician users. Several have been identified to be 
more pressing issues, and thus will be considered as updates in the near future. 
 
4.4. Limitations of the database 
The main limitation of the OncoRx database is its ability to only detect 
interactions with certain classes of psychotropics and CAMs. However, the interaction 
data in the database is compiled in modular format, therefore modules on DDIs with 
other classes of psychotropic agents, prescription medicines and CAMs can be added 
to make the database more comprehensive.  
The database is also limited to searching one interaction at any one time. If 
users want to search for more than one DDI, separate searches have to be carried out, 
and this can be troublesome for the users. Furthermore, doses and frequencies of 
chemotherapy, and psychotropic and CAM therapies are not included; hence users 
have to refer to other drug information resources for this information. In the CAM 
module, users can only search for HDIs based on the common names of the CAMs. 
Some CAMs are known by various names (e.g. Asian, Chinese, Korean and Oriental 
ginsengs all fall under the Panax genus), and it is difficult for users to search for the 
CAM if they are not familiar with the name that is currently indexed in the OncoRx 








database. Enabling multiple DDI searches, as well as the ability to search based on 
various drug or CAM names, could improve the usability of the database for its users.  
Although OncoRx compiles interaction data from in-vitro, animal and human 
studies, the database does not rank this information for clinician users. Instead, a 
summary of the evidence from all these studies would be provided together with the 
appropriate reference citations and their links, where available. With advances in 
biomedical informatics technologies and new evidence taxonomies,
291,292
 the use of 
various ontologies supported by specific evidence sets is definitely attractive as a 
value-added component to the database.  
Some interactions are complex in nature and cannot be easily predicted. 
Moreover, there is a lack of recommendations for the management of specific DDIs in 
published literature. As such, this database proposes general management plans such 
as clinical and laboratory monitoring of plasma drug levels and the need for dosage 
adjustments. Additionally, other management plans may not be feasible for clinicians 
in particular settings due to variations in institutional practices, clinical practices of 
the practitioners, and availability of equipment or facilities for monitoring and 
management. However, the information provided by OncoRx is intended to be both 
broad-based to cater to a pool of clinicians from a wide variety of clinical settings, 
and evidence-based so that healthcare professionals dealing with their patients on-the-
spot in their practices can make the final decision. In cases whereby there is more 
detailed information in published literature regarding the management of an 
interaction, this information will be provided for users as well. For example, the 
interaction between temsirolimus and fluvoxamine may lead to increased plasma 
concentrations of the ACD due to inhibition of CYP3A4-mediated metabolism by 
fluvoxamine. As the manufacturer recommends a reduction of temsirolimus dose to 








12.5 mg per week, and a washout period of approximately one week before its dose is 
adjusted back to the dose prior to co-administration with the inhibitor;
293
 this piece of 
information will be shown as part of the recommended management to clinician users 
of the database. Since DDI literature is continually being updated with new evidences, 
more detailed information regarding specific management of particular DDIs will be 
incorporated into the database as and when they become publicly available. 
In terms of the OncoRx-MI application interface, the links provided can be 
small and difficult for users to tap or “click” with their fingers because the original 
database was designed with mouse-clicks in mind. The interface has also not been 
tested on other handheld devices other than the iPhone, hence technical disparities 
with the screen resolution and interface designs may differ when viewed with other 
mobile devices. Nevertheless, OncoRx-MI is still useful since it leverages on 3G and 
Wi-Fi networks to operate. Therefore, it can be used on any mobile device that has a 
browser as part of its application suite. Furthermore, OncoRx-MI is able to identify a 
substantial number of interactions with single-agent and combination regimens in its 
current stage, and thus will be useful to clinicians in a variety of clinical settings and 
who are always on-the-go. 
 
4.5. The OncoRx database as a pharmacoinformatics-based search engine for 
prevention of drug-related problems in oncology practice 
Chapters 3 and 4 have demonstrated how pharmacoinformatics can be utilised 
as an aid for clinicians through the creation and development of the OncoRx database. 
It is prudent that clinicians recognise potentially harmful DDIs with ACDs and CRegs 
as early as possible when treating patients with cancer on chemotherapy. The OncoRx 
database provides a solution for clinicians to search for these DDIs “on-the-spot” in 








their clinical practices; and also helps reduce the potential of DRPs, such as omission 
errors, by providing a search strategy based on CReg acronyms. User feedback has 
demonstrated the usefulness of this database to clinicians, and work on this database 
should definitely be continued to make it more comprehensive and user-centred. The 
OncoRx and OncoRx-MI applications are unique in that they are not developed by 
multidisciplinary teams of healthcare professionals and informaticians from 
commercial organisations. Instead, they are created as part of an institutional research 
project by a pharmacist dual-trained in informatics. Hence, the information provided 
by these applications is considered by users as being objective and non-biased. The 
downside of this project is that there is a limitation in manpower in terms of the 
frequency of content and interface updates to the database. As such, it is intended that 
this database be updated on an annual basis once it is able to detect a substantial 
amount of DDIs with other categories of drugs. The content provided by this database 
is dynamic and any feedback provided by clinician users will be positively received, 
so that the OncoRx and OncoRx-MI applications can remain clinically useful and 
relevant to healthcare professionals in various specialist practices. 
 









Application of a pharmacoinformatics tool to predict potential risks for 
chemotherapy-induced nausea and vomiting 
In the preceding chapter, pharmacoinformatics was utilised to create a 
platform for the consolidation of evidence-based drug information, in the form of an 
oncology DDI search engine, so that clinicians could use this data for their daily 
practices. However, there is a plethora of patient-related information that can 
potentially be clinically useful as well, if harnessed properly. Pharmacoinformatics 
can provide a means to harness these data for the appropriate management of patients, 
especially in the prediction of ADRs. 
This chapter discusses how a pharmacoinformatics tool, known as principal 
component analysis (PCA), can be used for the clinical prediction of CINV through 
the identification of several patient-related and chemotherapy-related risk factors. 
 
5.1. Designing an observational study for evaluating chemotherapy-induced 
nausea and vomiting in a prospective cohort of Asian patients with cancer 
5.1.1. Study design and setting 
This was a single-centre, prospective, observational study conducted between 
January 2007 and July 2010 at the ambulatory treatment unit of the National Cancer 
Centre, Singapore (NCCS). Patients who were at least 21 years of age with confirmed 
diagnoses of breast, head and neck, and gastrointestinal cancers were recruited into 
the study. Patients were treated with a variety of chemotherapy protocols. Exclusion 
criteria were the inability to complete the survey due to mental or cognitive problems, 
inability to understand English or Mandarin, and those who refused follow-up for the 
duration of the study. This study was approved by the NCCS‟s institutional review 








board and written informed consent was obtained from all patients prior to 




Figure 5.1. Summary of how the study on chemotherapy-induced nausea and 
vomiting (CINV) was conducted. 
 
5.1.2. Chemotherapy and antiemetic treatments 
Patients were treated with either single-day or multiple-day CRegs, 
with/without radiotherapy (Table 5.1). Highly-emetogenic chemotherapies (HECs) 
consisted of cisplatin-based regimens that were used for the treatment of head and 
neck cancers. The regimen PF (IV cisplatin 20 mg/m
2
/day and IV 5-fluorouracil 1000 
mg/m
2
/day, for 4 days) was a multiple-day regimen, while the others, such as 
CDDP40 and CDDP100 (IV cisplatin 40 and 100 mg/m
2
/day respectively), were 
single-day regimens. On the other hand, MECs comprised of AC-based regimens with 








an anthracycline and cyclophosphamide, and the XELOX regimen (IV oxaliplatin 130 
mg/m
2
/day and oral capecitabine 2000 mg/m
2
/day), used for the treatments of breast 
and gastrointestinal cancers respectively. The AC-based regimens for breast cancer 
included AC (IV doxorubicin 60 mg/m
2
/day and IV cyclophosphamide 600 
mg/m
2
/day), FAC (IV doxorubicin 50 mg/m
2
/day, IV cyclophosphamide 500 
mg/m
2
/day and IV fluorouracil 500 mg/m
2
/day), and FEC (IV epirubicin 75-100 
mg/m
2
/day, IV cyclophosphamide 500 mg/m
2
/day and IV fluorouracil 500 
mg/m
2
/day). All the MECs were single-day regimens. 
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 FEC (500/ 
75/ 500) 
IV Epirubicin 75 mg/m
2
/day, IV Cyclophosphamide 
500 mg/m
2





XELOX IV Oxaliplatin 130 mg/m
2




Head and neck 
cancer regimens 
CDDP 40 IV Cisplatin 40 mg/m
2
/day 
 CDDP 100 IV Cisplatin 100 mg/m
2
/day 
 PF IV Cisplatin 20 mg/m
2
/day, IV Fluorouracil 1000 
mg/m
2
/day, for 4 days 
IV: intravenous, PO: oral 
 
All patients received either IV granisetron (3 mg) or IV ondansetron (8 mg), 
and IV dexamethasone (8 mg) for acute antiemetic prophylaxis on the days of 
chemotherapy (day 1 for single-day regimens, days 1 to 4 for the multiday-regimen 








PF). Patients who were on CDDP100 or had a previous history of uncontrolled CINV 
despite standard antiemetic therapy were given additional oral aprepitant (125 mg on 
day 1, 80 mg on days 2 and 3). Oral delayed antiemetic prophylaxis included 
dexamethasone (4 mg twice daily) or granisetron (1 mg once daily) for up to 5 days 
after chemotherapy, and metoclopramide (20 mg orally) was given when necessary 
for breakthrough CINV. 
 
5.1.3. Definitions of chemotherapy-induced nausea and vomiting responses 
Several CINV parameters were defined in order for this study to be carried 
out. A patient was considered to have experienced acute vomiting or acute nausea, 
respectively, if at least one vomiting episode or numerical scores greater than or equal 
to 1 (on a scale of 0-10) for nausea was reported on day 1 of single-day 
chemotherapies and days 1-4 on the multiple-day chemotherapy (Figure 5.1).
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Similarly, a patient was considered to have had delayed vomiting or nausea, 
respectively, if at least one vomiting episode or a numerical score greater than or 
equal to 1 for nausea was reported any day after the acute phase of chemotherapy 
(days 2-5 for single-day regimens, days 5-9 for the multiple-day regimen).
294
 A 
vomiting episode was defined as a single vomit or retch, or any number of continuous 
vomits or retches, separated from each other for at least 1 minute.
295
 In addition, a 
number of other CINV parameters, referred to as clinical or CINV endpoints, were 
employed in this study:
296-302
 (a) complete response (CR, defined as no vomiting and 
no rescue antiemetics), (b) complete protection (CP, defined as no vomiting, no 
significant nausea (scores 0-2) and no rescue antiemetics), and (c) complete control 
(CC, defined as no vomiting, no nausea (score 0), and no rescue antiemetics). 
 








5.1.4. Procedures and instruments for data collection 
Patients were interviewed face-to-face on their first day of chemotherapy for 
purposes of documenting their demographics, CINV risk factors and dispensed 
antiemetics. The risk factors included the emetogenic potentials of chemotherapy, 
age, gender, degree of fatigue, presence of anxiety, concurrent radiotherapy, and 
earache or ringing in the ears, as well as histories of alcohol use, CINV, morning and 
motion sicknesses (Table 5.2).  
Patients‟ anxiety characteristics were evaluated using the Beck Anxiety 
Inventory (BAI),
303
 a 21-item instrument for assessing the severity of various anxiety 
symptoms. Each symptom was rated by the patients on a 4-point scale ranging from 0 
to 3 in increasing order of severity. The total severity rating was summed across all 
the 21 symptoms, and capped at a maximum score of 63, with higher scores indicating 
a greater degree of anxiety. This instrument was previously demonstrated by the 
authors to have a high internal consistency of 0.92 and test-retest reliability of 0.75, 
and was also validated in our local population.
304
 Furthermore, the symptoms could be 
categorised into 4 main dimensions reflecting the neuro-physiological, autonomic, 
subjective and panic domains (Table 5.3).
305,306
 
A standardised self-administered CINV diary was given to patients to record 
the number of vomiting events and intensity of nausea after chemotherapy, as well as 
their use of antiemetics. Recording of CINV events was done on a daily basis. 
Patients on single-day regimens completed a 5-day diary while patients on the 
multiple-day regimen (PF) completed a 9-day diary. Nausea intensity was evaluated 
using a Likert scale numbered from 0 to 10 in order of increasing intensity. Patients 
also documented the antiemetic drugs which they took for delayed and breakthrough 
CINV, and the periods of the day (morning, afternoon, evening, night) in which the 








antiemetics were taken. A telephone interview was conducted after completion of the 
diary for documentation of their CINV responses. 
 
Table 5.2. List of risk factors analysed in the study population. 
 
Risk factors Parameters analysed 
Age Less than 50 years old / equal to or greater than 50 
years old 
Anxiety Scores of anxiety symptoms based on the Beck 
Anxiety Inventory 
Concurrent radiotherapy Presence / absence 
Earache / ringing in the ears Presence / absence before the initiation of 
chemotherapy 
Emetogenicity of chemotherapy Minimal / low / moderate / high 
Fatigue / tiredness a) Fatigue interference: Degree in which fatigue 
interferes with the patient‟s ability to engage in 
daily activities (since time of cancer diagnosis 
or the last 6 months, whichever is shorter) 
b) Fatigue severity: Degree of fatigue severity that 
the patient is experiencing at the time of survey 
administration 
Both parameters were analysed based on a Likert 
scale of 0 to 10 
Gender Female / male 
History of alcohol use a) Non-drinker (or drank negligible amounts of 
alcohol throughout lifetime) / drinker 
b) Period of drinking: Ex-drinker / current drinker 
c) Frequency of drinking: Social drinker (<1 
drink/day) / chronic drinker (≥1 drink/day) 
History of chemotherapy-
induced nausea and vomiting 
a) Nausea: None / mild / moderate / severe 
b) Vomiting: None / mild / moderate / severe 
History of morning sickness Presence / absence 
















Table 5.3. List of anxiety characteristics in the Beck Anxiety Inventory, classified 
into 4 main dimensions. 
 
Dimension / domain of anxiety Anxiety symptom / characteristic 
Autonomic Feeling hot, indigestion, flushed face, hot/cold 
sweats 
Neuro-physiological Numbness, wobbliness, dizziness, unsteady, hands 
trembling, shaky, faintness 
Panic Heart pounding, feelings of choking, breathing 
difficulty, fear of dying 
Subjective Unable to relax, terrified, nervousness, scared, fear 
of the worst, fear of losing control 
 
5.2. Pharmacoinformatic and statistical analyses of data 
Descriptive statistics were used to summarise the patient demographics and 
CINV characteristics. PCA, an unsupervised machine learning technique, was 
performed to analyse the risk factors and BAI scores of each anxiety symptom. The 
number of principal components (PCs) selected for the analyses was based on a 
combination of Jolliffe‟s eigenvalue cut‐off, Catell‟s scree plot and an 80% variance 
cut‐off. The eigenvectors (or weightage) of the variables (i.e. risk factors and anxiety 
symptoms) were used to interpret the PC data based on decomposition of the 
correlation or covariance matrices.  
A subset of the variables, known as principal variables (PVs), was used to 
represent the variation in the dataset, rather than doing an overall interpretation of the 
PCs themselves. In this study, the PVs were represented by the risk factors or anxiety 
symptoms that had the highest weightings on its corresponding PC. The PVs were 
identified for patients with and without the clinical endpoints (CR, CP and CC). From 
this subset, those PVs that were able to distinguish patients who suffered from CINV 
from those who did not were determined. PVs that were exhibited by the former 
group of patients (i.e. those who did not achieve the clinical endpoints), but not in the 








latter group, were identified as potential clinical predictors of CINV. The percentage 
contributions of these clinical predictors to their PCs were compiled together with 
their direction cosines, which were reflective of the correlations between their PCs 
and symptom axes. A value closer to 1 would mean a greater correlation between the 
PC and that particular predictor. The medians and interquartile ranges (IQRs, defined 
as the difference between the first and third quartiles) of these predictors were also 
calculated, where applicable, and statistical significance was defined as p<0.05 based 
on the Wilcoxon rank-sum test. The software programmes StatistiXL v1.8 
(StatistiXL, Nedlands, Western Australia) and XLStat v2010.6.01 (Addinsoft, New 
York, NY) were used for PCA and SPSS v17.0 (SPSS Inc., Chicago, IL) was used to 
calculate the descriptive statistics and tests for statistical significance. 
 
5.2.1. Exploratory principal component analysis and the principal variable 
approach for identifying clinical predictors 
PCA is a multivariate projection technique in unsupervised machine learning 
that investigates relationships among multiple variables and explains causes of 
variance in the dataset.
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 The principle of this technique is to linearly transform an 
original set of variables (in this case, the CINV risk factors) into a substantially 
smaller set of uncorrelated variables known as PCs that represent most of the 
information in the original dataset. Thus, the goals of PCA are to simplify and reduce 
the data so that classes, similarities and relationships can be found among the multiple 
variables. 
The data for PCA can be represented by a data matrix (R) for a set of “P” 
variables as a function of the eigenvalues (λ) and eigenvectors (a), shown by the 
following equation: 















      (1) 
In the equation, the eigenvalues and eigenvectors explain the variation and the 
weightage of the variables in the set of data respectively, and the amount of variance 
explained by a PC is the ratio of its eigenvalue over the number of variables, 
expressed as a percentage. The choice of number of PCs to represent the variation can 
be based on a combination of Jolliffe‟s eigenvalue cut‐off criteria of either 0.7 or 0.7 
of the average eigenvalue for correlation and covariance matrices respectively, 
Catell‟s scree plot principle, and/or an 80% variance cut‐off.307 
PCA is an upcoming technique that has been employed to investigate the 
relationships among multiple variables for various medical purposes, such as in the 
interpretation of repetitive nerve stimulation results.
308
 The basic idea of PCA is that it 
combines 2 correlated variables into one component known as a PC, which maximises 
the rotation of the original variable spaces. This process runs consecutively, resulting 
in a number of consecutive PCs that maximises the remaining variability that is not 
captured by the preceding component, and is independent of each other.
308
 In recent 
years, this technique has also become popular in studies dealing with cancer. For 
example, PCA has been used to evaluate various symptom clusters in patients 
suffering from brain and bone metastases.
309,310
  
Factor analysis, another technique similar to PCA, has been used to identify 
different symptom clusters in lung cancer patients as well.
311,312
 However, important 
differences exist between these 2 techniques, even though the goals of both 
techniques try to explain the variation in an observed variable set. Factor analysis has 
an underlying statistical model that separates the total variance into a common and 
unique variance, and focuses on explaining the common variance in the observed 








variables, based on a few underlying factors.
307,313
 On the other hand, PCA focuses on 
explaining the total variation in the observed variables and does not assume an 
underlying statistical model of the observed variables. Although some authors have 
suggested that researchers do not usually collect data without an a priori idea on the 
relationship among the variables,
313
 that is the case in this study.  
As mentioned previously, this study focuses on identifying several risk factors 
and state anxiety symptoms as clinical predictors of CINV. Many risk factors have 
been identified for CINV,
174,181,185,186,188,189
 but the evidences for some of these risk 
factors have been sparse. There are also limited studies comparing among these risk 
factors, particularly in the Asian population. Furthermore, since previous studies 
analysing anxiety as a risk factor for CINV have been inconsistent,
180,185,186
 it is 
difficult to ascertain an underlying structure with regards to whether anxiety is 
positively or negatively correlated with CINV, and what variables or symptoms (if 
any) can be used by healthcare professionals in the practice setting as clinical 
predictors. The only way is to “visualise” the data in this study through exploratory 
PCA rather than a confirmatory factor analysis.  
On the other hand, the PV approach is in contrast to that commonly done by 
researchers, in which the data is interpreted as an overall assessment of the PCs based 
on the loadings (correlations) of the variables. In the latter case, variables with high 
loadings are considered to be important for that PC, while those with small loadings 
are largely ignored. This latter approach is suggested to be largely due to the 
preferences of the researchers, which stems from interpreting the factor loading 
matrices in the factor analysis technique.
307
 However, since the eigenvectors are 
proportional to the loadings in PCA, either vector can be used for interpretation of the 
PC data.
307
 It is important to note that the purpose of this study is to identify a 








subgroup of risk factors and anxiety symptoms as PVs that can largely play a role in 
determining whether patients with cancer suffer from CINV, so that these symptoms 
can be useful clinical predictors in the practice setting. Thus, it is only logical that 
PVs, which represent the PCs, are interpreted in relation to their weightings or 
eigenvectors.  
In this study, there are several advantages of using PVs over overall 
interpretation of the PCs.
314
 Some variables, such as anxiety and fatigue, can be 
difficult to measure due to their subjectivity, hence may not accurately reflect the PC 
when an overall interpretation is made. Moreover, if there are many non-trivial 
loadings on multiple variables, the PCs can be difficult to interpret, in contrast to the 
variables themselves which are usually readily interpretable. Additionally, the results 
for identifying the risk factors and anxiety symptoms will be based on the correlation 
and covariance matrices respectively, because unlike the risk factors, the anxiety 
symptoms that are evaluated have exactly the same scores ranging from 0 to 3. There 
is no need to standardise the anxiety symptom variables to unit variance, in contrast to 





5.3. Demographics and chemotherapy-induced nausea and vomiting 
characteristics of the study population 
A total of 1,027 patients were approached for this study. There were 233 
patients (23%) who rejected participation in the study, and 84 patients (8%) were 
either lost to follow up or handed in incomplete CINV diaries. The resultant number 
of patients who were recruited was 710 (69%). Among these 710 recruited patients, 
139 (20%) were on HECs, 361 (51%) were on AC-based regimens and 210 (30%) 








were on XELOX regimens. Table 5.4 shows the patient demographics and the CINV 
characteristics of the study population.  
 
Table 5.4. Demographics and chemotherapy-induced nausea and vomiting (CINV) 























Age (years)     
< 30 8 (1) 4 (3) 2 (1) 2 (1) 
30-39 61 (9) 19 (14) 41 (11) 1 (1) 
40-49 195 (28) 46 (33) 130 (36) 19 (9) 
50-59 266 (38) 46 (33) 138 (38) 82 (39) 
≥60 180 (25) 24 (17) 50 (14) 106 (51) 
 
Race 
    
Chinese 593 (84) 114 (82) 293 (81) 186 (89) 
Malay 72 (10) 15 (11) 43 (12) 14 (7) 
Indian 23 (3) 3 (2) 14 (4) 6 (3) 
Others 22 (3) 7 (5) 11 (3) 4 (2) 
 
Gender 
    
Male 233 (33) 110 (79) 1 (0.3) 122 (58) 
Female 477 (67) 29 (21) 360 (99.7) 88 (42) 
 
Marital status 
    
Single 94 (13) 17 (12) 56 (16) 21 (10) 
Married 571 (80) 121 (87) 278 (77) 172 (82) 
Divorced 13 (2) 0 (0) 7 (2) 6 (3) 




    
No education 34 (5) 0 (0) 19 (5) 15 (7) 
Primary 185 (26) 30 (22) 91 (25) 64 (31) 
Secondary 295 (42) 60 (43) 151 (42) 84 (40) 
Pre-university 118 (17) 26 (19) 61 (17) 31 (15) 
Graduate 56 (8) 16 (12) 30 (8) 10 (5) 
Postgraduate 22 (3) 7 (5) 9 (3) 6 (3) 





























    
Acute 387 (55) 75 (54) 240 (67) 72 (34) 




    
Acute 103 (15) 16 (12) 77 (21) 10 (5) 




    
Acute 537 (76) 110 (79) 243 (67) 184 (88) 
Delayed 450 (63) 77 (55) 213 (59) 160 (76) 




    
Acute 428 (60) 89 (64) 173 (48) 166 (79) 
Delayed 325 (46) 58 (42) 129 (36) 138 (66) 




    
Acute 308 (43) 62 (45) 112 (31) 134 (64) 
Delayed 219 (31) 43 (31) 75 (21) 101 (48) 
Overall 194 (27) 35 (25) 62 (17) 97 (46) 
+Percentages may not add to 100% due to missing data and rounding of figures. 
*Percentages may be over 100% due to patients suffering from multiple effects. 
 
The mean age of the patients were 52.9±10.3 years, with majority of them 
(63%) being over 50 years of age. More than half of the whole patient population 
(67%) was females, and this proportion was mainly skewed by the percentage of 
females on AC-based regimens (99.7%). In contrast, females explained only 21% and 
42% of the patients on HECs and XELOX regimens respectively. Most of the patients 
were Chinese (84%), married (80%) and of a secondary school education (42%). 








Generally, most patients suffered from delayed CINV; with approximately 
triple the proportion suffering from delayed nausea (67%) than vomiting (22%). A 
decreasing trend was observed in terms of the patient proportions that achieved the 
endpoints of CR (58%), CP (42%) and CC (27%). This trend occurred for both the 
acute and delayed responses, as well as among the various categories of CRegs. 
Patients on XELOX regimens achieved the highest clinical CINV endpoints (CR, CP 
and CC), which was consistent with the low proportions who suffered from acute and 
delayed NV.  
 
5.4. Risk factors of chemotherapy-induced nausea and vomiting as clinical 
predictors in patients with cancer 
Emetogenicity of the CRegs was the only risk factor that could not be used as 
a distinguishing PV for the prediction of the CINV endpoints in the study population 
because it was identified in both the groups of patients who achieved and did not 
achieve these endpoints. On the other hand, histories of morning and motion 
sicknesses only played minor roles in distinguishing these endpoints, except for 
patients on XELOX, whereby the history of morning sickness explained 24.3% of 
PC1 in patients who did not achieve acute CR (Table 5.5). Surprisingly, the variance 
explained by this risk factor was lower for patients on AC-based regimens (6.4-7.3% 
of PC6), probably because the highly emetogenic nature of these CRegs could have 
masked this risk factor, compared to the XELOX regimen, which was less 
emetogenic.  
Female gender was a predictor of the clinical endpoints, particularly in the 
acute phase (16.2-17.7% of PC1). This risk factor separated patients who did not 
achieve acute CR, CP and CC apart from those who did. While this risk factor could 








be identified as a predictor in patients on HECs and XELOX due to their mixed ratios 
of males to females (4:1 and 1:1 respectively), the almost homogeneous female 
population in patients receiving AC-based regimens made it difficult for PCA to 
identify this risk factor as a clinical predictor. Increasing the number of males on this 
CReg could probably circumvent this limitation, but it would be difficult to recruit 
large numbers of male patients who manifest breast cancers due to the nature of the 
disease. 
A history of alcohol drinking also differentiated patients who achieved the 
CINV endpoints from those who did not. In general, the period of drinking (ex-/ 
current drinkers) played a more important role than the frequency of drinking (social/ 
chronic drinkers) in CRegs that exhibited highly emetogenic patterns, such as the 
HECs (20.6-26.0% of PC1) and AC-based regimens (11.8-12.3% of PC3). On the 
other hand, the frequency of drinking was also able to differentiate acute CR for AC-
based patients (17.3% of PC1). Both the period (13.7% of PC2) and frequency of 
drinking (17.4-17.6% of PC1) differentiated CR for the patients on the moderately 
emetogenic XELOX regimen, albeit the period playing a lesser role than frequency. 
However, the latter also played a role in differentiating acute CP in this group of 
patients (18.0% of PC1). In contrast, non-drinkers could only be identified as a 
clinical predictor of delayed and overall CP (6.1-6.2% of PC6) when all the patients 
on the various CRegs were taken into account. 
The roles that histories of chemotherapy-induced nausea and vomiting played 
in distinguishing the endpoints were more obvious in those on AC-based and XELOX 
regimens, and HECs, respectively. While history of nausea explained a high 
proportion of variance in AC-based (12.7% of PC3 – 12.9% of PC2) and XELOX 
patients (8.3% of PC5 – 17.0% of PC2), not surprisingly, history of vomiting 








explained a much higher proportion of variance (19.2-21.6% of PC1) for HECs due to 
their highly emetogenic nature. 
Generally, fatigue was also a risk factor that could distinguish the clinical 
endpoints in patients, with fatigue interference being a better predictor than fatigue 
severity in the overall patient population. Patients on HECs (10.3% of PC5 – 12.5% 
of PC3) and XELOX (12.2% of PC3 – 14.9% of PC2) tended to be more easily 
distinguished based on fatigue interference. However, both factors managed to 
distinguish CC in the AC-based population (9.8% of PC4 – 13.4% of PC2).  
Younger age, the presence of anxiety and concurrent radiotherapy played 
almost similar roles in explaining the variances in patients who did not achieve the 
endpoints. Age explained up to 6.0% of PC7 and 5.3% of PC8 for CR and CC 
respectively when all the CRegs were considered, while the presence of concurrent 
radiotherapy explained 6.0-7.0% of PC7 for CC specifically in patients on AC-based 
and XELOX regimens. Anxiety, on the other hand, accounted for the variances in 
patients who were on the different categories of regimens, particularly for CP (5.0% 
of PC10 – 6.6% of PC6) and CC (4.9% of PC10 – 6.1% of PC7). Although these 
variances imply that the 3 risk factors could only play minor roles in distinguishing 
the CINV endpoints in our population, they could nevertheless be used to complement 
the other major risk factors as clinical predictors to provide a better overall picture 














Table 5.5. Risk factors of chemotherapy-induced nausea and vomiting identified in 




Variation in patients with 
regards to complete 
response (CR) 
(% variation, eigenvector) 
Variation in patients with 
regards to complete 
protection (CP) 
(% variation, eigenvector) 
Variation in patients with 
regards to complete control 
(CC)  
(% variation, eigenvector) 
















HEC -- -- -- -- -- -- -- -- -- 
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All -- -- -- -- -- -- -- -- -- 
HEC -- -- -- -- -- -- -- -- -- 
























Ex- / current drinkers 
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Non-drinkers 







-- -- -- 
HEC -- -- -- -- -- -- -- -- -- 
AC-based -- -- -- -- -- -- -- -- -- 
XELOX -- -- -- -- -- -- -- -- -- 
Earache / ringing 































Emetogenicity of regimen 
All -- -- -- -- -- -- -- -- -- 
HEC -- -- -- -- -- -- -- -- -- 
AC-based -- -- -- -- -- -- -- -- -- 














































































































































History of morning sickness 



















-- -- -- -- -- -- -- -- 
History of motion sickness 
All -- -- -- -- -- -- -- -- -- 









AC-based -- -- -- -- -- -- -- -- -- 
XELOX -- -- -- -- -- -- -- -- -- 
History of chemotherapy-induced nausea 


























0.427 0.549 0.483 0.442 






















-- -- -- -- -- 
History of chemotherapy-induced vomiting 




































-- -- -- -- -- 
All: All regimens inclusive of HEC, AC-based and XELOX regimens 
HEC: Highly-emetogenic regimens (CDDP40, CDDP100 and PF regimens) 
AC-based: AC-based regimens (AC, FAC and FEC regimens) 
XELOX: XELOX regimen 




There were 5 risk factors that played essential roles in distinguishing the 
clinical endpoints for patients on MECs and HECs (Table 5.6). They were histories of 
alcohol drinking, chemotherapy-induced nausea, chemotherapy-induced vomiting, 
fatigue and gender. The former 3 risk factors clearly exhibited their roles in 
distinguishing the clinical endpoints in patients on HECs and XELOX. The period of 
drinking (demonstrated by ex-/ current drinkers) was more important in differentiating 
patients on CRegs that are of higher emetogenicity, in contrast to the frequency of 
drinking (demonstrated by social/ current drinkers) which accounted for CRegs that 
were less emetogenic (e.g. XELOX). Similarly, this trend was also observed for 
histories of CINV, with vomiting being able to better distinguish overall CR than 
nausea in more highly emetogenic CRegs. On the other hand, fatigue interference 
could distinguish overall CR in patients across all the CRegs, as well as those on 








HECs and XELOX. In fact, its role was of a higher priority (PC3) compared to fatigue 
severity (PC4) when analysed in the separate CReg categories. Gender was a more 
useful predictor for CRegs that incorporated heterogeneous populations, as 
exemplified by the mixed male to female ratios in our local HEC and XELOX 
populations. Thus, in summary, these risk factors can potentially be used in 
combination as clinical predictors of CINV in oncology supportive care. 
 
Table 5.6. Risk factors identified as principal variables for the prediction of clinical 

































 Gender (PC4) 
--  Social/chronic 
drinkers 
(PC1) 
































CR: No vomiting and no rescue antiemetics 
CP: No vomiting, no significant nausea and no rescue antiemetics 
CC: No vomiting, no nausea and no rescue antiemetics 
 








5.5. Clinically-relevant descriptors of state anxiety in patients with cancer 
undergoing emetogenic chemotherapy 
Among the 21 symptoms detailed by the BAI, those in the panic and 
subjective domains seemed to be most able to distinguish CINV between patients who 
achieved the clinical endpoints and patients who did not (Table 5.7). On the other 
hand, autonomic and neuro-physiological symptoms seemed to play a lesser role in 
distinguishing CINV. Specifically, there were 4 symptoms („feeling hot‟, 
„indigestion‟, „unsteady‟ and „hands trembling‟) that were not identified by PCA to 
explain the percentage variation in our local population.   
In the panic domain, „fear of dying‟ was the most distinguishable symptom 
that was able to explain the variance in patients on all categories of CRegs, 
particularly for those who did not achieve acute CC (23.5-44.5% of PC1, direction 
cosines >0.71). This symptom explained nearly half (39.0-45.8%) of PC1 in patients 
on XELOX without the clinical endpoints, and approximately one-fifth (20.3-23.5%) 
of PC1 in patients on HECs who did not achieve CP and CC. „Breathing difficulty‟ 
(4.7% of PC7 – 7.2% of PC5) and „heart pounding‟ (4.0-4.4% of PC8) seemed to 
explain a smaller percentage variance in patients on HECs, particularly in the overall 
phases of these clinical endpoints. However, „breathing difficulty‟ was only able to 
distinguish patients on XELOX in relation to the vomiting response (3.8% of PC7 in 
patients who did not achieve delayed CR), in contrast to „heart pounding‟, which 
could distinguish the endpoints that incorporated the nausea component, such as acute 
and overall CP (3.6-4.0% of PC7) in these patients. „Feelings of choking‟, on the 
other hand, played a more important role than „breathing difficulty‟ or „heart 
pounding‟ for patients on XELOX, accounting for 7.5% of PC4 in patients without 
acute CR. 








Subjective symptoms played a role in distinguishing between people who 
achieved and did not achieve the clinical endpoints, especially among patients on AC-
based chemotherapies. „Fear of the worst‟ (35.6-35.7% of PC1) and „unable to relax‟ 
(14.8-15.0% of PC2) were able to explain approximately half of the total variance in 
patients who did not achieve delayed and overall CC. On the other hand, „fear of 
losing control‟ explained nearly half (44.3%) of PC1 in patients on XELOX who did 
not achieve acute CP. While „nervousness‟ and „scared‟ could account for the 
variation in acute CR among patients on HECs (19.0% of PC2) and AC-based CRegs 
(29.2% of PC1), these symptoms also played major roles in distinguishing the overall 
and delayed phases of this endpoint in patients on XELOX and HECs. Although 
feeling „terrified‟ was a symptom that was mainly identified in patients on AC-based 
CRegs, its role in those on HECs was lesser, and it was not identified as a 
distinguishing symptom in those on XELOX at all.  
Among the neuro-physiological symptoms, „numbness‟ (6.0-7.0% of PC4) and 
„faintness‟ (4.1% of PC6 – 5.2% of PC5) were able to distinguish delayed and overall 
CR, as well as overall CC, in patients on AC-based regimens. However, „faintness‟ 
played a more important role in distinguishing patients on XELOX for acute and 
overall CP (9.8-10.6% of PC3) instead. „Wobbliness‟ could explain a small 
percentage of variance for the endpoints which incorporated nausea as a component 
(4.5-4.6% of PC6 in CP, 3.9% of PC7 – 4.3% of PC6 in CC) in patients on AC-based 
regimens, but surprisingly, feeling „shaky‟ was the only neuro-physiological symptom 
that could distinguish the endpoints in patients on HECs (3.7-4.1% of PC8 for CP). 
Among the autonomic symptoms, patients on HECs and AC-based regimens could be 
distinguished by having „hot/cold sweats‟ and „flushed face‟ respectively, but the 
former symptom was more highly distinguishable for CP and CC.  














Variation in patients with no 
complete response (CR) 
(% variation, eigenvector) 
Variation in patients with no 
complete protection (CP) 
(% variation, eigenvector) 
Variation in patients with no 
complete control (CC)  
(% variation, eigenvector) 
 Acute Delayed Overall Acute Delayed Overall Acute Delayed Overall 
Flushed face (autonomic) 
All -- -- -- -- -- -- -- -- -- 








-- -- -- -- -- -- 
XELOX -- -- -- -- -- -- -- -- -- 
Hot/cold sweats (autonomic) 



























AC-based -- -- -- -- -- -- -- -- -- 






-- -- -- -- -- -- -- 
HEC -- -- -- -- -- -- -- -- -- 
AC-based -- -- -- -- -- -- -- -- -- 
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-- -- -- 
Numbness (neuro-physiological) 
All -- -- -- -- -- -- -- -- -- 



















XELOX -- -- -- -- -- -- -- -- -- 









All -- -- -- -- -- -- -- -- -- 
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-- -- -- -- 
Wobbliness (neuro-physiological) 









HEC -- -- -- -- -- -- -- -- -- 
















XELOX -- -- -- -- -- -- -- -- -- 




































































-- -- -- -- -- -- -- 
Feelings of choking (panic) 
All -- -- -- -- -- -- -- -- -- 
HEC -- -- -- -- -- -- -- -- -- 
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0.393* 0.412* 0.403* 0.396* 0.391* 0.395* 0.396* 0.394* 
Heart pounding (panic) 




























-- -- -- -- -- 








-- -- -- 
Fear of losing control (subjective) 
All -- -- -- -- -- -- -- -- -- 
HEC -- -- -- -- -- -- -- -- -- 
AC-based -- -- -- -- -- -- -- -- -- 




-- -- -- -- -- 
Fear of the worst (subjective) 
All -- -- -- -- -- -- -- -- -- 
HEC -- -- -- -- -- -- -- -- -- 











XELOX -- -- -- -- -- -- -- -- -- 
Nervousness (subjective) 










AC-based -- -- -- -- -- -- -- -- -- 




-- -- -- -- -- -- 
Scared (subjective) 














-- -- -- -- -- 
XELOX -- -- -- -- -- -- -- -- -- 
Terrified (subjective) 
All -- -- -- -- -- -- -- -- -- 
HEC -- -- -- -- 
4.3% of 
PC7, 
-- -- -- -- 




























XELOX -- -- -- -- -- -- -- -- -- 
Unable to relax (subjective) 
All -- -- -- -- -- -- -- -- -- 
HEC -- -- -- -- -- -- -- -- -- 











XELOX -- -- -- -- -- -- -- -- -- 
All: All regimens inclusive of HEC, AC-based and XELOX regimens 
HEC: Highly-emetogenic regimens (CDDP40, CDDP100 and PF regimens) 
AC-based: AC-based regimens (AC, FAC and FEC regimens) 
XELOX: XELOX regimen 
*Direction cosine is greater than 0.71, therefore the anxiety symptom is closely related to its principal 
component. 
 
Among all the anxiety symptoms, 7 were identified as PVs that could 
potentially be used to predict whether patients would achieve the clinical CINV 
endpoints (Table 5.8). „Fear of dying‟ and „fear of the worst‟ played the most 
important roles (PC1) in differentiating CP and CC in patients on HEC and XELOX 
regimens, and AC-based regimens, respectively. In fact, the BAI scores obtained for 
these symptoms from the whole patient population were significantly different 
(p<0.001) between those with and without these endpoints (Table 5.9). Although 
„fear of dying‟ also accounted for differentiating CR in patients on XELOX, „unable 
to relax‟ (PC2) and „hot/cold sweats‟ (PC3) were able to distinguish this endpoint in 
patients on AC-based and HEC regimens. While the latter was shown by PCA to be 
the only symptom that could be used to differentiate CR when the CRegs were 
analysed in combination, the former symptom played a more significant role 
(p<0.001) in distinguishing between people with and without CC based on their 
symptom scores. „Nervousness‟ and „faintness‟ were able to distinguish CR and CP in 
patients on XELOX therapy, albeit lesser roles (both PC3) than „fear of dying‟; while 








„numbness‟ (PC4) could distinguish CR and CC in patients on AC-based regimens. 
These 7 PVs could potentially be useful to oncology clinicians as clinical anxiety 
predictors in the management of CINV in patients on MECS and HECs. 
 
Table 5.8. Anxiety symptoms identified as principal variables for the prediction of 











































 Fear of the 
worst (PC1) 







--  Fear of dying 
(PC1) 
 Fear of the 
worst (PC1) 




 Fear of dying 
(PC1) 
CR: No vomiting and no rescue antiemetics 
CP: No vomiting, no significant nausea and no rescue antiemetics 
















Table 5.9. Comparison of symptom scores from the Beck Anxiety Inventory (BAI) 
between patients with and without the clinical endpoints.  
 
Principal variables 











Patients with overall complete 
response (CR) 
(n=316) (n=211)  
Fear of dying 0.00, 1.00 0.00, 1.00 0.089 
Hot/cold sweats 0.00, 0.00 0.00, 0.00 0.705 
Nervousness 0.00, 1.00 0.00, 1.00 0.217 
Numbness 0.00, 1.00 0.00, 1.00 0.901 
Unable to relax 0.00, 1.00 0.00, 1.00 0.098 
Patients with overall complete 
protection (CP) 
(n=241) (n=286)  
Faintness 0.00, 0.00 0.00, 1.00 0.021* 
Fear of dying 0.00, 1.00 1.00, 1.00 <0.001* 
Fear of the worst 0.00, 1.00 1.00, 2.00 <0.001* 
Hot/cold sweats 0.00, 0.00 0.00, 0.25 0.609 
Patients with overall complete 
control (CC) 
(n=158) (n=369)  
Fear of dying 0.00, 1.00 0.00, 1.00 <0.001* 
Fear of the worst 0.00, 1.00 1.00, 1.00 <0.001* 
Numbness 0.00, 1.00 0.00, 1.00 0.748 
Unable to relax 0.00, 0.00 0.00, 1.00 <0.001* 
+
Values for interquartile range are reflected as the difference between the first and 
third quartiles of the BAI scores. 
*Statistical significance of p<0.05 in symptom scores between patients with and 
without clinical endpoint. 
 
5.6. Clinical relevance of results to practitioners in oncology supportive care  
This study has explored the risk factors of CINV using an unsupervised 
machine learning technique, known as PCA, to identify the ones that are useful as 
clinical predictors for practitioners in supportive cancer care. Although there is much 
literature on the risk factors of CINV, to the author‟s knowledge, no study has 
actually compared the risk factors in as much detail as what this study has done – in 
terms of breath and depth. While studies have generally concentrated on analysing 
either individual risk factors or a variety of separate risk factors,
174,185,191,316-319
 this 
study analysed a total of 12 risk factors in combination, to explore their roles in 








CRegs of different emetogenic potentials (Table 5.2). Furthermore, some of the risk 
factors, such as fatigue and history of alcohol drinking, were analysed in detail with 
regards to the degree of interference and severity of fatigue experienced by patients, 
as well as their periods and frequencies of alcohol drinking. In addition, this study has 
demonstrated that state anxiety could potentially be used in combination with other 
risk factors to predict the clinical endpoints of CR, CP and CC in patients prone to 
CINV, and also suggested several symptoms that clinicians should be aware of when 
assessing state anxiety in these patients. Since most studies on CINV describe the risk 
factors in populations whereby non-Asians form a majority, the results presented here 
also provide an invaluable addition to current CINV literature by giving an insight to 
clinicians as to how these risk factors affect Asians.  
The CRegs analysed by PCA were categorised into 4 main categories 
according to their emetogenicities, based on current antiemetic guidelines.
189,196,320
 All 
CRegs were listed under the „all‟ category and analysed as a whole. Cisplatin-based 
regimens (CDDP, PF) and anthracycline-based regimens (AC, FAC, FEC) were 
analysed under the „HEC‟ and „AC-based‟ categories respectively, while XELOX was 
analysed separately. In addition, the clinical endpoints of CR, CC and CP were used 
for PCA instead of NV alone because the antiemetics prescribed by the oncologists 
for the patients had to be taken into account. Consideration of these endpoints would 
make the results of this study more relevant to clinical practice. Similarly, overall 
phases of the endpoints were used to identify the risk factors and anxiety symptoms as 
PVs, since it would be more important to keep patients free from CINV for the whole 
duration of their chemotherapy treatments, rather than just the acute or delayed 
phases. 








The 5 risk factors that were identified as PVs to predict CINV in our local 
Asian population were consistent with the literature. Female gender was reported to 
be more likely to suffer from post-chemotherapy NV,
317,321
 and this was identified as 
a useful clinical predictor, particularly in “gender neutral” CRegs – those that are not 
dominated by a particular gender group. In fact, more males seemed to achieve better 
overall CR and CP than females,
322,323
 which was also reflected in the results of this 
study. However, the present study went a step further to show that gender could also 
be used to predict patients who might not achieve acute and delayed CC.  
Fatigue, another PV that was identified as a predictor of the CINV endpoints, 
was reported as a predisposing factor to post-chemotherapy nausea,
317
 and also 
contributed to the duration and frequency of acute vomiting.
185
 Among the 2 
parameters analysed in this study, fatigue interference seemed to be a better clinical 
predictor in patients on HECs and XELOX, since it demonstrated a higher priority 
role than severity in the PCA results. However, these endpoints in patients on AC-
based regimens were differentiated by fatigue severity instead. Although clinicians 
using fatigue as a clinical predictor of CINV could base their assessments of patients 
on both interference and severity, they might have to be aware that in AC-based 
populations, fatigue severity might be more useful as a predictor.  
Histories of chemotherapy-induced nausea and vomiting accounted for 
relatively high percentage variances among all the clinical predictors. History of 
vomiting was more predictive of overall CR in HECs, and this result was consistent 
with literature suggesting that chemotherapy-induced vomiting may cause emesis in 
subsequent chemotherapies.
188,324
 On the other hand, the distinguishing of clinical 
endpoints through history of nausea in our local patients was supported by trials 
reporting that higher nausea severity was experienced by non-chemo-naïve patients, 








and that acute and delayed nausea control was adversely affected by prior 
chemotherapy NV experience in breast cancer patients.
325,326
 However, the present 
study extrapolated this result to XELOX patients as well, thus adding to the already 
sparse literature on this CReg.  
There has been some controversy regarding the history of alcohol use as a risk 
factor for CINV. In the 1980s and 1990s, many CINV studies had reported on the 
impact of alcohol drinking on CINV 
192,327-332
 as it was postulated that long-term 
alcohol drinking could possibly decrease the sensitivity of the chemoreceptor trigger 
zone in the brain, and thus potentially reduce the number of CINV episodes.
327
 
However, in recent years, several authors have disputed these findings, suggesting 
that the history of alcohol intake might not have any significant associations with 
CINV control.
193-195
 A comparison of these studies showed that majority of the earlier 
studies had concentrated on emesis and CR, but the more recent ones had also 
considered CC, which took into account both nausea and vomiting. The different 
clinical endpoints assessed in these studies could have led to this discrepancy. In fact, 
just this year alone, 2 phase III trials by Hesketh 
191
 and Warr 
316
 reported that patients 
on cisplatin-based and AC-based regimens, who had 5 or more drinks per week, had 
lower incidences of vomiting and better CR rates. It was difficult to do a direct 
comparison of the studies because of their different criteria in assessing alcohol 
drinking. Many of them assessed the frequency (by quantifying the amount of alcohol 
drunk on a daily or weekly basis) instead of the period of drinking (when the patient 
was a drinker). Furthermore, most studies only compared heavy drinkers with light or 
non-drinkers. The present study tried to assess these 2 factors separately in our local 
population. Due to time limitations during the interviews, the period and frequency of 
drinking were assessed based on whether the patients were ex- or current drinkers, 








and social or chronic drinkers, respectively. The results of this study showed that 
while the period of drinking played a more important role as a clinical CINV predictor 
for patients on HECs and AC-based regimens, possibly due to their high 
emetogenicity; the frequency of drinking could also be used for the latter CReg 
category, as well as for patients on XELOX. In addition, the results supported the fact 
that history of alcohol drinking was a better predictor of vomiting and CR than nausea 
and CC. Although this risk factor accounted for a large proportion of variance in our 
population, clinicians should be aware that it was not an independent prognostic 
factor for CINV in multivariate analysis,
332
 and thus should be considered in 
combination with other clinical predictors that accounted for an equivalent percentage 
variance in patients, such as histories of CINV.  
The main rationale of selecting the BAI for this study is because this scale has 
been validated in our local population.
304
 Even though other anxiety scales (e.g. State-
Trait Anxiety Inventory (STAI), Profile of Mood States, Morrow Assessment of 
Nausea and Emesis) have been used to evaluate anxiety in patients with cancer,
185,333
 
the BAI is not inferior in terms of its internal consistency and test-retest reliabilities. 
In fact, the BAI was reported to be highly internally consistent (Cronbach‟s alpha = 
0.92-0.94) and reliable over one week (r = 0.73-0.75),
303,334
 and it also correlated 0.58 
and 0.47 to the Trait and State scales of the STAI respectively.
334
 Additionally, the 
BAI was able to discriminate between anxiety and depression, as well as state and 
trait anxiety;
303,334,335
 both of which were essential for the assessment of state anxiety 
in our population. Even though several studies done on the BAI have classified the 
symptoms into 2, 4 or even 5 domains, this study utilised the 4-domain model 
(autonomic, neuro-physiological, subjective, panic), as it was shown to be the “best-
fitted” among all the models.336 Besides, the utility of the 4-domain model was better 








demonstrated in clinical samples,
305,306,337
 compared to the 5-domain model 
(muscular/ motoric, neuro-physiological, respiration, somatic nervousness, subjective 
fear), which was more common in non-clinical samples.
335,338
  
Although state anxiety did not account for a major proportion of the variance 
in our patient population, it would still be useful as a clinical predictor if used 
complementarily to the other PVs mentioned previously. Notably, when the individual 
CReg categories were analysed, anxiety was consistently identified as a PV that 
differentiated CP and CC for HECs and AC-based regimens, and CR and CP for 
XELOX (Table 5.5). Consequently, anxiety could be considered as an additional 
CINV predictor by oncology practitioners who only treat patients having certain 
cancer types. The 7 anxiety symptoms identified by PCA would, therefore, be useful 
predictors in the clinic setting to assess whether their patients would be at risk for 
CINV.    
 
5.7. Limitations of cohort study 
The main limitations of this study were its small sample size, particularly in 
the group of patients with head-and-neck cancers, and the predominance of males and 
females in the populations having head-and-neck (79.1% males), and breast cancers 
(99.7% females). However, the gender ratios were representative of the respective 
cancer populations here in Singapore.
339-341
 The small sample sizes in each of the 
CReg groups led to even smaller numbers when the patients were separately analysed 
according to whether they achieved the CINV responses, but it would be untoward 
and unethical to deny our patients appropriate antiemetics considering the moderate to 
high emetogenic risks of their chemotherapies; since clinical antiemesis guidelines 
have already been established by organisations such as ASCO, the Multinational 








Association of Supportive Care in Cancer and the National Comprehensive Cancer 
Network.  
PCA was selected as the main technique for analysis of the patient cohort due 
to its exploratory nature, but unlike traditional multivariate analysis techniques, the 
adequacy of sample size in PCA has not yet been clearly defined. Although there have 
been a few sample size guidelines for PCA and factor analysis, many lack the 
empirical evidence and theoretical rationale.
342
 There are 2 schools of thought with 
regards to determining an adequate sample size for PCA – a minimum total sample 
size, or the ratio of subjects to variables.
343
 However, even within these 2 approaches, 
there is also inconsistency in the evidence; with minimum total sample sizes ranging 
from 50 to 400, and ratios of 5:1 to 30:1.
343
 Studies evaluating suitable sample sizes 
for PCA in published literature have showed that much of the peer-reviewed literature 
have utilised inadequate sample sizes of equal or less than 2:1 (14.7%), 5:1 (27.3-
40.5%) and 10:1 (56.0-63.2%), some of which have even used fewer subjects than 
items or parameters analysed that still drew substantive conclusions.
343-345
 On the 
other hand, utilising large sample sizes (above 1000) or subject to item ratios (such as 
20:1) in PCA can also produce error rates of up to 30%,
343
 hence bringing a 
questionable doubt to the “critical ratio” needed for such analyses. Nevertheless, the 
consensus is that a greater sample size, hence a larger subject to variable ratio, is 
always better.
343
 Even though the sample size ratios in the separate CReg categories 
were small in this study, the aim of this study was to illustrate the potential of using 
unsupervised learning techniques, particularly PCA, to analyse data from clinical 
populations. However, clinicians should be cautioned against extrapolating these 
results to patients with other types of cancers, or having different CRegs until more 
studies have been done in a variety of different cancer types and chemotherapies.  








This study was also subjected to a number of biases, such as selection and 
information biases. Patients with head-and-neck cancers might have experienced 
difficulties in being interviewed due to their medical condition. Furthermore, some 
patients might have been less open to share certain personal details, such as whether 
they felt hopeless about their cancer condition or were afraid of dying. These biases 
could have resulted in the high rejection numbers in this study. However, analysis of 
the non-respondents‟ characteristics showed that their demographics were similar to 
those of the patients who participated in this study. Therefore, the results that were 
obtained could possibly be extrapolated to our local cancer population getting 
treatment at the NCCS.  
Other biases (e.g. recall bias) could also have occurred during the interviews 
due to the subjectivity of some questions, such as those regarding fatigue and anxiety. 
An attempt was made to control for this bias by excluding patients who had mental or 
cognitive problems which would hinder them from understanding and completing the 
survey. Since there were 6 interviewers involved in this prospective cohort study, 
interviewer bias could have occurred as well. Moreover, in a multi-cultural society 
like Singapore, different symptoms could mean differently to patients, and the 
meanings of certain questions could have been lost-in-translation. In order to achieve 
consistent results, it was imperative that each interviewer would follow-up on the 
same patient for the duration of the study. Certain subjective risk factors, such as 
fatigue interference and severity, would be quantified using a Likert scale, and the 
extreme ends of the scale would also be explained to patients. In addition, the 
interviewers came to a consensus with regards to how patients should be asked for 
certain anxiety symptoms, so that a baseline could be captured. For example, „fear of 
losing control‟ would be described as having a sense of hopelessness or being 








resigned to fate or chance, and „terrified‟ would be differentiated from being „scared‟ 
by explaining to the patient that the intensity of fear in the former symptom would be 
greater and could possibly lead to nightmares. Another way to overcome this 
limitation would be to compare the results of the subgroups of patients interviewed by 
each of the 6 interviewers. However, this method could not be done here because the 
interviewers did not interview the same numbers of patients in each CReg, due to the 
different periods of time in which they were involved in the study. Hence, some 
interviewers had patient numbers that resulted in low patient-to-variable ratios for 
certain CRegs, which would affect the PCA results.  
Lastly, the results of this study were not validated due to the nature of the PCA 
technique. PCA is an unsupervised learning technique that is used to investigate 
relationships among multiple variables; hence its results can be affected by different 
sample sizes. The only way to validate this technique in this study would be to 
compare the PCA results with another group of patients on the same CRegs, which 
would require much larger sample sizes than the number that was already recruited. 
This was also a reason as to why PCA was used as an exploratory technique, so that 
the CINV predictors identified from this study could provide a basis for analyses by 
other computational strategies. 
 
5.8. Principal component analysis as a pharmacoinformatics tool for the 
prediction of chemotherapy-induced adverse drug reactions 
This study has utilised PCA, an unsupervised machine learning technique, to 
distinguish the clinical endpoints of CR, CP and CC in patients with cancer having 
certain risk factors and state anxiety symptoms. In addition, through the use of PVs, 5 
risk factors (histories of alcohol drinking, chemotherapy-induced nausea, 








chemotherapy-induced vomiting, fatigue, gender) and 7 anxiety symptoms (fear of 
dying, fear of the worst, unable to relax, hot/cold sweats, nervousness, faintness, 
numbness) have been identified as potential clinical predictors of CINV that can be 
useful to practitioners in oncology supportive care. This study not only illustrates the 
usefulness of PCA as a potential technique in analysing clinical population data for 
chemotherapy-induced ADRs, specifically CINV, but also provides clinicians with an 
insight as to which clinical predictors to look out for in their patients, so that 
appropriate management can be taken to relieve the distress in patients undergoing 
emetogenic chemotherapy, and ultimately, improve their quality of life.  
 









Conclusions and recommendations for future work 
With the advent of e-Health, many informatics and internet applications have 
emerged for healthcare professionals. Improvements in IT have led to the 
development of new models of pharmaceutical care for patients with cancer. 
Traditional practices in oncology have prevented and solved DRPs through the use of 
conventional drug information services, so that pharmacotherapy can be optimised in 
patients. As e-Health evolves through the years, health practitioners can look forward 
to keeping up with the accelerated information overload through the use of 
technologies, so as to improve on the standards of pharmaceutical care. As IT tools 
become more freely accessible and user-friendly, oncology healthcare professionals 
can add value by utilising their skills and knowledge to leverage on the roles of 
pharmacoinformatics, e-Health, and the internet in the clinical practice setting to help 
reduce the incidence of DRPs. 
This project has demonstrated how the upcoming area of pharmacoinformatics 
can be exploited to target 2 specific areas relevant to improving pharmaceutical care. 
The first is in the area of oncology DDIs. Research has shown that the DDI 
knowledge among healthcare professionals, including physicians and pharmacists, can 
be improved with the use of computers.
206,208,220
 DDIs are a form of DRP that is 
commonly encountered in daily clinical practice, particularly for oncology healthcare 
professionals, since patients with cancer are often at high risk for DDIs. This project 
explored the niche role of pharmacoinformatics as an aid for clinicians to solve DRPs 
in the oncology setting, through the creation and development of an oncology-specific 
DDI database targeting interactions with ACDs and CRegs. 








The recent attention on advancing the adoption of health technologies and 
clinical-decision support tools by the US Office of the National Coordinator for 
Health Information Technology has led to a consensus that such systems must be 
pertinent and beneficial to clinician users, as well as prevent “alert fatigue” in users, 
which may cause clinician desensitisation to excessive, irrelevant or repetitive 
alerts.
346-349
 However, alert fatigue may compromise patient safety if clinicians ignore 
or over-ride clinically significant DDIs.
350
 Furthermore, DDI software systems that 
are created and maintained by a number of companies (e.g. Wolters Kluwer Health, 
Cerner, Thomson Reuters Healthcare, First DataBank) generally have their own 
classification systems for DDIs.
351
 These different classification systems may be 
confusing to users of the softwares. OncoRx, the online database developed in this 
study, can in part, address these issues. DDIs that are both theoretical and described in 
human, animal, in-vitro and in-silico studies are incorporated into this database so as 
to cater towards a large group of users. However, these studies are summarised with 
the clinician users in mind so that they know how clinically-relevant these DDIs are to 
their practices. Since the content in OncoRx is compiled from various hardcopy and 
softcopy resources, it is also able to provide users with any conflicting information 
regarding the DDIs, as well as an overview of how the DDIs are classified in terms of 
severity and risk from the different software companies. Additionally, the fact that 
OncoRx is available online and as a mobile application tapping on Wi-Fi and 3G 
networks, means that clinicians are given the choice to search for the DDIs on a 
voluntary basis, yet are given the flexibility to do so anywhere, so long as they have 
access to a browser. This flexibility can help combat alert fatigue since clinicians can 
check for only the DDIs which they are unsure of. Through a discussion of the 
OncoRx database features and the types of DDIs encountered in the treatment of 








various cancer types, the usefulness of a pharmacoinformatics platform that targets 
such DDIs in patients with cancer is clearly demonstrated. As shown from the 
previous study on practitioner sources of ACD interaction information, traditional 
methods of searching for such DDIs have been through the use of hardcopy resources 
and consultations with other healthcare professionals or colleagues. OncoRx provides 
an additional option for healthcare professionals to access this information directly. 
Furthermore, based on user feedback, OncoRx is a non-biased and reliable database 
that is comparable to the currently available resources used by clinicians. Healthcare 
professionals are generally impressed with the accuracy and level of detail with 
regards to the DDI content provided by OncoRx, and majority of the users also find 
this database relevant to their clinical practices. Hence, the opportunity of OncoRx as 
a pharmacoinformatics tool for healthcare professionals is definitely appealing, and 
can ultimately improve the pharmaceutical care of patients with cancer.  
Further development of OncoRx will involve the addition of more modules, so 
that the database will be more comprehensive in terms of its detection of DDIs with 
ACDs and CRegs. Modules that are being considered include DDIs with other classes 
of psychotropic agents (e.g. antipsychotics, anxiolytics, hypnotics), cardiovascular 
drugs (e.g. anti-hyperlipidaemics, anti-platelets, anticoagulants) and other natural 
products and dietary supplements. With sufficient bandwidth, ACD and CReg 
interactions with combination TCM prescriptions are also attractive options which can 
bring another level of sophistication to the DDI detection strategy of the database. As 
biomedical informatics becomes more advanced and newer literature is being 
published, other pharmacogenetic and epigenetic information involving relevant DDIs 
will be incorporated into the database, and the evidence sets can be ranked through 
the use of various ontologies. 








Furthermore, improvements to the OncoRx-MI search interface will be done to 
enhance the usability of this application, especially to users of smartphones 
supporting other operating systems, such as Android and Windows 7. In addition, 
drug administration information, alternative indexed drug and CAM names, as well as 
the ability for OncoRx to search for multiple DDIs within an interaction search will be 
included in future updates. 
The second area that this project targeted was in relation to oncology ADRs, 
specifically CINV. An unsupervised machine learning technique, PCA, was employed 
to explore the risk factors that could explain the variances in our local population in 
terms of the clinical endpoints CR, CP and CC. In addition, the PV approach was 
utilised to identify the potential risk factors that could be used as clinical CINV 
predictors. Five risk factors (gender, fatigue, histories of alcohol drinking, 
chemotherapy-induced nausea, and vomiting) and 7 anxiety symptoms (faintness, fear 
of dying, fear of the worst, hot/cold sweats, nervousness, numbness, and unable to 
relax) were identified as PVs that would be useful for practitioners in the clinic setting 
to identify patients at risk of CINV. Recently, a prediction tool was developed to help 
clinicians ascertain patients at risk of developing acute and delayed CINV.
318,319
 
However, this model had a major limitation for use in clinical practice – it was 
developed at a time when the neurokinin-1 antagonist aprepitant was not yet 
available.
352
 Current antiemetic guidelines support the use of aprepitant in the 
proactive treatment of CINV.
189,196,320
 As such, it is essential that the prediction of 
CINV is in relation to its clinical endpoints (CR, CC and CP), rather than NV alone. 
This project considered these endpoints, thus making its results clinically-relevant to 
the current treatment of CINV. Even though this is only an exploratory study, the use 
of a computational tool, such as PCA, as an application in pharmacoinformatics to 








reduce the risk of ADRs, particularly CINV, has been successfully demonstrated. The 
results of this study can provide a foundation for future research to be done so that the 
roles of the clinical CINV predictors that are identified can be better established.  
Although this project studied a variety of risk factors for CINV, there were 
other parameters reported as risk factors that were not being considered. These 
included the level of social functioning,
317
 number of chemotherapy cycles,
318
 
expectation of developing pain,
185
 disease stage and level of food intake.
170,318
 This 
omission was due in part to the difficulty of getting the information and the 
subjectivity involved during the interviews. Moreover, the evidences of these factors 
as CINV predictors have been scarce.  
The advent of statistical learning techniques, which motivates a set of 
supervised learning methods that can be used for classification and regression data,
353-
355
 can be utilised to further develop prediction models for CINV as a future 
expansion of this project. Among these techniques, support vector machines (SVMs) 
have been popular as generalized classifiers to predict future data.
353
  The main 
advantage of SVMs over other statistical methods (e.g. logistic regression, decision 
trees, neural networks) is their relatively low sensitivities to overfitting of data, even 
with the use of a large number of redundant and overlapping descriptors, hence 
implying that even the CINV risk factors that have been scarcely reported in literature 
can be used in this machine learning model. However, the limitation of SVMs is that 
they require a sufficiently large number of samples in order to develop the 
classification system, and irrelevant descriptors may reduce the prediction accuracies 
of the classification system. 
Therefore, future work on the prediction of CINV based on statistical learning 
techniques and the clinical predictors identified in this study, or other risk factors 








reported in literature, should include larger sample sizes to achieve approximate 
subject to variable ratios of 5:1 to 10:1.
343
 These sample sizes can be achieved by 
involving a range of other cancer types and chemotherapy regimens that are 
moderately or highly emetogenic. However, subgroup analyses of the moderately and 
highly emetogenic regimens should be carried out as well, so that the accuracies and 
reliabilities of such prediction models can be ascertained. 
In conclusion, there is a tremendous potential for the application of 
pharmacoinformatics in enhancing the pharmaceutical care of patients with cancer. 
The research question posed in this project has been answered through the 
achievement of the 2 main objectives set out – a pharmacoinformatics platform which 
houses a novel oncology database for the detection of ACD and CReg interactions has 
been successfully implemented for use by healthcare practitioners; and a 
pharmacoinformatics tool has been successfully employed for the clinical prediction 
of CINV. Albeit the fact that more can be done to leverage on the potential of 
pharmacoinformatics for improving pharmaceutical care, this project has managed to 
illustrate how pharmacoinformatics can fill the “gap” in clinical oncology practice by 
demonstrating its usefulness as an aid to healthcare professionals for the reduction of 
DRPs, in particular, oncology DDIs and ADRs. 
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Appendix 1. List of drug- and oncology-related information warehouses with short descriptions 
of the websites and their hyperlinks. 
 
Name of website Description of website Link 
Drug information databases 
American Hospital 
Formulary Service 
This site consists of over 1,200 monographs on over 50,000 
products. Drug information is evidence-based, peer 
reviewed, compiled and evaluated by the American Society 
of Health-System Pharmacists. Content includes uses, 
pharmacokinetics, interactions, cautions, dosages, and 
linked references to PubMed citations. The database also 
comprises of regular updates on newly approved drugs, 







This database provides guidance on the prescription, 
dispensing and administration of medicines generally used 
in the UK. Content includes uses, cautions, contra-
indications, side-effects, dosage and relative costs. Drug 
information is drawn from product, medical and 
pharmaceutical literature, regulatory and professional 
bodies. Published by the British Medical Association and 





This database consists of drug information on US 
prescription drugs, herbal supplements, nutritional and over-
the-counter products. Content includes product information, 
uses, dosages, administration and preparation guidelines, 
precautions and boxed warning indicators, product images, 
chemical structures and references. The database also 
features drug class overviews, reports on adverse reactions 
and drug interactions, clinical and product comparisons, 





The database, operated by the US National Library of 
Medicine, comprises of monographs of 3657 FDA approved 
drugs categorised in alphabetical order. Drug information is 
comprehensive and up-to-date as found in package inserts. 
Content includes physical and chemical characteristics of 
the drug, uses, pharmacology, warnings and precautions, 






This database includes more than 24,000 prescription drugs, 
over-the-counter medicines and natural products. Content 
includes pharmacology, pharmacokinetics, uses, 
precautions, adverse reactions, and potential drug 
interactions. Powered by MicromedexTM, Facts & 







This database comprises of more than 3,300 drug 
monographs by generic and brand names. Content includes 
uses, dosing, mechanisms of action, adverse reactions, 
interactions, contraindications, black box warnings, pricing 
and pill images. Drug information is compiled by a team of 
healthcare professionals from primary literature, clinical 
guidelines, society recommendations, manufacturer data, 






Drug information is based on a reference library which 
includes Drugs Facts and Comparisons® and Drug 
Interaction FactsTM. Content includes indications, black box 
warnings, dosing and clinical trial information, adverse 
reactions, bioequivalency codes, manufacturer index, orphan 





The database provides clinical information on drugs, 
interactions, disease managements, formulary services, 
patient education resources and clinical support tools. Drug 
monographs are designed to cater towards various 
healthcare professionals. Content includes uses, dosing, 
warnings, adverse reactions, interactions, IV compatibility, 






Drug information on drugs, herbs and supplements are 
categorised in alphabetical order. Content includes uses, 
dosing, precautions, side effects and brand names. Powered 








This database provides comprehensive referenced 
information of more than 2,300 drugs. Drugs are searchable 
by generic or brand names. Content includes uses, dosing, 
black box warnings, interactions, adverse effects, 
toxicology, pharmacology, pharmacokinetics and IV 





Drug monographs are listed in alphabetical order based on 
both generic and brand names. Content includes chemical 
structures of drug, physical properties, uses, dosing, side 
effects, interactions, warnings and precautions, 
contraindications, pharmacology and pharmacokinetics. 




This database provides monographs of over 3,000 drugs, 
pharmaceuticals, herbs and dietary supplements. It also 
includes sections on uses, dosing, pharmacology, 
precautions, adverse reactions, and symptoms and treatment 
of overdose. References are also provided for herbal and 










This bulletin is produced 6 times a year by the Australian 
Adverse Drug Reactions Advisory Committee (ADRAC) at 
the Department of Health and Aging, Therapeutic Goods 
Administration. Various drug interactions and reactions are 






This database detects drug interactions in a prescription with 
other drugs, caffeine, alcohol, enteral feedings, food, 
grapefruit juice and tobacco. Therapeutic duplications are 
also displayed, when applicable. Drug interaction 
information includes the generic and brand names of the 






This is a commercially developed database which caters 
mainly towards patients. However, the information provided 
is also useful for healthcare professionals in their clinical 
practice. Users can check for drug interactions and side 
effects of the drugs in a prescription, as well as any 
symptoms experienced by the patient. Drug interaction 
information includes interaction effects, risk levels, 
precautions for patients and clinicians, monitoring and 







This site checks for interactions between 2 or more drugs, as 
well as with food and alcohol. Information provided include 
interaction effects, monitoring parameters, proposed 
management, severity level (major, moderate or minor), and 







This site displays information on food-drug and drug-drug 
interactions. Details include the interaction effects, level of 
severity (major, moderate or minor), monitoring parameters 






This software tool predicts interactions between drugs and 
genes based on genetic testing and cytochrome P450 
metabolism. The database consists of 2,000 drugs and 
metabolites, 1,500 substrates and 1,000 inducers and 
inhibitors. The programme is also able to predict and weigh 
interactions which are not reported in literature. Details 
include the interacting drug-drug or drug-gene pairs, an 






This database can detect interactions of drugs, herbs and 
vitamins with other drugs, food, alcohol, nicotine and 
caffeine. Any duplication in therapy will also be shown. 
Severity indices are provided for drug-drug and drug-food 
interactions, together with the interaction effects, 








Institute for Safe 
Medication 
Practices 
This site is operated in collaboration with the US 
Pharmacopeia under a national Medication Errors Reporting 
Programme. It allows voluntary submission of medication 
errors by practitioners, and these are independently reviewed 
by the Institute for Safe Medication Practices, a non-profit 
organisation. The site provides safety alerts, error reporting 
information, self-assessment tools, consumer medication 
safety information, and a message board for discussion of 





This site checks for interactions in a multidrug regimen. 
Individual drugs are entered into a search box and checked 
against each other. Details of the detected interaction 
include a severity level, mechanism of interaction, clinical 
effects, case reports and a proposed management plan. Free 
online registration and Flash plugin is required for access to 










Created by the University of Washington, this database 
contains in-vitro and in-vivo information on drug 
interactions referenced from publications in PubMed, New 
Drug Applications and product labels. Also includes 
sections on clinical case reports, pharmacokinetic drug 
profiles and drug interactions for recently approved drugs 






This drug interaction tool detects potential drug-drug, drug-
food, drug-alcohol and drug-tobacco interactions. A 
summary of the interaction effects and precautions for 
patients are provided together with a severity index. Drug 











This site provides safety alerts for drugs, medical devices, 
vaccines and other biologics, dietary supplements and 
cosmetic products. Information includes drug safety 
labelling changes that are updated monthly, and an adverse 
event reporting system. The safety alerts are archived online 
since 2000, while data from 1996-2007 can be downloaded 










This bulletin archives articles from year 2005 onwards, and 
is published quarterly. Articles communicate the latest news 
and trends regarding information which impacts the safety, 
efficacy and quality of medicines, medical products, herbals, 
biomedicine and their related products. These include 









Oncology databases for healthcare professionals 
Adjuvant Online 
The programme in this site is designed to help healthcare 
professionals in the oncology setting make estimates of risks 
of negative outcomes in patients with cancer, such as side 
effects, relapses and mortality. The software also estimates 
the reduction of these risks from therapy. User input of 
patient and tumour characteristics is needed to perform the 
calculations. Requires free online registration and java 







This site provides evidence-based practice guidelines and 
comprehensive information on cancer-related topics, 
practice management issues and initiatives for health 
professionals to enhance their quality of patient care. The 
site also provides resources for the continuing education of 
students and healthcare practitioners in oncology-related 
fields. Set up by American Society of Clinical Oncology, a 
non-profit organisation represented by oncology 
practitioners in all disciplines and subspecialties, this site is 
useful for health professionals to keep abreast with current 
knowledge on cancer-related topics, and establishing and 







This manual consists of over 100 anticancer drug 
monographs written, reviewed and edited by the healthcare 
team at the provincial government-funded organisation. 
Information is designed for healthcare professionals in 
general practice. Content of the monographs include the 
pharmacological classification, whether the drug is a 
cytotoxic, mechanism of action, pharmacokinetics, uses, 









This site provides an extensive coverage on matters related 
to oncology. Information is organised based on various 
cancer types and malignancies. Users have access to 
published journal articles, management and treatment 
updates, conference coverages, expert viewpoints, case 
challenges and other interactive tools such as webcasts. 








This site is managed by the National Comprehensive Cancer 
Network, a non-profit alliance of 21 of the world’s leading 
cancer centres in the US. The resources available on this site 
include treatment and clinical practice guidelines in 
oncology, a drugs and biologics compendium, 
chemotherapy order templates, presentations and additional 
information on clinical trials and continuing education, as 
well as an online catalogue. News and announcements about 






recent press coverage are also frequently updated on the site. 
The information provided is based on the independent 
evaluation of available scientific evidence, integrated with 





Managed by the Faculty of Medicine, University of Toronto, 
this site provides current information on important scientific 
and clinical developments in oncology. Topics and content 
span a wide variety of areas, including diagnosis, treatment 











This is a scientific organisation which focuses its efforts on 
providing high-quality and innovative cancer research to its 
readers. Their published magazine CR (Collaborations  
Results) is catered towards cancer survivors and their 
families, patient advocates and other scientists in related 
fields. The website also provides opportunities for sharing 
evidence-based information and perspectives on cancer 
research through collaborations with the public, media 





This site provides the public with accurate, up-to-date 
information on all aspects of cancer. Patients and their 
families or caregivers can learn about the disease through 
support resources, treatment decision tools, news updates 




Previously known as “People Living with Cancer (PLWC)”, 
this site is the supported patient information website of the 
American Society of Clinical Oncology. All the information 
and content in this website is developed, peer-reviewed and 
approved by healthcare professionals who are members of 
the society. Content includes comprehensive guides to the 
different types of cancer and their related syndromes, 
diagnosis and treatment options, and side effects. An 
overview of cancer statistics, risk factors, prevention 
strategies, cancer staging, genetics and clinical trial 
information is also provided. In addition, practical advice on 
coping with the physical and emotional aspects of cancer is 







This website is set up by the US National Institutes of 
Health and is the government's principal agency for cancer 
research. It provides accurate, up-to-date and comprehensive 
cancer-related information on a wide variety of topics 
oriented towards the consumer. Resources are provided for 






treatment, and other available management options. In 
addition, a comprehensive dictionary of terms related to 
cancer and medicine is also included. 
OncoLink 
This site is set up by the Abramson Cancer Center, 
University of Pennsylvania, and comprises of information 
about various cancer types and treatments, treatment 
updates, news and research advances. There is also an “Ask 
the Experts” section in which questions posed by the general 








Published by the British Medical Journal Group, the 
Archives of Disease in Childhood (ADC) Archimedes blogs 
provide evidence-based answers to clinical questions in 
paediatric practice. A topic summary of the clinical question 
is followed by a short narrative of the clinical episode, its 
evidence and applications, as well as critical appraisals. 










Also published by the British Medical Journal Group, the 
Archives of Disease in Childhood (ADC) Precis blogs 
provide a brief description of article contents every month 
from its parent journal. The blog summarises each article in 
a one to 2 line format and includes hyperlinks to the original 
web version of the article in ADC. Entries categorised under 









This site provides a good repertoire of case studies for 
medical students and professionals to apply their clinical 
knowledge and practice. Cases which are on oncology are 
categorised under haematology and oncology. Each topic 
explores challenging clinical dilemmas through discussions 
of case and medication histories, imaging and clinical 











This blog is operated by GE Healthcare to provide an 
avenue for communication with GE Healthcare leaders 
about their activities, project and events in Europe. Recently 
revamped, its entries are archived from September 2009 to 
October 2010 and are categorised into anaesthesia, 
cardiology, oncology and radiology. Blog entries which are 












This blog is moderated by oncology healthcare professionals 
of various specialties and discusses about current research, 
trials, treatments and issues in the haematology and 
oncology fields. Entries are categorised based on their areas 
of specialty, such as breast and genitourinary cancers, 






The Lancet Global 
Health Network 
Owned and operated by Elsevier Limited, the entries in this 
site discuss a wide range of health topics from infectious 







This site provides a gateway to medical information in 
oncology and is maintained by a physician who is American 
board-certified in oncology, haematology and internal 
medicine. Blogs are categorised into various cancers such as 
breast, lung, prostate and colon cancers. The content covers 
a wide variety of cancer-related issues such as research 
news, treatment advances and personal stories and 











Appendix 2. The OncoRx-IQ tool for quality assessment of anticancer drug interaction 
information. 
 
Section A: Content Accuracy (27 points)  
 (a) Please refer to the following profile for the interaction between the chemotherapy regimen 
EP (etoposide, cisplatin) and valproic acid. 
 
 

































In a cohort study of 70 
patients, the risk of 
haematological toxicity 
was shown to be 3 












1. Bourg V, et al. Nitroso-
urea-cisplatin-based 
chemotherapy associated 
with valproate: increase of 


















resulting in a loss 























cisplatin. Her plasma 
valproic acid 
concentrations were 
found to have 





A 34 year old male 
epileptic patient 
concurrently receiving 
valproic acid and 
cisplatin-based 
chemotherapy for the 









A) Monitor for seizure 
control. Consider adding 
gabapentin or 
levetiracetam only if 
seizure control with 




1. Neef C, et al. An 
interaction between 
cytostatic and 





2. Ikeda H, et al. 
Pharmacokinetic interaction 
on valproic acid and 
recurrence of epileptic 
seizures during 
chemotherapy in an 
epileptic patient. Br J Clin 
Pharmacol 2005;59(5):593-
7. [PMID: 15842559] 
 
3. Bourg V, et al. Nitroso-
urea-cisplatin-based 
chemotherapy associated 
with valproate: increase of 












5. Vecht CJ, et al. Treating 
seizures in patients with 




Semin Oncol 2003;30(6 
Suppl 19):49-52. [PMID: 
14765386] 
 
B) Increased risk 
of haematological 
toxicity. 









In a cohort study of 70 
patients, the risk of 
haematological toxicity 
was shown to be 3 

















Interacting drug pair: etoposide and valproic acid 
 
1. Is / are the correct interaction effect(s) provided for the above drug pair? 
 (0) No / incorrect effect(s) provided    
 (1) General effect(s) provided     
 (2) Detailed effect(s) provided       
 
2. Is / are the correct mechanism(s) of interaction provided for the above drug pair? 
 (0) No / incorrect mechanism(s) provided    
 (1) General mechanism(s) provided    
 (2) Specific mechanism(s) provided      
 
3. Is / are the correct evidence(s) (e.g. case reports, animal, human or in-vitro studies) provided 
for the interaction concerning the above drug pair? 
 (0) No / incorrect evidence(s) provided    
 (1) Only reference(s) provided     
 (2) Summarised evidence(s) (w/o details) provided  
 (3) Detailed evidence(s) provided       
 
4. Is / are the appropriate recommendation(s) provided to manage the interaction for the above 
drug pair? 
 (0) No / incorrect recommendation(s) provided   
 (1) General recommendation(s) provided    
 (2) Specific recommendation(s) provided    
 
Interacting drug pair: cisplatin and valproic acid 
 
5. Is / are the correct interaction effect(s) provided for the above drug pair? 
 (0) No / incorrect effect(s) provided    
 (1) General effect(s) provided     
 (2) Detailed effect(s) provided       
 
6. Is / are the correct mechanism(s) of interaction provided for the above drug pair? 
 (0) No / incorrect mechanism(s) provided    
 (1) General mechanism(s) provided    














7. Is / are the correct evidence(s) (e.g. case reports, animal, human or in-vitro studies) provided 
for the interaction concerning the above drug pair? 
 (0) No / incorrect evidence(s) provided    
 (1) Only reference(s) provided     
 (2) Summarised evidence(s) (w/o details) provided  
 (3) Detailed evidence(s) provided       
 
8. Is / are the appropriate recommendation(s) provided to manage the interaction for the above 
drug pair? 
 (0) No / incorrect recommendation(s) provided   
 (1) General recommendation(s) provided    
 (2) Specific recommendation(s) provided    
 
 
(b) Please refer to the following profile for the interaction between the anticancer drug 
vorinostat and valproic acid. 
 












Details of Case 






























In-vitro and animal 
studies have shown 
the HDAC inhibitory 





vorinostat, a HDAC 
inhibitor, with other 
HDAC inhibitors has 









monitoring of the 
patient's platelet count 




1. Göttlicher M, et al. 
Valproic acid defines 








2. Eyal S, et al. The 
activity of antiepileptic 






3. Phiel CJ, et al. 
Histone deacetylase is 
a direct target of 
valproic acid, a potent 
anticonvulsant, mood 
stabilizer, and 
teratogen. J Biol 
Chem 
2001;276(39):36734-
41. [PMID: 11473107] 
 
















Interacting drug pair: vorinostat and valproic acid 
 
9. Is / are the correct interaction effect(s) provided for the above drug pair? 
 (0) No / incorrect effect(s) provided    
 (1) General effect(s) provided     
 (2) Detailed effect(s) provided       
 
10. Is / are the correct mechanism(s) of interaction provided for the above drug pair? 
 (0) No / incorrect mechanism(s) provided    
 (1) General mechanism(s) provided    
 (2) Specific mechanism(s) provided      
 
11. Is / are the correct evidence(s) (e.g. case reports, animal, human or in-vitro studies) provided 
for the interaction concerning the above drug pair? 
 (0) No / incorrect evidence(s) provided    
 (1) Only reference(s) provided     
 (2) Summarised evidence(s) (w/o details) provided  
 (3) Detailed evidence(s) provided       
 
12. Is / are the appropriate recommendation(s) provided to manage the interaction for the above 
drug pair? 
 (0) No / incorrect recommendation(s) provided   
 (1) General recommendation(s) provided    
 (2) Specific recommendation(s) provided    
 
Section B: Overall Quality (40 points)  
 
(a) Ease of use (12 points) 
 
13. Does the database contain a help feature? 
 (0) No        
 (1) Yes        
  
14. Does the database contain a site map, index or menu system that facilitates navigation? 
 (0) No        















15. Can the database search for drug interactions using chemotherapy regimen acronyms (e.g. 
BEACOPP, ESHAP, R-CHOP)?  
 (0) No        
 (1) Yes        
  
16. Can the database search for more than one drug interaction simultaneously (e.g. drug 
interactions between valproic acid and the following anticancer drugs: cisplatin, etoposide, 
vorinostat? 
 (0) No        
 (1) Yes        
  










(b) Reliability (28 points) 
 
18. Does the database state its source(s) of funding?  
 (0) No        
 (1) Yes        
  
19. Does the database contain any evidence of bias (e.g. advertisements)? 
 (0) Yes        
 (1) No        
  
20. Does the database state the name(s) and credential(s) of its author(s)? 
 (0) No information provided      
 (1) Only name(s) provided       
 (2) Name(s) and credential(s) provided     
 (3) Name(s) and credential(s) (with explanations) provided  
  
21. Does the database state how it is reviewed for information accuracy?  
 (0) No information       
 (1) Reviewed internally      















i) Loads within an 
acceptable time period 
     











22. Is the probability AND the severity of the interactions stated? 
 (0) None stated / unclear      
 (1) Only probability OR severity stated    
 (2) Both stated       
  
23. How does the database cite the source(s) used to compile the drug interaction information? 
 (0) No sources cited        
 (1) Information extracted from external drug database(s)    
 (2) Exact source(s) (e.g. journal articles, books, product inserts) cited  
  
24. Are there links to other sources (e.g. PubMed abstracts and/or original articles, online drug 
databases) to verify the drug interaction information in the database? 
 (0) No        
 (1) Yes        
  









































i)  Clearly states the 
types of drug-related 
information it provides 
     
ii)  Clearly states the 
types of personal 
information it collects 
and how the information 
is used 
     
iii)  Clearly states who 
the target audiences are 
     
iv)  Specifies that the 
information is 
NOT meant to replace 
the advice of a healthcare 
professional 








Appendix 3. List of anticancer drugs, chemotherapy regimens, psychotropic agents, and 
complementary and alternative medicines in the OncoRx database . 
 
List of anticancer drugs classified according to pharmacological categories 
Alkylating agents 
Altretamine, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, 
estramustine, ifosfamide, lomustine, mechlorethamine, melphalan, procarbazine, thiotepa, 
temozolomide, treosulfan 
Antimetabolites 
Azacitidine, capecitabine, cladribine, clofarabine, cytarabine, fludarabine, fluorouracil, 
gemcitabine, mercaptopurine, methotrexate, pemetrexed, pentostatin, raltitrexed, tegafur, 
thioguanine 
Antimicrotubules 
Docetaxel, ixabepilone, paclitaxel, vinblastine, vincristine, vindesine, vinorelbine 
Biological modifiers 
Aldesleukin, denileukin, filgrastim, interferon alfa-2a and -2b, pegfilgrastim, sargramostim 
Corticosteroids 
Dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone 
Hormone agonists/antagonists 
Anastrozole, bicalutamide, buserelin, cyproterone, exemestane, flutamide, fulvestrant, 
goserelin, lanreotide, letrozole, leuprolide, medroxyprogesterone, megestrol, nilutamide, 
norethisterone, octreotide, tamoxifen, toremifene, triptorelin 
Platinum compounds 
Cisplatin, carboplatin, oxaliplatin 
Topoisomerase inhibitors 
Amsacrine, daunorubicin, doxorubicin, epirubicin, etoposide, idarubicin, irinotecan, 
mitoxantrone, topotecan 
Tyrosine kinase inhibitors and monoclonal antibodies 
Alemtuzumab, bevacizumab, bortezomib, cetuximab, dasatinib, erlotinib, gefitinib, 
gemtuzumab, ibritumomab, imatinib, lapatinib, rituximab, sorafenib, sunitinib, tositumomab, 
trastuzumab 
Other anticancer drugs 
Angiogenesis inhibitor: Thalidomide 





Cytotoxic antibiotics: Bleomycin, dactinomycin, mitomycin 
Histone deacetylase inhibitor: Vorinostat 
Mammalian target of rapamycin inhibitor: Temsirolimus 
Photosensitising agent: Temoporfin 
Retinoid: Alitretinoin, bexarotene, tretinoin 
Miscellaneous: Arsenic trioxide, asparaginase, hydroxyurea, mitotane, palifermin, 
pegaspargase, porfimer, trabectedin 
 
List of chemotherapy regimens classified based on types of cancer they treat 
Bone and tissue cancers 
Single-agent: doxorubicin, trabectedin  
Combination: AD, DI/AIM, ICE, IFoVP, MAID, MTX-CDDP/Adria, P6, Topo/CTX, VAC, 
vincristine/doxorubicin/cyclophosphamide 
Breast cancers 
Single-agent: Abraxane, anastrazole, capecitabine, docetaxel, exemestane, fulvestrant, 
gemcitabine, ixabepilone, letrozole, megestrol, paclitaxel, tamoxifen, toremifene, 
trastuzumab, vinorelbine 
Combination: AC, ACTH, AT, A-T-C, CAF, CEF, CMF, FNC, GT, HEC, 
ixabepilone/capecitabine, NA, NFL, paclitaxel/vinorelbine, sequential AC-T, sequential 
Dox-CMF, TAC, tamoxifen/epirubicin, TCH, TH, X+T 
Central nervous system and brain cancers 
Single-agent: carboplatin, temozolomide 
Combination: A1, A3, BCNU, CAV+P/VP, CDDP/VP-16, COPE (Baby Brain I), high-risk 
neuroblastoma regimen, PCV, POC, vincristine/cisplatin/cyclophosphamide, 
vincristine/etoposide/carboplatin/cyclophosphamide/mesna 
Gastrointestinal, colorectal, liver and pancreatic cancers 
Single-agent: capecitabine, cetuximab, fluorouracil, gemcitabine, imatinib, irinotecan 
Combination: 5-FU/LV, cetuximab/irinotecan, Douillard regimen, ECF, ELF, FAMTX, 
FLOX, FOLFIRI, FOLFOX, FUP, GEMOX, IFL/BV, Mayo regimen, OXAFI, Roswell Park 
regimen, Saltz regimen, TC, XELOX 
Genitourinary cancers 
Single-agent: estramustine, goserelin, interferon alfa-2b, interleukin-2, leuprolide, 
nilutamide, prednisone, sorafenib, sunitinib, temsirolimus, triptorelin 
Combination: BEP, bicalutamide with leuprolide/goserelin, cisplatin/docetaxel, CMV, 
docetaxel/estramustine, docetaxel/prednisone, EP, estramustine/vinblastine, FL, FZ, 
gemcitabine/cisplatin, interleukin-2/interferon alfa-2a, mitoxantrone/prednisone, MVAC, 





Single-agent: alemtuzumab, arsenic trioxide (induction, post-remission), chlorambucil, 
cyclophosphamide, cytarabine, fludarabine, gemtuzumab, interferon alfa-2a, imatinib, 
prednisone 
Combination: 5+2, 6-MP/CPM/Ara-C, 6-MP/MTX, 7+3, 7+3+7, ATRA, CA, CALGB 8811 
(induction, early intensification, central nervous system prophylaxis and interim 
maintenance, late intensification, maintenance), DA, DAT, DAV, DCTER, double-delayed 
intensification regimen, HI-C DAZE, HDAC, Hyper-CVAD (central nervous system 
prophylaxis, even cycles, odd cycles), idarubicin/cytarabine/etoposide, IDMTX, interferon 
alfa-2b/hydroxyurea/cytarabine, MTX/6-MP, MTX/6-MP/VP, OD, PVA, PVDA, TIT, 
vincristine/prednisone/pegaspargase/cytarabine/methotrexate 
Lung cancers 
Single-agent: docetaxel, erlotinib, etoposide, gefitinib, gemcitabine, paclitaxel, topotecan, 
vinorelbine 
Combination: CAE, carboplatin/paclitaxel/etoposide, Carbo-Tax, CAV, CAV/EP, 
CDDP+CPT-11, docetaxel/cisplatin, EC, EP, gemcitabine/cisplatin, 
gemcitabine/docetaxel/filgrastim, gemcitabine/paclitaxel, gemcitabine/vinorelbine, PC, 
pemetrexed/cisplatin, vinorelbine/cisplatin, VIP 
Lymphomas and myelomas 
Single-agent: bexarotene, bortezomib, denileukin, dexamethasone, fludarabine, interferon 
alfa-2b, melphalan, rituximab, thalidomide, tositumomab, vorinostat 
Combination: ABVD (adult and paediatric regimens), BEACOPP, CDE, CHOP (AIDs-
related, adult and paediatric regimens for non-Hodgkin’s lymphoma), CNOP, CODOX-
M/IVAC, COP, CVP, DeAngelis protocol, DHAP, EPOCH, ESHAP, Hyper-CVAD/MTX-
Ara-C (courses 1 and 2), ibritumomab/rituximab, m-BACOD, MINE-ESHAP, MOPP, 
MOPP/ABVD, MP, Ommaya regimen, RCHOP, RICE, SNCCL/B-ALL, Stanford V, 
thalidomide/dexamethasone, VAD 
Other cancers 
Adenocarcinomas: CaT, EP, paclitaxel/carboplatin/etoposide 
AIDs-related Kaposi’s sarcoma: alitretinoin, liposomal daunorubicin, pegylated liposomal 
doxorubicin, paclitaxel 
Gynaecologic cancers: altretamine, cisplatin, doxorubicin, pegylated liposomal doxorubicin, 
gemcitabine, medroxyprogesterone, paclitaxel, topotecan, Carbo-docetaxel, Carbo-Tax, 
cisplatin/fluorouracil, cisplatin/vinorelbine, C-P, CT, TAP 
Head, neck and oesophageal cancers: carboplatin/fluorouracil, cisplatin/fluorouracil 
Melanomas: aldesleukin, dacarbazine, interferons alfa-2a and -2b, temozolomide, 
cisplatin/dacarbazine/carmustine/tamoxifen, CVD 





List of psychotropic agents classified based on the types of conditions they treat
+
 
Agents for depression 
Tricyclic antidepressants: Amitriptyline, clomipramine, dosulepin/dothiepin, doxepin, 
imipramine, nortriptyline 
Selective serotonin reuptake inhibitors: Citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline 
Other antidepressants 
Dopamine reuptake inhibitor: Bupropion 
Monoamine oxidase inhibitor: Moclobemide, selegiline 
Phenyltriazine derivative: Lamotrigine 
Selective serotonin reuptake enhancer: Tianeptine  
Serotonin antagonist and reuptake inhibitor: Trazodone 
Serotonin / norepinephrine reuptake inhibitor: Duloxetine, venlafaxine 
Tetracyclic / noradrenergic and specific serotonergic antidepressant: Mirtazepine 
Agents for epilepsy 
Acetazolamide, carbamazepine, clobazam, clonazepam, diazepam, ethosuximide, felbamate, 
fosphenytoin, gabapentin, lamotrigine, levetiracetam, lorazepam, midazolam, oxcarbazepine, 
paraldehyde, phenobarbital, phenytoin, piracetam, pregabalin, primidone, riluzole, tiagabine, 
topiramate, valproic acid, vigabatrin, zonisamide 
Central nervous system stimulants and agents for attention-deficit hyperactivity 
disorder 
Atomoxetine, methylphenidate 
Substance dependence agents 
Bupropion, chlordiazepoxide, disulfiram, naltrexone 





Fenugreek (Trigonella foenum-graecum), psoralea fruit (Psoralea corylifolia), swertiae 
herba (Swertia pseudochinensis, Swertia diluta, Swertia chinensis, Swertia yunnanensis, 
Swertia japonica) 
Cancer treatment and prevention 
714X (trimethylaminohydroxybicycloheptane chloride), agrimony grass (Agrimonia pilosa), 
alpha-lipoic acid (1,2-dithiolane-3-pentanoic acid), amygdalin (D-mandelonitrile-b-D-
glucosido-6-b-D-glucoside), anvirzel (oleandrin) (Nerium oleander), arisaema rhizome 
(Arisaema consanguineum, Arisaema heterophyllum, Arisaema amurense), astragalus 
(Astragalus membranaceus), barley (Hordeum vulgare), bee pollen, bilberry fruit 
(Vaccinium myrtillus), bitter melon (Momordica charantia), black nightshade (Solanum 




Aphanizomenon flos-aquae), bupleurum (Bupleurum chinense, Bupleurum 
scorzoneraefolium), burdock (Arctium majus), calcium glucarate (D-glucaro-1,4-lactone), 
cascara (Rhamnus purshiana), cassia bark (Cinnamomum aromaticum, Cinnamomum 
cassia), cat's claw (Uncaria tomentosa), cephalotaxaceae (Cephalotaxus fortunei), chaparral 
(Larrea tridentate, Larrea divaricata), Chinese anemone root pulsatilla (Pulsatilla 
chinensis), Chinese asparagus (Asparagus cochinchinensis), cordyceps (Cordyceps sinensis), 
coriolus versicolor (Coriolus versicolor, Trametes versicolor, Polyporus versicolor, 
Polystictus versicolor), dong quai (Angelica sinensis), evening primrose oil (Oenothera 
biennis), evodia (Evodia rutaecarpa, Evodia officinalis), fenugreek (Trigonella foenum-
graecum), forskolin (Coleus forskohlii), fourstamen stephania root (Stephania tetrandra), 
garlic (Allium sativum), american ginseng (Panax quinquefolius), Siberian ginseng 
(Eleutherococcus senticosus, Acanthopanax senticosus), glossy privet fruit (Ligustrum 
lucidum Ait), goldenseal (Hydrastis canadensis), gotu kola (Centella asiatica, Hydrocotyle 
asiatica), green tea (Camellia sinensis), indigo (Isatis tinctoria), isatis leaf (Isatidis 
baphicacanthi, Isatis tinctoria, Isatis indigotica), isatis root (Isatidis baphicacanthi, Isatis 
tinctoria, Isatis indigotica), licorice (Glycyrrhiza glabra, Glycyrrhiza uralensis), maitake 
(Grifola frondosa), milk thistle (Silybum marianum, Carduus marianum), european mistletoe 
(Viscum album, Viscum coloratum), mume fruit (Prunus mume), noni (Morinda citrifolia), 
pau d'arco (Tabebuia impetiginosa, Tabebuia avellanedae, Tabebuia heptaphylla), 
pennyroyal (Mentha pulegium, Hedeoma pulegioides), pinellia rhizome (Pinella ternata, 
Pinella pedatisecta), pokeweed (Phytolacca americana), rabdosia rubescens (Rabdosia 
rubescens), rhizoma iphigenia indica (Iphigenia indica), rhubarb (Rheum palmatum, Rheum 
officinale), saw palmetto (Serenoa repens), skullcap (Scutellaria baicalensis, Scutellaria 
lateriflora), sheep sorrel (Rumex acetosella), shiitake mushroom (Lentinula edodes), slippery 
elm (Ulmus rubra), sophora root (Sophora subprostata), soy (Glycine max), spreading 
hedyotis (Hedyotis diffusa, Hedyotis corymbosa), stillingia (Stillingia sylvatica), 
trichosanthes root (Trichosanthes kirilowii, Trichosanthes japonica, Trichosanthes uniflora), 
turmeric (Curcuma longa, Curcuma domestica) 
Fatigue syndrome 
Blue-green algae (Spirulina sp., Aphanizomenon flos-aquae), cordyceps (Cordyceps 
sinensis), guarana (Paullinia cupana), maté (Ilex paraguariensis), St. John's wort 
(Hypericum perforatum) 
Immune-system-related 
Astragalus (Astragalus membranaceus), bee pollen, bitter melon (Momordica charantia), 
blue-green algae (Spirulina sp., Aphanizomenon flos-aquae), cat’s claw (Uncaria 
tomentosa), cordyceps (Cordyceps sinensis), Coriolus versicolor (Coriolus versicolor, 
Trametes versicolor, Polyporus versicolor, Polystictus versicolor), echinacea (Echinacea 
purpurea, Echinacea angustifolia, Echinacea pallida), american ginseng (Panax 
quinquefolius), asian ginseng (Panax ginseng), Siberian ginseng (Eleutherococcus 
senticosus, Acanthopanax senticosus), glossy privet fruit (Ligustrum lucidum Ait), 
goldenseal (Hydrastis canadensis), maitake (Grifola frondosa), european mistletoe (Viscum 
album, Viscum coloratum), mume fruit (Prunus mume), noni (Morinda citrifolia), reishi 
mushroom (Ganoderma lucidum), rhubarb (Rheum palmatum, Rheum officinale), shiitake 





Achyranthes root (Achyranthes bidentata, Achyranthes longifolia, Achyranthes aspera), aloe 
vera (Aloe barbadensis, Aloe capensis), arnica (Arnica montana), berberidaceae (Berberis 
soulieana, Berberis wilsonae, Berberis poirettii, Berberis vernae), black nightshade 
(Solanum nigrum), bupleurum (Bupleurum chinense, Bupleurum scorzoneraefolium), 
butcher's broom (Ruscus aculeatus), cat's claw (Uncaria tomentosa), german chamomile 
(Matricaria recutita L.), chaparral (Larrea tridentate, Larrea divaricata), cinnamon 
(Cinnamomum verum, Cinnamomum zeylanicum), comfrey (Symphytum officinale), devil's 
claw (Harpagophytum procumbens), divaricate saposhnikovia root (Ledebouriella 
divaricata, Ledebouriella seseloids, Siler divaricatum, Saposhnikovia divaricata, 
Stenocoelium divaricatum), eucommia bark (Eucommia ulmoides), fenugreek (Trigonella 
foenum-graecum), forsythia fruit (Forsythia suspensa, Syringa suspensa, Forsythia 
viridissima, Forsythia koreana), fourstamen stephania root (Stephania tetrandra), gotu kola 
(Centella asiatica, Hydrocotyle asiatica), licorice (Glycyrrhiza glabra, Glycyrrhiza 
uralensis), lobelia (Lobelia inflata), nettle (Urtica dioica), pennyroyal (Mentha pulegium, 
Hedeoma pulegioides), pseudoginseng (Panax notoginseng), pygeum (Pygeum africanum, 
Prunus Africana), rehmannia root (Rehmannia glutinosa), reishi mushroom (Ganoderma 
lucidum), rhizoma sinomenii acuti (Sinomenium acutum), rhubarb (Rheum palmatum, Rheum 
officinale), sassafras (Sassafras albidum), saw palmetto (Serenoa repens), skullcap 
(Scutellaria baicalensis, Scutellaria lateriflora), sheep sorrel (Rumex acetosella), slippery 
elm (Ulmus rubra), solomon’s seal (Polygonatum multiflorum, Polygonatum odoratum, 
Polygonatum pluriforum), tea tree oil (Melaleuca alternifolia), tree peony bark (Paeonia 
suffruiticosa), turmeric (Curcuma longa, Curcuma domestica), willow bark (Salix alba) 
Nausea and vomiting 
Ginger (Zingiber officinale), peppermint (Mentha haplocalyx, Mentha piperita, Mentha 
lavanduliodora, Mentha arvensis) 
Peripheral neuropathy and pain 
Achyranthes root (Achyranthes bidentata, Achyranthes longifolia, Achyranthes aspera), aloe 
vera (Aloe barbadensis, Aloe capensis), capsaicin (Capsicum frutescens, Capsicum annuum), 
corydalis (Corydalis turtschaninovii), devil's claw (Harpagophytum procumbens), divaricate 
saposhnikovia root (Ledebouriella divaricata, Ledebouriella seseloids, Siler divaricatum, 
Saposhnikovia divaricata, Stenocoelium divaricatum), eucommia bark (Eucommia 
ulmoides), fourstamen stephania root (Stephania tetrandra), asian ginseng (Panax ginseng), 
maté (Ilex paraguariensis), noni (Morinda citrifolia), rhizoma sinomenii acuti (Sinomenium 
acutum), schefflera (Schefflera arboricola, Schefflera kwangsiensis, Schefflera venulosa), St. 
John's wort (Hypericum perforatum), willow bark (Salix alba) 
Non-cancer-related 
Acorus (Acorus gramineus), alangiaceae (Alangium chinense), atractylodes rhizome 
(Atractylodes lancea, Atractylodes chinensis), biond magnolia flower (Magnolia biondii, 
Magnolia fargessi, Magnolia dedudata, Magnolia heptepeta, Magnolia liliflora, Magnolia 
quinquepeta), birthwort fruit (Aristolochia contorta, Aristolochia debilis), black cohosh 
(Cimicifuga racemosa), borage (Borago officinalis), buffalo horns (Bubalus bubalis), cattle 




(Gentiana manshurica, Gentiana scabra, Gentiana triflora, Gentiana regescens), Chinese 
lobelia (Lobelia radicans, Lobelia chinensis), Chinese magnoliavine fruit (schisandra) 
(Schisandra chinensis), Chinese plantain and plantain seed (Plantago asiatica, Plantago 
major, Plantago depressa), chocolate vine stem (Akebia quinata, Aristolochia 
manshuriensis), chrysanthemum (Chrysanthemum morifolium, Chrysanthemum sinense, 
Chrysanthemum japonense), climbing groundsel (Senecio scandens), cocklebur fruit 
(Xanthium sibiricum, Xanthium strumarium), common aucklandia root (costus root) 
(Saussurea lappa, Saussurea costus, Aucklandia costus, Aplotaxis lappa), corn silk (Zea 
mays), croton seed (Croton tiglium), danshen (Salvia miltiorrhiza), dwarf lilyturf tuber 
(Ophiopogon japonica, Liriope spicata), earthworm (Pheretima aspergillum, Allolobophora 
caliginosa), endothelium corneum glgeriae galli (Mucusa ventriculi gali), ephedra (Ephedra 
sinica, Ephedra equisetina), feverfew (Tanacetum parthenium), figwort (Scrophularia 
marilandica, Scrophularia nodosa, Scrophularia ningpoensis, Scrophularia buergeriana), 
finger citron fruit (Citrus medica L. var. sarcodactylis), fleeceflower root (Polygonum 
multiflorum), folium ilicis chinensis (Ilex chinensis), gelatin, ginkgo (Ginkgo biloba), 
glehnia (Glehnia littoralis), green tangerine orange peel (Citrus reticulata, Citrus tangerina, 
Citrus sinensis, Citrus aurantium, Citrus wilsonii), gypsum mineral, hawthorn (Crataegus 
monogyna), herba euphorbiae humifusae (Euphorbia humifusa), horse chestnut (Aesculus 
hippocastanum), ilex (Ilex pubescens), kava (Piper methysticum), largehead atractylodes 
rhizome (Atractylodes macrocephala), lightyellow sophora root (Sophora flavescens), nux 
vomica seed (Strychnos nux-vomica), passionflower (Passiflora incarnate), qing hao 
(Artemisia annua), red clover (Trifolium pratense), rhizoma menispermi (Menispermum 
dauricum), safflower flower (Carthamus tinctorius), senega root (Polygala tenuifolia), 
shrubalthea flower (Vitex negundo L. var. cannabifolia), snakegourd fruit (Trichosanthes 
kirilowii, Trichosanthes uniflora, Trichosanthes braeteata, Trichosanthes multiloba, 
Trichosanthes truncata, Trichosanthes hylonoma, Trichosanthes japonica), song luo (Usnea 
diffracta, Usnea longissima), spicebush root (Lindera strychnifolia), stemona root (Stemona 
japonica), szechwan lovage rhizome (Ligusticum chuanxiong), tall gastrodia tuber and 
armillaria (Gastrodia elata), tangerine peel (Citrus reticulate), tendrilleaf fritillary bulb 
(Fritillaria cirrhosa, Fritillaria unibracteata, Fritillaria przewalskii, Fritillaria delavayi), 
valerian (Valeriana officinalis), wild indigo (Baptisia tinctoria), wolfberry tree bark (Lycium 
chinense), wolly grass root (Imperata clindrica), wormwood (Artemisia absinthium) 
 
+
 Psychotropic agents and complementary and alternative medicines that are indicated for 
multiple conditions are classified into their respective categories. 
ACD: anticancer drug, CAM: complementary and alternative medicine, CReg: 












Appendix 4. Summary of anticancer drug interactions with psychotropic agents and complementary and alternative medicines.  
 
Anticancer drugs 
(ACDs) / drug 
classes 
Interacting 
agents / classes 
Effects and mechanisms of 
interaction 
Proposed management References for interactions 







Increased risk of 
hepatotoxicity. Mechanism is 
unknown, but combined use of 
naltrexone with other 
hepatotoxic agents can 
theoretically potentiate the 
risk of hepatotoxicity, based 
on placebo-controlled studies 




Concurrent use of naltrexone 
and hepatotoxic drugs is not 
recommended, unless the 
potential benefit outweighs the 
risk of hepatotoxicity. Periodic 
monitoring of patient’s liver 
function, and signs and 
symptoms of hepatotoxicity 
(e.g. fever, rash, anorexia, 
nausea, vomiting, fatigue, dark 
urine, upper right quadrant 
pain, and jaundice) is advised. 
 
 Drugsite Trust. Drugs.com: drug interactions 
checker. Available at: 
http://www.drugs.com/drug_interactions.html. 
Accessed 8 August 2009. 
 Barr Laboratories Inc. Naltrexone hydrochloride 





  Naltrexone may also play a 
role in improving the 
anticancer effects of 
interleukin-2 in humans. 
Improvement of anticancer 
effects could be due to 
blockage of the brain opioid 
system leading to 
physiological suppression of 
the neurological system. 
 
Patient’s response to 
anticancer therapy should also 
be monitored. 
 Lissoni P, Malugani F, Bordin V, Conti A, Maestroni 
G, Tancini G. A new neuroimmunotherapeutic 
strategy of subcutaneous low-dose interleukin-2 plus 
the long-acting opioid antagonist naltrexone in 
metastatic cancer patients progressing on interleukin-










should be monitored when 
patients are concurrently 




 Pharmacia & Upjohn Co. Aromasin (exemestane) 
tablets [product information]. New York, NY; 2007. 
 
Bleomycin Phenytoin Phenytoin concentration 
decreases due to antineoplastic 
Phenytoin concentrations 
should be monitored during 
 Sylvester RK, Lewis FB, Caldwell KC, Lobell M, 












damage to intestinal mucosa 
and impaired gastrointestinal 
absorption.  
 
and after chemotherapeutic 
course, and doses changed as 
necessary.  
 
bioavailability secondary to cisplatinum, vinblastine, 
and bleomycin. Ther Drug Monit. 1984;6(3):302-
305. 
 Dofferhoff AS, Berendsen HH, vd Naalt J, Haaxma-
Reiche H, Smit EF, Postmus PE. Decreased 
phenytoin level after carboplatin treatment. Am J 
Med. 1990;89(2):247-248. 
 Bollini P, Riva R, Albani F, et al. Decreased 
phenytoin level during antineoplastic therapy: a case 
report. Epilepsia. 1983;24(1):75-78. 
 Jarosinski PF, Moscow JA, Alexander MS, Lesko 
LJ, Balis FM, Poplack DG. Altered phenytoin 
clearance during intensive chemotherapy for acute 
lymphoblastic leukemia. J Pediatr. 1988;112(6):996-
999. 
 Fincham RW, Schottelius DD. Decreased phenytoin 
levels in antineoplastic therapy. Ther Drug Monit. 
1979;1(2):277-283. 
 Riva R, Albani F, Baruzzi A. On the interaction 
between phenytoin and antineoplastic agents (letter). 
Ther Drug Monit. 1985;7(1):123-126. 
 
Capecitabine Phenytoin Phenytoin concentration 
increases possibly due to 
inhibition of CYP2C9 
isozyme. 
Phenytoin concentrations 
should be monitored in 
patients receiving concomitant 
capecitabine. Dose reduction 
of phenytoin may be required. 
 
 Roche Pharmaceuticals Inc. Xeloda (capecitabine) 
tablets [product information]. Nutley, NJ; 2003. 
 Brickell K, Porter D, Thompson P. Phenytoin 
toxicity due to fluoropyrimidines 
(5FU/capecitabine): three case reports. Br J Cancer. 
2003;89(4):615-616. 
 Zucchero FJ, Hogan MJ, Sommer CD. Evaluations 
of Drug Interactions. St. Louis, MO: First Databank; 
2001. 
 
Carboplatin Phenytoin Phenytoin concentration 
decreases due to decreased 
gastrointestinal absorption, 
protein displacement, and 
increased hepatic clearance.  
Phenytoin concentrations 
should be monitored during 
chemotherapeutic course, and 
checked again after course is 
completed, and doses changed 
as necessary. 
 
 Dofferhoff AS, Berendsen HH, vd Naalt J, Haaxma-
Reiche H, Smit EF, Postmus PE. Decreased 
phenytoin level after carboplatin treatment. Am J 
Med. 1990;89(2):247-248. 
 Riva R, Albani F, Baruzzi A. On the interaction 
between phenytoin and antineoplastic agents (letter). 
Ther Drug Monit. 1985;7(1):123-126. 












phenytoin levels in patients receiving chemotherapy. 





Naltrexone  Increased risk of 
hepatotoxicity. Mechanism is 
unknown, but combined use of 
naltrexone with other 
hepatotoxic agents can 
theoretically potentiate the 
risk of hepatotoxicity, based 
on placebo-controlled studies 
reported by the manufacturer. 
 
Concurrent use of naltrexone 
and hepatotoxic drugs is not 
recommended, unless the 
potential benefit outweighs the 
risk of hepatotoxicity. Periodic 
monitoring of patient’s liver 
function, and signs and 
symptoms of hepatotoxicity 
(e.g. fever, rash, anorexia, 
nausea, vomiting, fatigue, dark 
urine, upper right quadrant 
pain, and jaundice) is advised. 
 
 Drugsite Trust. Drugs.com: drug interactions 
checker. Available at: 
http://www.drugs.com/drug_interactions.html. 
Accessed 8 August 2009. 
 Barr Laboratories Inc. Naltrexone hydrochloride 












increased possibly due to 
impaired metabolism by 
valproate. 
 
Alternative AED should be 
considered. AED 
concentrations should be 
closely monitored in patients 
to ensure adequate 
antiepileptic coverage. 
 
Haematologic toxicities of 
cisplatin should be monitored. 
 Glantz MJ, Cole BF, Forsyth PA, et al. Practice 
parameter: anticonvulsant prophylaxis in patients 
with newly diagnosed brain tumors: report of the 
Quality Standards Subcommittee of the American 
Academy of Neurology. Neurology. 
2000;54(10):1886-1893. 
 Sylvester RK, Lewis FB, Caldwell KC, Lobell M, 
Perri R, Sawchuk RA. Impaired phenytoin 
bioavailability secondary to cisplatinum, vinblastine, 
and bleomycin. Ther Drug Monit. 1984;6(3):302-
305. 
 Grossman SA, Sheidler VR, Gilbert MR. Decreased 
phenytoin levels in patients receiving chemotherapy. 
Am J Med. 1989;87(5):505-510. 
 Neef C, de Voogd-van der Straaten I. An interaction 
between cytostatic and anticonvulsant drugs. Clin 
Pharmacol Ther. 1988;43(4):372-375. 
 Parke-Davis. Cerebyx (fosphenytoin sodium) 
[product information]. Morris Plains, NJ; 1999. 
 Ghosh C, Lazarus HM, Hewlett JS, Creger RJ. 
Fluctuation of serum phenytoin concentrations 
during autologous bone marrow transplant for 













 Bourg V, Lebrun C, Chichmanian RM, Thomas P, 
Frenay M. Nitroso-urea-cisplatin-based 
chemotherapy associated with valproate: increase of 




















psychotropic decrease due to 
induction of CYP3A4 by 






The clinical significance of the 
interaction is limited, but the 
possibility of a reduced 
response to the psychotropic 
should be considered. 
Monitoring of psychotropic 
plasma concentrations and/or 
therapeutic response is 
advised. 
 
 Villikka K, Kivistö KT, Neuvonen PJ. The effect of 
dexamethasone on the pharmacokinetics of 
triazolam. Pharmacol Toxicol. 1998;83(3):135-138. 
 Nakajima M, Suzuki T, Sasaki T, et al. Effects of 
chronic administration of glucocorticoid on 







corticosteroids increase due to 
CYP3A4 inhibition by 




Caution is advised. Clinical 
monitoring and dosage 
adjustments may be necessary 
whenever fluvoxamine is 
added to or withdrawn from 
therapy. 
 
 Fleishaker JC, Hulst LK. A pharmacokinetic and 
pharmacodynamic evaluation of the combined 
administration of alprazolam and fluvoxamine. Eur J 
Clin Pharmacol. 1994;46(1):35-39. 
 Kashuba ADM, Nafziger AN, Kearns GL, et al. 
Effect of fluvoxamine therapy on the activities of 
CYP1A2, CYP2D6, and CYP3A as determined by 
phenotyping. Clin Pharmacol Ther. 1998;64(3):257-
268. 
 Damkier P, Hansen LL, Brøsen K. Effect of 
fluvoxamine on the pharmacokinetics of quinidine. 
Eur J Clin Pharmacol. 1999;55(6):451-456. 
 Sandoz Inc. Fluvoxamine maleate tablet [product 
information]. Princeton, NJ; 2007. 
 






concentration decreases due to 
increased metabolism to active 
metabolites. May lead to 
increased risk for toxicity. 
Blood concentrations should 
be monitored to assess 
cyclophosphamide exposure 
during therapy. Altered doses 
of cyclophosphamide may be 
needed. Alternative non-
enzyme-inducing AED should 
be considered.  
 
 Perucca E. Clinically relevant drug interactions with 
antiepileptic drugs. Br J Clin Pharmacol. 
2006;61(3):246-255. 
 Bristol-Myers Squibb. Cytoxan (cyclophosphamide) 
for injection and tablets [product information]. 
Princeton, NJ; 2000. 
 Alberts DS, Peng YM, Chen HS, Struck RF. Effect 
of phenobarbital on plasma levels of 












Br J Cancer. 1978;38(2):316-324. 
 Weber GF, Waxman DJ. Activation of the anti-
cancer drug ifosphamide by rat liver microsomal 
P450 enzymes. Biochem Pharmacol. 
1993;45(8):1685-1694. 
 de Jonge ME, Huitema ADR, van Dam SM, Beijnen 
JH, Rodenhuis S. Significant induction of 
cyclophosphamide and thiotepa metabolism by 
phenytoin. Cancer Chemother Pharmacol. 
2005;55(5):507-510. 
 Chen T-L, Passos-Coelho JL, Noe DA, et al. 
Nonlinear pharmacokinetics of cyclophosphamide in 
patients with metastatic breast cancer receiving high-
dose chemotherapy followed by autologous bone 





















increase due to CYP3A4 
inhibition by fluvoxamine, 
leading to decreased 








Caution is advised during 
concurrent administration of 
fluvoxamine with CYP3A4 
substrates. Clinical monitoring 
and dosage adjustments may 
be necessary whenever 
fluvoxamine is added to or 





 Fleishaker JC, Hulst LK. A pharmacokinetic and 
pharmacodynamic evaluation of the combined 
administration of alprazolam and fluvoxamine. Eur J 
Clin Pharmacol. 1994;46(1):35-39. 
 Kashuba ADM, Nafziger AN, Kearns GL, et al. 
Effect of fluvoxamine therapy on the activities of 
CYP1A2, CYP2D6, and CYP3A as determined by 
phenotyping. Clin Pharmacol Ther. 1998;64(3):257-
268. 
 Damkier P, Hansen LL, Brøsen K. Effect of 
fluvoxamine on the pharmacokinetics of quinidine. 
Eur J Clin Pharmacol. 1999;55(6):451-456. 
 Sandoz Inc. Fluvoxamine maleate tablet [product 





increases due to inhibition of 
CYP2B6 by ACDs, leading to 
decreased clearance of 
bupropion. 
Signs and symptoms of 
bupropion toxicity should be 
monitored during concurrent 
administration with CYP2B6 
substrates or inhibitors (e.g. 
agitation, anxiety, tremor, 
insomnia, seizures, or 
neuropsychiatric symptoms). 
 Richter T, Mürdter TE, Heinkele G, et al. Potent 
mechanism-based inhibition of human CYP2B6 by 
clopidogrel and ticlopidine. J Pharmacol Exp Ther. 
2004;308(1):189-197. 
 Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, 
Pelkonen O, Laine K. Effect of clopidogrel and 
ticlopidine on cytochrome P450 2B6 activity as 












 Pharmacol Ther. 2005;77(6):553-559. 
 GlaxoSmithKline Inc. Zyban (bupropion 
hydrochloride) tablets [product information]. 
Research Triangle Park, NC; 2007. 
 
Cytarabine Phenytoin Cytarabine possibly reduces 
absorption of phenytoin. 
Phenytoin concentrations 
should be frequently measured 
to ensure seizure control. 
 
 British Medical Association, Pharmaceutical Society 
of Great Britain. British National Formulary. 53rd 







decreases possibly due to 
induction of CYP1A2-
mediated metabolism. 
Blood concentrations should 
be monitored to assess 
dacarbazine exposure during 
therapy. Altered doses may be 
needed. 
 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 
Drug Information Handbook with International 
Trade Names Index. 15th ed. Hudson, OH: Lexi-








decreases due to increased 
hepatic clearance. Phenytoin 
absorption may be impaired. 
 
Alternative AED should be 
considered. AED 
concentrations should be 
monitored for seizure control.  
 
 British Medical Association, Pharmaceutical Society 
of Great Britain. British National Formulary. 53rd 
ed. London, UK: BMJ Publishing Group Ltd & RPS 
Publishing; 2007. 
 Aventis Pharmaceuticals Inc. Taxotere (docetaxel) 
injection concentrate [product information]. 






increases due to CYP3A4 
inhibition by psychotropics, 
leading to decreased clearance 
of docetaxel. 
 
Caution is advised. Close 
monitoring for altered efficacy 
and safety (e.g. bone marrow 
suppression) is recommended 
during concurrent therapy. 
 
 Grimsley SR, Jann MW, Carter JG, D'Mello AP, 
D'Souza MJ. Increased carbamazepine plasma 
concentrations after fluoxetine coadministration. Clin 
Pharmacol Ther. 1991;50(1):10-15. 
 Greenblatt DJ, Preskorn SH, Cotreau MM, Horst 
WD, Harmatz JS. Fluoxetine impairs clearance of 
alprazolam but not of clonazepam. Clin Pharmacol 
Ther. 1992;52(5):479-486. 
 Marre F, Sanderink GJ, de Sousa G, Gaillard C, 
Martinet M, Rahmani R. Hepatic biotransformation 
of docetaxel (Taxotere) in vitro: involvement of the 
CYP3A subfamily in humans. Cancer Res. 
1996;56(6):1296-1302. 
 Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher 
BL. Assessment of the potential for a 












terfenadine. Clin Pharmacol Ther. 1997;62(6):643-
651. 
 Aventis Pharmaceuticals Inc. Taxotere (docetaxel) 
injection concentrate [product information]. 
Bridgewater, NJ; 2003. 
 DeVane CL, Donovan JL, Liston HL, et al. 
Comparative CYP3A4 inhibitory effects of 
venlafaxine, fluoxetine, sertraline, and nefazodone in 
healthy volunteers. J Clin Psychopharmacol. 
2004;24(1):4-10. 
 Sandoz Inc. Fluvoxamine maleate tablet [product 
information]. Princeton, NJ; 2007. 
 Eli Lilly and Company. Prozac (fluoxetine 
hydrochloride) capsules [product information]. 
Indianapolis, IN; 2008. 
 Zhou S-F. Drugs behave as substrates, inhibitors and 
inducers of human cytochrome P450 3A4. Curr 
Drug Metab. 2008;9(4):310-322. 
 














decreases, possibly due to 










decreases due to increased 
hepatic metabolism. 
 
Alternative AED should be 
considered. AED 
concentrations should be 
monitored for seizure control.  
 
Adequate response to 
doxorubicin should be 
monitored. Doses of 




concentrations should be 
considered during and after 
chemotherapy. Adjustment of 
phenytoin doses may be 
required. 
 
 Neef C, de Voogd-van der Straaten I. An interaction 
between cytostatic and anticonvulsant drugs. Clin 
Pharmacol Ther. 1988;43(4):372-375. 
 Bristol-Myers Squibb. Rubex (doxorubicin 
hydrochloride) injection [product information]. 
Princeton, NJ; 2001. 
 Bogush TA, Sitdikova SM, Syrkin AB. Comparative 
study of the effect of Zixoryn and phenobarbital on 
the toxicity of anthracycline antibiotics and liver 
monooxygenase activity in mice. Vestn Akad Med 
Nauk SSSR. 1985;11:82-86 [abstract]. 
 Sturgill MG, August DA, Brenner DE. Hepatic 
enzyme induction with phenobarbital and 
doxorubicin metabolism and myelotoxicity in the 
rabbit. Cancer Invest. 2000;18(3):197-205. 
 Parke-Davis. Cerebyx (fosphenytoin sodium) 








Increased risk of drug-induced 
QT prolongation and torsades 
de pointes, due to theoretical 
Measurements of QT intervals 
and clinical monitoring of 
symptoms that could indicate 
 De Ponti F, Poluzzi E, Montanaro N. QT-interval 
prolongation by non-cardiac drugs: lessons to be 





















postulations of additive 
arrhythmogenic potential 
related to blockade of the 
potassium rectifier channel, 
causing disruption to the 
normal balance between 
depolarising and repolarising 
currents of the action 
potential. 
 
the occurrence of torsades de 
pointes (e.g. dizziness, 
palpitations, or syncope) are 
recommended. If marked QT 
prolongation occurs, dose 
reduction of the offending 
agent should be considered. 
 
Pharmacol. 2000;56(1):1-18. 
 De Ponti F, Poluzzi E, Vaccheri A, et al. Non-
antiarrhythmic drugs prolonging the QT interval: 
considerable use in seven countries. Br J Clin 
Pharmacol. 2002;54(2):171-177. 
 Tamargo J. Drug-induced torsade de pointes: from 
molecular biology to bedside. Jpn J Pharmacol. 
2000;83(1):1-19. 
 Towbin JA, Vatta M. Molecular biology and the 
prolonged QT syndromes. Am J Med. 
2001;110(5):385-398. 
 Crouch MA, Limon L, Cassano AT. Clinical 
relevance and management of drug-related QT 
interval prolongation. Pharmacotherapy. 
2003;23(7):881-908. 
 Witchel HJ, Hancox JC, Nutt DJ. Psychotropic 





Fluvoxamine Plasma concentrations of the 
ACDs increase due to 
competitive inhibition of 
CYP3A4 by fluvoxamine, 
leading to decreased 
clearances of the ACDs. 
Caution is advised. Dosage 
adjustments and monitoring 
may be required whenever 
fluvoxamine is added to or 
withdrawn from therapy. 
 Fleishaker JC, Hulst LK. A pharmacokinetic and 
pharmacodynamic evaluation of the combined 
administration of alprazolam and fluvoxamine. Eur J 
Clin Pharmacol. 1994;46(1):35-39. 
 Damkier P, Hansen LL, Brøsen K. Effect of 
fluvoxamine on the pharmacokinetics of quinidine. 
Eur J Clin Pharmacol. 1999;55(6):451-456. 
 Sandoz Inc. Fluvoxamine maleate tablet [product 





reduces absorption of 
phenytoin. No formal studies 
are available. 
Phenytoin concentrations 
should be frequently measured 
to ensure seizure control. 
 
 British Medical Association, Pharmaceutical Society 
of Great Britain. British National Formulary. 53rd 














Concurrent use of erlotinib 
with enzyme-inducing AEDs 
should be avoided. If 
alternative treatments are 
unavailable, increasing 
erlotinib dose as tolerated at 2-
 OSI Pharmaceuticals Inc., Genentech Inc. Tarceva 
(erlotinib) tablets [product information]. Melville, 













week intervals should be 
considered. Patient's 
tolerability to drug should be 
monitored. If erlotinib dose is 
increased, reduce it 
immediately to the indicated 





Midazolam Midazolam concentration 
decreases. Mechanism is 
unknown, but is postulated to 
be due to induction of 
CYP3A4-mediated 
metabolism of midazolam. 
 
Caution is advised. The 
clinical significance of the 
interaction is limited, but the 
possibility of a reduced 
therapeutic response to the 
psychotropic should be 
considered. 
 
 Shou M, Grogan J, Mancewicz JA, et al. Activation 
of CYP3A4: evidence for the simultaneous binding 
of two substrates in a cytochrome P450 active site. 
Biochemistry. 1994;33(21):6450-6455. 
 Ueng Y-F, Kuwabara T, Chun Y-J, Guengerich FP. 
Cooperativity in oxidations catalyzed by cytochrome 
P450 3A4. Biochemistry. 1997;36(2):370-381. 
 Calvert H, Twelves C, Ranson M, et al. The effect of 
erlotinib on CYP3A4 activity, as quantified by the 
erythromycin breath test and oral midazolam kinetics 
in cancer patients: preliminary results. J Clin Oncol. 
2005;23(16S):3076. 
 Fujita K, Ando Y, Narabayashi M, et al. Gefitinib 
(Iressa) inhibits the CYP3A4-mediated formation of 
7-ethyl-10-(4-amino-1-
piperidino)carbonyloxycamptothecin but activates 
that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-
piperidino]carbonyloxycamptothecin from 
irinotecan. Drug Metab Dispos. 2005;33(12):1785-
1790. 
 Li J, Zhao M, He P, Hidalgo M, Baker SD. 
Differential metabolism of gefitinib and erlotinib by 











Alteration to effects of TCAs. 
Simultaneous TCA toxicity 
and reduced effects have been 
reported. Mechanism is 
possibly due to increased TCA 
bioavailability or inhibition of 
Signs and symptoms of altered 
TCA effects should be 
monitored during concurrent 
therapy (e.g. dyskinesia, 
akathisia, myoclonus, rabbit 
syndrome, dystonia). TCA 
 Khurana RC. Estrogen-imipramine interaction. 
JAMA. 1972;222(6):702-703. 
 Somani SM, Khurana RC. Mechanism of estrogen-
imipramine interaction. JAMA. 1973;223(5):560. 
 Abernethy DR, Greenblatt DJ, Shader RI. 


















hepatic TCA metabolism. 
Estrogens may facilitate the 
development of TCA-induced 
extrapyramidal effects through 
modulation of dopamine 
function. 
 
dose adjustments may be 
required. 
steroids. Clin Pharmacol Ther. 1984;35(6):792-797. 
 Krishnan KR, France RD, Ellinwood Jr. EH. 
Tricyclic-induced akathisia in patients taking 
conjugated estrogens. Am J Psychiatry. 
1984;141(5):696-697. 
 Edelbroek PM, Zitman FG, Knoppert-van der Klein 
EAM, van Putten PM, de Wolff FA. Therapeutic 
drug monitoring of amitriptyline: impact of age, 
smoking and contraceptives on drug and metabolite 
levels in bulimic women. Clin Chim Acta. 
1987;165(2-3):177-187. 
 Vandel P, Bonin B, Leveque E, Sechter D, Bizouard 
P. Tricyclic antidepressant-induced extrapyramidal 













Etoposide and phenytoin 
concentrations decrease, 







increases due to inhibition of 
metabolism. Leads to 
enhanced systemic exposure 
and toxicity. 
 
Adequate response to 
etoposide should be 
monitored. Doses of etoposide 
may need to be increased. 
Alternative AED should be 
considered, and patient 
monitored for seizure control.  
 
Signs and symptoms of 
haematological toxicity should 
be monitored. 
 
 Perucca E. Clinically relevant drug interactions with 
antiepileptic drugs. Br J Clin Pharmacol. 
2006;61(3):246-255. 
 Ghosh C, Lazarus HM, Hewlett JS, Creger RJ. 
Fluctuation of serum phenytoin concentrations 
during autologous bone marrow transplant for 
primary central nervous system tumors. J 
Neurooncol. 1992;12(1):25-32. 
 Baker DK, Relling MV, Pui C-H, Christensen ML, 
Evans WE, Rodman JH. Increased teniposide 
clearance with concomitant anticonvulsant therapy. J 
Clin Oncol. 1992;10(2):311-315. 
 Patsalos PN, Perucca E. Clinically important drug 
interactions in epilepsy: interactions between 
antiepileptic drugs and other drugs. Lancet Neurol. 
2003;2(8):473-481. 
 Rodman JH, Murry DJ, Madden T, Santana VM. 
Altered etoposide pharmacokinetics and time to 
engraftment in paediatric patients undergoing 







Exemestane concentrations in 
patients concurrently receiving 
 Pharmacia & Upjohn Co. Aromasin (exemestane) 















aromatase inhibitors with 
CYP3A4-inducing AEDs 






increases, possibly due to 




should be frequently measured 
in patients. Monitoring should 
continue after chemotherapy is 
completed to ensure that the 
phenytoin concentration is 
sufficient to prevent seizures. 
 
 Brickell K, Porter D, Thompson P. Phenytoin 
toxicity due to fluoropyrimidines 
(5FU/capecitabine): three case reports. Br J Cancer. 
2003;89(4):615-616. 
 Wakisaka S, Shimauchi M, Kaji Y, Nonaka A, 
Kinoshita K. Acute phenytoin intoxication associated 
with the antineoplastic agent UFT. Fukuoka Igaku 
Zasshi. 1990;81(4):192-196 [abstract]. 
 Gilbar PJ, Brodribb TR. Phenytoin and fluorouracil 






















Concurrent use of gefitinib 
and enzyme-inducing AEDs 
should be avoided. If 
alternative treatments are 
unavailable, gefitinib dose can 
be increased to 500 mg/day in 
the absence of a severe 
adverse drug reaction. Clinical 
response and adverse events 
should be carefully monitored. 
 
 AstraZeneca Pharmaceuticals LP. Iressa (gefitinib) 










increases due to inhibition of 
CYP2D6 by gefitinib, leading 
to decreased clearance of 
atomoxetine. 
 
The potential of gefitinib to 
increase plasma 
concentrations should be 
considered if it is concurrently 
administered with CYP2D6 
substrates that have a narrow 
therapeutic indices or are 
individually dose-titrated. 
 
 Belle DJ, Ernest CS, Sauer J-M, Smith BP, 
Thomasson HR, Witcher JW. Effect of potent 
CYP2D6 inhibition by paroxetine on atomoxetine 
pharmacokinetics. J Clin Pharmacol. 
2002;42(11):1219-1227. 
 Swaisland HC, Ranson M, Smith RP, et al. 
Pharmacokinetic drug interactions of gefitinib with 
rifampicin, itraconazole and metoprolol. Clin 
Pharmacokinet. 2005;44(10):1067-1081. 
 Eli Lilly and Company. Strattera (atomoxetine 
hydrochloride) capsules [product information]. 















Naltrexone Increased risk of 
hepatotoxicity. Mechanism is 
unknown, but combined use of 
naltrexone with other 
hepatotoxic agents can 
theoretically potentiate the 
risk of hepatotoxicity, based 
on placebo-controlled studies 
reported by the manufacturer. 
 
Concurrent use of naltrexone 
and hepatotoxic drugs is not 
recommended, unless the 
potential benefit outweighs the 
risk of hepatotoxicity. Periodic 
monitoring of patient’s liver 
function, and signs and 
symptoms of hepatotoxicity 
(e.g. fever, rash, anorexia, 
nausea, vomiting, fatigue, dark 
urine, upper right quadrant 
pain, and jaundice) is advised. 
 
 Drugsite Trust. Drugs.com: drug interactions 
checker. Available at: 
http://www.drugs.com/drug_interactions.html. 
Accessed 8 August 2009. 
 Barr Laboratories Inc. Naltrexone hydrochloride 






























Plasma concentrations of 
psychotropics increase due to 
inhibition of CYP2D6 and/or 






















Caution is advised during 
concurrent administration of 
imatinib and other 
medications that undergo 
CYP2C9, 2D6 and/or 3A4 
metabolism, particularly those 
with a narrow therapeutic 
range. Dosage adjustments, 
clinical and laboratory 
monitoring may be required 
whenever imatinib is added to 














 Greenblatt DJ, von Moltke LL, Harmatz JS, et al. 
Kinetic and dynamic interaction study of zolpidem 
with ketoconazole, itraconazole, and fluconazole. 
Clin Pharmacol Ther. 1998;64(6):661-671. 
 Novartis Pharmaceuticals Corporation. Gleevec 
(imatinib mesylate) capsules [product information]. 
East Hanover, NJ; 2001 & 2005. 
 Belle DJ, Ernest CS, Sauer J-M, Smith BP, 
Thomasson HR, Witcher JW. Effect of potent 
CYP2D6 inhibition by paroxetine on atomoxetine 
pharmacokinetics. J Clin Pharmacol. 
2002;42(11):1219-1227. 
 Peng B, Lloyd P, Schran H. Clinical 



























Plasma concentrations of both 
imatinib and psychotropic 
increase due to inhibition of 
CYP isozymes by both 
imatinib and psychotropic. 
 
Monitoring for prolonged 
and/or increased effects of 
psychotropic drug and 
imatinib is recommended, 
including serious adverse 
effects such as oedema, 
haematologic toxicity and 
immunosuppression. 
 
 Novartis Pharmaceuticals Corporation. Gleevec 
(imatinib mesylate) capsules [product information]. 
East Hanover, NJ; 2001 & 2005. 
 Peng B, Lloyd P, Schran H. Clinical 
pharmacokinetics of imatinib. Clin Pharmacokinet. 
2005;44(9):879-894. 
 Eli Lilly and Company. Prozac (fluoxetine 
hydrochloride) capsules [product information]. 
Indianapolis, IN; 2008. 
 Roerig. Zoloft (sertraline hydrochloride) tablets 





Disulfiram Increased risk of peripheral 
neuropathy due to additive 
neurotoxic effects. 
 
Patients should be closely 
monitored for symptoms of 
peripheral neuropathy 
(burning, tingling, pain, or 
numbness in the hands and 
feet). Dosage reductions or 
immediate discontinuation of 
these medications should be 
considered in such patients to 
limit further damage. If 
necessary, therapy should 
generally be reinstituted only 
after resolution of neuropathy 
symptoms or return of 
symptoms to baseline status. 
 
 Gardner-Thorpe C, Benjamin S. Peripheral 
neuropathy after disulfiram administration. J Neurol 
Neurosurg Psychiatry. 1971;34(3):253-259. 
 Moddel G, Bilbao JM, Payne D, Ashby P. 
Disulfiram neuropathy. Arch Neurol. 
1978;35(10):658-660. 
 Argov Z, Mastaglia FL. Drug-induced peripheral 
neuropathies. Br Med J. 1979;1(6164):663-666. 
 Roche Pharmaceuticals Inc. Roferon-A (interferon 
alfa-2a, recombinant) [product information]. Nutley, 
NJ; 2001. 
 Schering Corporation. Intron A (interferon alfa-2b, 
recombinant for injection) [product information]. 














decreases due to induction of 








inducing AED should be 
considered. Begin substitution 
at least 2 weeks prior to 





 Perucca E. Clinically relevant drug interactions with 
antiepileptic drugs. Br J Clin Pharmacol. 
2006;61(3):246-255. 
 Pharmacia & Upjohn Co. Camptosar (irinotecan 
hydrochloride) injection [product information]. New 
York, NY; 2007. 
 Murry DJ, Cherrick I, Salama V, et al. Influence of 
phenytoin on the disposition of irinotecan: a case 



















increase due to inhibition of 
CYP3A4-mediated 
metabolism by irinotecan, 
leading to increased risk of 
myopathy or rhabdomyolysis. 
 
Monitoring of creatine kinase 
levels and for signs and 
symptoms of myopathy or 
rhabdomyolysis (muscle pain, 
tenderness or weakness) 
should be considered. Use of 
psychotropics should be 
discontinued if creatine kinase 
levels show a marked 
increase, or if myopathy or 
rhabdomyolysis is suspected. 
 
 Richards S, Umbreit JN, Fanucchi MP, Giblin J, 
Khuri F. Selective serotonin reuptake inhibitor-
induced rhabdomyolysis associated with irinotecan. 
South Med J. 2003;96(10):1031-1033. 
 Forest Pharmaceuticals Inc. Lexapro (escitalopram 
oxalate) tablets and solution [product information]. 
























Effect of valproate (weak 
CYP3A4 inhibitor) has not 
been studied. Plasma 
ixabepilone concentration is 
expected to increase with 
strong CYP3A4 inhibitors.  




primidone) with ixabepilone 
should be avoided. AEDs with 
low enzyme induction 
potential should be 
considered.  
 
Caution is advised with co-
administration of mild/ 
moderate CYP3A4 inhibitors 
(valproate) with ixabepilone. 
Close and frequent monitoring 
for acute toxicities (e.g. 
peripheral blood counts) 
between ixabepilone treatment 
cycles should be carried out.  
 
 Mani S, McDaid H, Hamilton A, et al. Phase I 
clinical and pharmacokinetic study of BMS-247550, 
a novel derivative of epothilone B, in solid tumors. 
Clin Cancer Res. 2004;10(4):1289-1298. 
 Thomas ES, Gomez HL, Li RK, et al. Ixabepilone 
plus capecitabine for metastatic breast cancer 
progressing after anthracycline and taxane treatment. 
J Clin Oncol. 2007;25(33):5210-5217. 
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should be monitored when 
patients are concurrently 




 Pharmacia & Upjohn Co. Aromasin (exemestane) 

































decreases due to protein 





decreases due to protein 
displacement, intestinal 
mucosa damage, and impaired 
absorption.  
Methotrexate concentration 
and antifolate effect increases, 




decreases due to decreased 
absorption. 
 
Adequate response to 
methotrexate should be 
monitored. Doses of 




should be obtained during/ 
after combination 
chemotherapy. Patients should 






Alternative AED should be 
considered. Patients should be 
monitored for seizure control. 
 
 Perucca E. Clinically relevant drug interactions with 
antiepileptic drugs. Br J Clin Pharmacol. 
2006;61(3):246-255. 
 Relling MV, Pui C-H, Sandlund JT, et al. Adverse 
effect of anticonvulsants on efficacy of 
chemotherapy for acute lymphoblastic leukaemia. 
Lancet. 2000;356(9226):285-290. 
 Xanodyne Pharmacal Inc. Methotrexate sodium for 
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 Sylvester RK, Lewis FB, Caldwell KC, Lobell M, 
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levels in antineoplastic therapy. Ther Drug Monit. 
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Naltrexone Increased risk of 
hepatotoxicity. Mechanism is 
unknown, but combined use of 
naltrexone with other 
hepatotoxic agents can 
theoretically potentiate the 
risk of hepatotoxicity, based 
on placebo-controlled studies 
reported by the manufacturer. 
 
Concurrent use of naltrexone 
and hepatotoxic drugs is not 
recommended, unless the 
potential benefit outweighs the 
risk of hepatotoxicity. Periodic 
monitoring of patient’s liver 
function, and signs and 
symptoms of hepatotoxicity 
(e.g. fever, rash, anorexia, 
nausea, vomiting, fatigue, dark 
urine, upper right quadrant 
pain, and jaundice) is advised. 
 
 Drugsite Trust. Drugs.com: drug interactions 
checker. Available at: 
http://www.drugs.com/drug_interactions.html. 
Accessed 8 August 2009. 
 Barr Laboratories Inc. Naltrexone hydrochloride 





decreases due to increased 
hepatic clearance. Phenytoin 
Alternative AED should be 
considered. AED 
concentrations should be 
 Perucca E. Clinically relevant drug interactions with 
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[product information]. Morris Plains, NJ; 1999. 
 Fetell MR, Grossman SA, Fisher JD, et al. 
Preirradiation paclitaxel in glioblastoma multiforme: 
efficacy, pharmacology, and drug interactions. J Clin 
Oncol. 1997;15(9):3121-3128. 
 Chang SM, Kuhn JG, Rizzo J, et al. Phase I study of 
paclitaxel in patients with recurrent malignant 
glioma: a North American Brain Tumor Consortium 
report. J Clin Oncol. 1998;16(6):2188-2194. 
 
 Fluvoxamine Paclitaxel concentration 
increases due to inhibition of 
CYP3A4 by fluvoxamine, 
leading to decreased clearance 
of paclitaxel. 
 
Patients should be monitored 
for dose-related toxicities of 
paclitaxel during concurrent 
administration, such as 
myelosuppression or 
neuropathy. 
 Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, 
Vieira I, Wright M. Taxol metabolism by human 
liver microsomes: identification of cytochrome P450 
isozymes involved in its biotransformation. Cancer 
Res. 1994;54(2):386-392. 
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information]. Los Angeles, CA; 2007. 
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decreases leading to central 









decreases due to increased 




























Concurrent administration of 
carbamazepine and 
monoamine oxidase inhibitors 
is contraindicated. 
Monoamine oxidase inhibitors 
should be discontinued for a 




Caution is advised when 
concurrently administering 
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 metabolites against L1210 ascites leukemia cells in 
CDF1 mice and the effects of pretreatment with 
procarbazine, phenobarbital, diphenylhydantoin, and 
methylprednisolone upon in vivo procarbazine 




































Increased risk of central 
nervous system toxicity or 
serotonin syndrome (mental 
state changes, myoclonus, 
rigidity, hyperthermia, 
autonomic instability with 
possible fluctuation of vital 
signs), caused by excessive 
serotonergic activity in the 
central nervous system, 
possibly due to 
hyperstimulation of brainstem 
5HT1A receptors. 
Interaction with moclobemide 




Concomitant use of 
procarbazine and interacting 
psychotropic is not 
recommended. A minimum of 
14 days should elapse between 
discontinuation of 
procarbazine and initiation of 
the interacting psychotropic, 
or vice versa. Signs and 
symptoms of central nervous 
system toxicity or serotonin 
syndrome should be 
monitored. Due to the long 
half-life of fluoxetine and its 
metabolite (norfluoxetine), 
procarbazine should only be 
initiated at least 5 weeks after 
stopping chronic or high-dose 
fluoxetine therapy. 
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69. 
 Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. 
Five fatal cases of serotonin syndrome after 
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1993;342(8884):1419. 
 Sternbach H. The serotonin syndrome. Am J 
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 Coplan JD, Gorman JM. Detectable levels of 
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hydrochloride) capsules [product information]. 
Indianapolis, IN; 2008. 
 Hodgman MJ, Martin TG, Krenzelok EP. Serotonin 
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 Sweetman SC. Martindale: the complete drug 
reference. 33rd ed. London, UK: Pharmaceutical 
Press; 2002. 
 Eli Lilly and Company. Strattera (atomoxetine 
hydrochloride) capsules [product information]. 
Indianapolis, IN; 2007. 
 Organon USA Inc. Remeron (mirtazapine) tablets 




Increased risk of hypertensive 
crisis (occipital headache, 
palpitations, neck stiffness/ 
soreness, nausea/ vomiting, 
dilated pupils, photophobia). 
Synergistic sympathomimetic 
effects could be due to 
enhanced norepinephrine 
storage and increased 
liberation or decreased 
reuptake of catecholamines, or 
monoamine oxidase inhibition 
of serotonin metabolism. 
Concurrent use of 
procarbazine and psychotropic 
drug should be avoided. At 
least 14 days should elapse 
between discontinuation of 
procarbazine and initiation of 
psychotropic drug, and vice 
versa. 
If hypertensive crisis occurs, 
psychotropic drug should be 
discontinued immediately and 
therapy to lower blood 
pressure should be instituted 
immediately. 
 Sherman M, Hauser GC, Glover BH. Toxic reactions 
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 Markowitz JS, Patrick KS. Pharmacokinetic and 
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 McGrath PJ, Steward JW, Quitkin FM. A possible L-
deprenyl induced hypertensive reaction. J Clin 
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 Schulz R, Antonin K-H, Hoffmann E, et al. 
Tyramine kinetics and pressor sensitivity during 
monoamine oxidase inhibition by selegiline. Clin 
Pharmacol Ther. 1989;46(5):528-536. 
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possibly also reduces 
phenytoin absorption. 
An increase in systemic 
exposure to substrates of 
CYP2B6, CYP2C8, UGT1A1 
and UGT1A9 is expected due 
to inhibition of enzymes. 
 
Caution is advised when AED 
and sorafenib are administered 
concurrently. Patients should 
be monitored for clinical 
response to sorafenib and 





 British Medical Association, Pharmaceutical Society 
of Great Britain. British National Formulary. 53rd 
ed. London, UK: BMJ Publishing Group Ltd & RPS 
Publishing; 2007. 
 Bayer HealthCare Pharmaceuticals Inc. Nexavar 







Plasma concentrations of 
psychotropics increase due to 
inhibition of CYP2B6 by 
sorafenib, leading to decreased 
clearances of psychotropics. 
 
Caution is advised. Dosage 
adjustments, clinical and 
laboratory monitoring may be 
appropriate whenever 
sorafenib is added to or 
withdrawn from therapy. 
 
 Bayer HealthCare Pharmaceuticals Inc. Nexavar 









concentration decreases due to 
induction of CYP3A4-
mediated metabolism of 
sunitinib and its active 
metabolite. 
Sunitinib possibly also 
reduces phenytoin absorption. 
Alternative AED with no/ 
minimal enzyme induction 
potential should be 
considered. However, if used 
concurrently, sunitinib dose 
should be increased to a 
maximum of 87.5 mg/day 
depending on individual 
tolerability. Patients should be 
monitored carefully for 
toxicity. 
 
 British Medical Association, Pharmaceutical Society 
of Great Britain. British National Formulary. 53rd 
ed. London, UK: BMJ Publishing Group Ltd & RPS 
Publishing; 2007. 
 Pfizer Inc. Sutent (sunitinib malate) capsules 











concentration increases due to 
inhibition of metabolism. 
 
Caution is advised when 
concurrently administering 
tamoxifen with CYP3A4 
inducers, barbiturates, or 
CYP2D6 inhibitors. Patients 
 Perucca E. Clinically relevant drug interactions with 
antiepileptic drugs. Br J Clin Pharmacol. 
2006;61(3):246-255. 
 AstraZeneca Pharmaceuticals LP. Nolvadex 














Active endoxifen metabolite 
may be reduced with CYP2D6 
inhibitors. 
 
should be monitored for signs 
and symptoms of toxicity, or 
an alternative AED should be 
considered.  
 
Wilmington, DE; 2003. 
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tamoxifen metabolite plasma concentrations after 
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Increased risk of drug-induced 
QT prolongation and torsades 
de pointes, due to theoretical 
postulations of additive 
arrhythmogenic potential 
related to blockade of the 
potassium rectifier channel, 
causing disruption to the 
normal balance between 
depolarising and repolarising 







Measurements of QT intervals 
and clinical monitoring of 
symptoms that could indicate 
the occurrence of torsades de 
pointes (e.g. dizziness, 
palpitations, or syncope) are 
recommended. If marked QT 
prolongation occurs, dose 
reduction of the offending 
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(active metabolite of 
tamoxifen) decreases, possibly 
due to inhibition of CYP2D6-
mediated metabolism of 
tamoxifen to endoxifen. 
 
Caution is advised. Dosage 
adjustments and monitoring 
may be required whenever the 
SSRI is added to or withdrawn 
from therapy. 
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increases due to competitive 
inhibition by CYP3A4 by 
fluvoxamine, leading to 
decreased clearance of 
tamoxifen. 
 
Caution is advised. Dosage 
adjustments and monitoring 
may be required whenever 
fluvoxamine is added to or 
withdrawn from therapy. 
 Fleishaker JC, Hulst LK. A pharmacokinetic and 
pharmacodynamic evaluation of the combined 
administration of alprazolam and fluvoxamine. Eur J 
Clin Pharmacol. 1994;46(1):35-39. 
 Damkier P, Hansen LL, Brøsen K. Effect of 
fluvoxamine on the pharmacokinetics of quinidine. 
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Plasma concentrations of 
temsirolimus and sirolimus 
(active metabolite) decrease 
due to induction of CYP 
enzymes.  
Adequate response to 
temsirolimus should be 
monitored. Doses of 
temsirolimus may need to be 
increased from 25 to 50 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Boni J, Leister C, Burns J, Cincotta M, Hug B, 














with concomitant administration of cytochrome 

































Increased risk of central 
nervous system or respiratory 
depression, including 
drowsiness, decreased mental 
abilities or confusion. 
Mechanism is possibly due to 

















Monitoring for potentially 
excessive or prolonged central 
nervous system and 
respiratory depression is 
recommended. Ambulatory 
patients are advised to avoid 
hazardous activities requiring 
complete mental alertness and 
motor coordination until they 
know how these agents affect 
them, and to notify their 
physician if they experience 
excessive or prolonged central 
nervous system effects that 
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Increased risk of peripheral 
neuropathy. Thalidomide can 
cause nerve damage and 
peripheral neuropathy. 
Disulfiram causes a 
sensorimotor neuropathy with 
axonal degeneration, possibly 
due to its neurotoxic 
Caution is advised. Early signs 
of neuropathy (e.g. burning, 
tingling, pain, numbness in the 
hands and feet) should be 
monitored at monthly intervals 
for the first 3 months of 
therapy, and periodically 
thereafter. 
 Hayman M, Wilkins PA. Polyneuropathy as a 
complication of disulfiram therapy of alcoholism. Q 
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 Gardner-Thorpe C, Benjamin S. Peripheral 
neuropathy after disulfiram administration. J Neurol 
Neurosurg Psychiatry. 1971;34(3):253-259. 
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metabolite carbon disulphide. 
Concurrent use of these agents 




may be performed at baseline 
and every 6 months during 
therapy to detect 
asymptomatic neuropathy. 
Immediate discontinuation of 
thalidomide should be 
considered in patients who 
develop peripheral neuropathy 
to limit further damage. If 
necessary, therapy should 
generally be reinstituted only 
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Caution is advised when 
concurrently administering 
toremifene and CYP3A4 
inducers or barbiturates. 
Adequate response to 
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Pharmacol. 1994;47(10):1883-1895. 
 
 Fluvoxamine Toremifene concentration 
increases due to theoretical 
inhibition of CYP3A4 by 
fluvoxamine, leading to 
decreased clearance of 
toremifene. 
 
Clinical and laboratory 
monitoring for altered safety 
and efficacy of toremifene 
(e.g. elevated liver enzymes, 
hypocalcaemia, leucopoenia, 
thrombocytopenia) may be 
appropriate. 
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Plasma concentrations of 
vinca alkaloids decrease, 
possibly due to induction of 
CYP enzymes. 
Adequate responses to vinca 
alkaloids should be monitored. 
Doses may need to be 
increased. 
 Perucca E. Clinically relevant drug interactions with 
antiepileptic drugs. Br J Clin Pharmacol. 
2006;61(3):246-255. 


































decreases, possibly due to 
antineoplastic damage to 















should be monitored. 
Increased phenytoin doses 
may be required. Phenytoin 
levels should be checked again 
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lymphoblastic leukemia. J Pediatr. 1988;112(6):996-
999. 
 Fincham RW, Schottelius DD. Decreased phenytoin 
levels in antineoplastic therapy. Ther Drug Monit. 
1979;1(2):277-283. 
 Villikka K, Kivistö KT, Mäenpää H, Joensuu H, 
Neuvonen PJ. Cytochrome P450-inducing 
antiepileptics increase the clearance of vincristine in 





Plasma concentrations of 
vinca alkaloids increase due to 
competitive inhibition of 
CYP3A4 by fluvoxamine, 
leading to decreased 
clearances of vinca alkaloids. 
 
Caution is advised. Dosage 
adjustments and monitoring 
may be required whenever 
fluvoxamine is added to or 
withdrawn from therapy. 
 Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement 
of human liver cytochrome P450 3A in vinblastine 
metabolism: drug interactions. Cancer Res. 
1993;53(21):5121-5126. 
 Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy 
GF, Warner E. Vinblastine and erythromycin: an 
unrecognized serious drug interaction. Cancer 
Chemother Pharmacol. 1995;35(3):188-190. 
 Chan JD. Pharmacokinetic drug interactions of vinca 
alkaloids: summary of case reports. 
Pharmacotherapy. 1998;18(6):1304-1307. 
 Gillies J, Hung KA, Fitzsimons E, Soutar R. Severe 
vincristine toxicity in combination with itraconazole. 
Clin Lab Haematol. 1998;20(2):123-124. 












injection USP [product information]. Bedford, OH; 
2001. 
 Jeng MR, Feusner J. Itraconazole-enhanced 
vincristine neurotoxicity in a child with acute 
lymphoblastic leukemia. Pediatr Hematol Oncol. 
2001;18(2):137-142. 
 Kamaluddin M, McNally P, Breatnach F, et al. 
Potentiation of vincristine toxicity by itraconazole in 
children with lymphoid malignancies. Acta Paediatr. 
2001;90(10):1204-1207. 
 Sathiapalan RK, El-Solh H. Enhanced vincristine 
neurotoxicity from drug interactions: case report and 
review of literature. Pediatr Hematol Oncol. 
2001;18(8):543-546. 
 Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen 
I, Al-Jumaah S. Vincristine-itraconazole interaction: 
cause for increasing concern. J Pediatr Hematol 
Oncol. 2002;24(7):591. 
 Ariffin H, Omar KZ, Ang EL, Shekhar K. Severe 
vincristine neurotoxicity with concomitant use of 
itraconazole. J Paediatr Child Health. 
2003;39(8):638-639. 
 Sicor Pharmaceuticals Inc. Vincasar PFS (vincristine 
sulfate injection USP) [product information]. Irvine, 
CA; 2003. 
 Mayne Pharma Inc. Vinorelbine tartrate injection 
solution [product information]. Paramus, NJ; 2004. 
 Bermúdez M, Fuster JL, Llinares E, Galera A, 
Gonzalez C. Itraconazole-related increased 
vincristine neurotoxicity: case report and review of 
literature. J Pediatr Hematol Oncol. 2005;27(7):389-
392. 
 Sandoz Inc. Fluvoxamine maleate tablet [product 
information]. Princeton, NJ; 2007. 
 Takahashi N, Kameoka Y, Yamanaka Y, et al. 
Itraconazole oral solution enhanced vincristine 
neurotoxicity in five patients with malignant 






















interactions expected. Severe 
thrombocytopenia and 
gastrointestinal bleeding may 
occur when used concurrently 
with AEDs that are histone 
deacetylase inhibitors, such as 
carbamazepine, 2-
pyrrolidinone-N-butyric acid 
(metabolite of levetiracetam), 
topiramate and valproic acid.  
 
Platelet counts should be 
monitored every 2 weeks for 




 Merck & Co. Inc. Zolinza (vorinostat) capsules 
[product information]. Whitehouse Station, NJ; 
2006. 








Bitter melon The immunomodulatory 
effects of bitter melon may 
lead to an increase in the 
activity of corticosteroids. 
 
Caution is advised during 
concurrent use of bitter melon 
with corticosteroids. 
Monitoring for altered 
corticosteroid efficacy is 
recommended.  
 
 Jilka C, Strifler B, Fortner GW, Hays EF, Takemoto 
DJ. In vivo antitumor activity of the bitter melon 
(Momordica charantia). Cancer Res. 
1983;43(11):5151-5155. 
 Pongnikorn S, Fongmoon D, Kasinrerk W, 
Limtrakul PN. Effect of bitter melon (Momordica 
charantia Linn) on level and function of natural 
killer cells in cervical cancer patients with 




 Increased risk of 
hypoglycaemia due to additive 
effects on glycaemic control. 
 
Caution is advised. Patients 
should be monitored for signs 
and symptoms of rituximab-
induced hypoglycaemia (e.g. 
fatigue, sweating, and 
restlessness). 
 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 
Drug Information Handbook with International 
Trade Names Index. 15th ed. Hudson, OH: Lexi-
comp Inc.; 2007-2008. 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Hussain BM, Geetha N, Lali V, Pandey M. 
Rituximab induced hypoglycemia in non-Hodgkin's 
lymphoma. World J Surg Oncol. 2006;4:89. 
 Cicero AF, Derosa G, Gaddi A. What do herbalists 
suggest to diabetic patients in order to improve 
glycemic control? Evaluation of scientific evidence 






Increased risk of 
hypoglycaemia due to additive 
Caution is advised. Patients 
should be monitored for signs 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 












effects on glycaemic control. 
 
and symptoms of rituximab-
induced hypoglycaemia (e.g. 
fatigue, sweating, and 
restlessness). 
 
Trade Names Index. 15th ed. Hudson, OH: Lexi-
comp Inc.; 2007-2008. 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Hussain BM, Geetha N, Lali V, Pandey M. 
Rituximab induced hypoglycemia in non-Hodgkin's 
lymphoma. World J Surg Oncol. 2006;4:89. 
 Cicero AF, Derosa G, Gaddi A. What do herbalists 
suggest to diabetic patients in order to improve 
glycemic control? Evaluation of scientific evidence 








The cytotoxic effect of 
cisplatin may be decreased, 
but that of doxorubicin and 
docetaxel may be increased. 
 
Clinical and laboratory 
monitoring for altered 
efficacies of these ACDs is 
recommended. 
 
 Rockwell S, Liu Y, Higgins SA. Alteration of the 
effects of cancer therapy agents on breast cancer 
cells by the herbal medicine black cohosh. Breast 
Cancer Res Treat. 2005;90(3):233-239. 
 
Tamoxifen  The proliferation-inhibiting 
effect of tamoxifen may be 
additively enhanced. Black 
cohosh also inhibits CYP2D6-
mediated metabolism of 
tamoxifen, resulting in 
increased plasma levels of the 
parent drug and decreased 
levels of its active metabolite 
(endoxifen). 
 
Caution is advised. Plasma 
levels and pharmacological 
effects of tamoxifen should be 
monitored in patients who 
concurrently take black 
cohosh with tamoxifen. 
 
 Bodinet C, Freudenstein J. Influence of Cimicifuga 
racemosa on the proliferation of estrogen receptor-
positive human breast cancer cells. Breast Cancer 
Res Treat. 2002;76(1):1-10. 
 Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo 
effects of goldenseal, kava kava, black cohosh, and 
valerian on human cytochrome P450 1A2, 2D6, 2E1, 
and 3A4/5 phenotypes. Clin Pharmacol Ther. 
2005;77(5):415-426. 
 Borges S, Desta Z, Li L, et al. Quantitative effect of 
CYP2D6 genotype and inhibitors on tamoxifen 
metabolism: implication for optimization of breast 






 Plasma levels of ACDs that 
are CYP2D6 substrates may 
be increased due to inhibition 
of CYP2D6 by black cohosh. 
 
Caution is advised during 
concurrent use of black 
cohosh with drugs that are 
CYP2D6 substrates. Plasma 
levels of ACDs should be 
closely monitored in patients 
concurrently administered 
with these ACDs and black 
 Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo 
effects of goldenseal, kava kava, black cohosh, and 
valerian on human cytochrome P450 1A2, 2D6, 2E1, 


























effects of blue-green algae 
may interfere with the 
immunosuppressive effects of 
corticosteroids, since blue-
green algae enhances the 
immune response by 
stimulating macrophage 
functions, phagocytosis and 
interleukin-1 production in-
vitro and in murine models. 
 
Caution is advised during 
concurrent use of blue-green 
algae with corticosteroids. 
Monitoring for altered 
corticosteroid efficacy is 
recommended. 
 
 Hayashi O, Katoh T, Okuwaki Y. Enhancement of 
antibody production in mice by dietary Spirulina 







Increased risk of 
hypoglycaemia due to additive 
effects on glycaemic control. 
 
Caution is advised. Patients 
should be monitored for signs 
and symptoms of rituximab-
induced hypoglycaemia (e.g. 
fatigue, sweating, and 
restlessness). 
 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 
Drug Information Handbook with International 
Trade Names Index. 15th ed. Hudson, OH: Lexi-
comp Inc.; 2007-2008. 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Hussain BM, Geetha N, Lali V, Pandey M. 
Rituximab induced hypoglycemia in non-Hodgkin's 
lymphoma. World J Surg Oncol. 2006;4:89. 
 Cicero AF, Derosa G, Gaddi A. What do herbalists 
suggest to diabetic patients in order to improve 
glycemic control? Evaluation of scientific evidence 
















Increased risk of 
hepatotoxicity possibly due to 
additive effects when cassia 
bark is used concomitantly 
with hepatotoxic ACDs. 
Animal studies have shown 
that coumarin, a constituent of 
cassia bark, causes 
hepatotoxicity. In addition, 
clinical studies have shown 
that high doses of coumarin 
Concurrent use of cassia bark 
and hepatotoxic ACDs is not 
recommended. If concurrent 
use is unavoidable, periodic 
monitoring of the patient’s 
liver function, and signs and 
symptoms of hepatotoxicity 
(fever, rash, anorexia, nausea, 
vomiting, fatigue, dark urine, 
upper right quadrant pain, and 
jaundice) is advised. 
 Guo JJ, Wigle PR, Lammers K, Vu O. Comparison 
of potentially hepatotoxic drugs among major US 
drug compendia. Res Social Adm Pharm. 
2005;1(3):460-479. 
 Felter SP, Vassallo JD, Carlton BD, Daston GP. A 
safety assessment of coumarin taking into account 
species-specificity of toxicokinetics. Food Chem 
Toxicol. 2006;44(4):462-475. 
 Donald S, Verschoyle RD, Greaves P, et al. 
Complete protection by high-dose dexamethasone 




























(50-7000mg daily) in humans 
can result in hepatotoxicity 
which can be resolved upon 
discontinuation of coumarin. 
 
 
In addition, trabectedin should 
not be administered in patients 
who have elevated bilirubin 
levels. Patients must receive 
20 mg of dexamethasone 
intravenously 30 minutes prior 
to trabectedin administration 
due to its hepatoprotective 
effects. The dose of 
trabectedin must be reduced to 
1.2 mg/m2 or 1 mg/m2 for 
subsequent treatment cycles if 
the baseline criteria defined by 
the manufacturer is not 
fulfilled or if toxicities 
reappear. Treatment 
discontinuation should be 
considered if further dose 
reductions are necessary. 
 
drug Yondelis (ET-743) in the rat. Cancer Res. 
2003;63(18):5902-5908. 
 Pharma Mar S.A. Yondelis (trabectedin) 0.25mg and 
1mg powder for concentrate for solution for infusion 
























Plasma levels of ACDs that 
are CYP3A4 substrates may 
be increased due to inhibition 
of the CYP3A4 isozyme by 
cat’s claw. 
 
Caution is advised during 
concurrent use of cat’s claw 
with ACDs that are CYP3A4 
substrates. Plasma levels of 




recommends that a dose 
reduction to 12.5 mg/week be 
considered if temsirolimus is 
co-administered with strong 
CYP3A4 inhibitors, and a 
washout period of 
approximately 1 week be 
allowed before the 
temsirolimus dose be adjusted 
back upon discontinuation of 
the inhibitor. 
 Budzinski JW, Foster BC, Vandenhoek S, Arnason 
JT. An in vitro evaluation of human cytochrome 
P450 3A4 inhibition by selected commercial herbal 
extracts and tinctures. Phytomedicine. 
2000;7(4):273-282. 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 














































 Cat’s claw has been shown to 
be a potent inhibitor of TNF-
alpha production in-vitro, 
possibly related to its 
immunomodulatory effects. 
The immunomodulatory 
effects of cat’s claw may 
interfere with the 
immunosuppressive effects of 
corticosteroids. 
 
Caution is advised during 
concurrent use of cat’s claw 
with corticosteroids. Close 
monitoring for altered efficacy 
and safety of corticosteroid 
treatment is recommended. 
 
 Sandoval M, Charbonnet RM, Okuhama NN, et al. 
Cat's claw inhibits TNFalpha production and 
scavenges free radicals: role in cytoprotection. Free 








Increased risk of 
hepatotoxicity possibly due to 
additive effects when 
chaparral is used 
Concurrent use of chaparral 
and hepatotoxic ACDs is not 
recommended. If concurrent 
use is unavoidable, periodic 
 Guo JJ, Wigle PR, Lammers K, Vu O. Comparison 
of potentially hepatotoxic drugs among major US 







































monitoring of patient’s liver 
function and signs and 
symptoms of hepatotoxicity 
(fever, rash, anorexia, nausea, 
vomiting, fatigue, dark urine, 
upper right quadrant pain, and 
jaundice) is advised. 
 
In addition, trabectedin should 
not be administered in patients 
who have elevated bilirubin 
levels. Patients must receive 
20 mg of dexamethasone 
intravenously 30 minutes prior 
to trabectedin administration 
due to its hepatoprotective 
effects. The dose of 
trabectedin must be reduced to 
1.2 mg/m2 or 1 mg/m2 for 
subsequent treatment cycles if 
the baseline criteria defined by 
the manufacturer is not 
fulfilled or if toxicities 
reappear. Treatment 
discontinuation should be 
considered if further dose 
reductions are necessary. 
 
 Donald S, Verschoyle RD, Greaves P, et al. 
Complete protection by high-dose dexamethasone 
against the hepatotoxicity of the novel antitumor 
drug Yondelis (ET-743) in the rat. Cancer Res. 
2003;63(18):5902-5908. 
 Pharma Mar S.A. Yondelis (trabectedin) 0.25mg and 
1mg powder for concentrate for solution for infusion 
[summary of product characteristics]. Madrid, Spain; 
2009. 
 Gordon DW, Rosenthal G, Hart J, Sirota R, Baker 
AL. Chaparral ingestion. The broadening spectrum 
of liver injury caused by herbal medications. JAMA. 
1995;273(6):489-490. 
 Batchelor WB, Heathcote J, Wanless IR. Chaparral-













effects of cordyceps may 
interfere with the 
immunosuppressive activity of 
corticosteroids. 
 
Caution is advised during 
concurrent use of cordyceps 
with immunosuppressant 
drugs. Close monitoring for 
altered efficacy and safety of 
corticosteroid treatment is 
recommended. 
 
 Chen YJ, Shiao MS, Lee SS, Wang SY. Effect of 
Cordyceps sinensis on the proliferation and 
differentiation of human leukemic U937 cells. Life 
Sci. 1997;60(25):2349-2359. 
 Chen GZ, Chen GL, Sun T, Hsieh GC, Henshall JM. 
Effects of Cordyceps sinensis on murine T 





 Cordyceps was shown to 
increase the number of T-
helper cells, T-helper to T-
Caution is advised. 
Monitoring for altered 
efficacy and safety of 
 Chen GZ, Chen GL, Sun T, Hsieh GC, Henshall JM. 
Effects of Cordyceps sinensis on murine T 












suppressor cell ratio, 
phagocyte counts and 
phagocytic activity in animal 
studies. In addition, protection 
of T-helper cells from the 
immunosuppressive effects of 
cyclophosphamide was also 
observed. The 
immunosuppressive effects of 
cyclophosphamide may be 
reduced by cordyceps. 
 



































Plasma levels of ACDs that 
are substrates of CYP2C and 
3A4 isozymes may be 
increased due to inhibition by 
devil’s claw. 
 
Caution is advised. Plasma 
levels and clinical efficacy of 
the ACDs should be closely 
monitored in patients 
concurrently on devil’s claw. 
 
The manufacturer 
recommends that a dose 
reduction to 12.5 mg/week be 
considered if temsirolimus is 
co-administered with strong 
CYP3A4 inhibitors and a 
washout period of 
approximately 1 week be 
allowed before the 
temsirolimus dose be adjusted 
back upon discontinuation of 
the inhibitor. 
 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Unger M, Frank A. Simultaneous determination of 
the inhibitory potency of herbal extracts on the 
activity of six major cytochrome P450 enzymes 
using liquid chromatography/mass spectrometry and 











































 Devil’s claw has been shown 
to be an inhibitor of TNF-
alpha production in-vitro, 
possibly related to its 
immunomodulatory effects. 
The immunomodulatory 
effects of devil’s claw may 
interfere with the 
immunosuppressive effects of 
corticosteroids. 
 
Caution is advised during 
concurrent use of devil’s claw 
with corticosteroids. Close 
monitoring for altered efficacy 
and safety of corticosteroid 
treatment is recommended. 
 
 Fiebich BL, Heinrich M, Hiller KO, Kammerer N. 
Inhibition of TNF-alpha synthesis in LPS-stimulated 
primary human monocytes by Harpagophytum 











Plasma levels of ACDs that 
are CYP2D6 and 3A 
substrates may be decreased. 
 
Caution is advised. Patients on 
drugs which are CYP2D6 
and/or 3A substrates should 
refrain from taking dong quai 
concurrently. Plasma levels of 
ACDs should be closely 
monitored if co-administration 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Tang JC, Zhang JN, Wu YT, Li ZX. Effect of the 
water extract and ethanol extract from traditional 
Chinese medicines Angelica sinensis (Oliv.) Diels, 

















































is unavoidable. Increased 
doses may be required to 
achieve therapeutic efficacy.  
 
The manufacturer 
recommends that a dose 
increase from 25 mg/week up 
to 50 mg/week be considered 
if temsirolimus is co-
administered with strong 
CYP3A4 inducers, and the 
dose be adjusted back upon 
discontinuation of the inducer. 
 





 Dong quai may antagonise the 
anti-estrogenic effects 
tamoxifen. The herb also 
Caution is advised. Patients on 
tamoxifen therapy should 
avoid taking dong quai 
 Tang JC, Zhang JN, Wu YT, Li ZX. Effect of the 
water extract and ethanol extract from traditional 












causes an increase in CYP2D6 
and 3A isozyme activities, of 





Ligusticum chuanxiong Hort. and Rheum palmatum 
L. on rat liver cytochrome P450 activity. Phytother 
Res. 2006;20(12):1046-1051. 
 Lau CB, Ho TC, Chan TW, Kim SC. Use of dong 
quai (Angelica sinensis) to treat peri- or 
postmenopausal symptoms in women with breast 







 Increased risk of bleeding due 
to additive haematological 
effects. 
 
Concurrent use of dong quai 
and these ACDS is not 
recommended. Patients should 
be monitored closely for signs 
and symptoms of bleeding, as 
well as haematological 
complications if concomitant 
administration cannot be 
avoided. 
 
 Page RL 2nd, Lawrence JD. Potentiation of warfarin 









Increased risk of bleeding 
possibly due to association 
between fenugreek and 
increased bleeding time. 
 
Concurrent use of fenugreek 
and these ACDS is not 
recommended. Patients should 
be monitored closely for signs 
and symptoms of bleeding, as 
well as haematological 
complications if concomitant 
administration cannot be 
avoided. 
 
 Lambert JP, Cormier J. Potential interaction between 





 Increased risk of 
hypoglycaemia due to additive 
effects on glycaemic control. 
 
Caution is advised. Patients 
should be monitored for signs 
and symptoms of rituximab-
induced hypoglycaemia (e.g. 
fatigue, sweating, and 
restlessness). 
 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 
Drug Information Handbook with International 
Trade Names Index. 15th ed. Hudson, OH: Lexi-
comp Inc.; 2007-2008. 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Hussain BM, Geetha N, Lali V, Pandey M. 
Rituximab induced hypoglycemia in non-Hodgkin's 
lymphoma. World J Surg Oncol. 2006;4:89. 
 Cicero AF, Derosa G, Gaddi A. What do herbalists 












glycemic control? Evaluation of scientific evidence 









































Garlic has a bimodal 
distribution of effects on CYP 
isozymes. Plasma levels of 
ACDs may be altered due to 
inhibition or induction of the 
CYP isozymes by garlic. 
 
Caution is advised. Plasma 
levels and clinical efficacy of 
ACDs should be closely 
monitored in patients 
concurrently on these agents.  
 
The manufacturer 
recommends that a dose 
reduction to 12.5 mg/week or 
a dose increase to 50 mg/week 
be considered if temsirolimus 
is co-administered with strong 
CYP3A4 inhibitors or 
inducers respectively. The 
temsirolimus dose should be 
adjusted back upon 
discontinuation of the 
inhibitor or inducer, and a 
washout period of 
approximately 1 week should 
be allowed if a strong inhibitor 
is discontinued. 
 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Meijerman I, Beijnen JH, Schellens JHM. Herb-drug 
interactions in oncology: focus on mechanisms of 
induction. Oncologist. 2006;11(7):742-752. 
 Zou L, Harkey MR, Henderson GL. Effects of herbal 
components on cDNA-expressed cytochrome P450 
enzyme catalytic activity. Life Sci. 
2002;71(13):1579-1589. 
 Piscitelli SC, Burstein AH, Welden N, Gallicano 
KD, Falloon J. The effect of garlic supplements on 
the pharmacokinetics of saquinavir. Clin Infect Dis. 
2002;34(2):234-238. 
 Foster BC, Foster MS, Vandenhoek S, et al. An in 
vitro evaluation of human cytochrome P450 3A4 and 





















































 Pharmacological effects of 
ACDs that are substrates of p-
glycoprotein may be 
decreased due to induction of 
p-glycoprotein. 
 
Caution is advised. 
Pharmacological effects of 
ACDs should be monitored in 
patients concurrently on these 
agents.  
 
In addition, regular monitoring 
of prostate specific antigen is 
recommended by the 
manufacturer of bicalutamide 
as part of the patients’ clinical 
response. If prostate specific 
antigen levels rise, patients 
should be monitored for 
clinical progression. A 
treatment-free period of 
antiandrogen while continuing 
bicalutamide may be 
considered in patients who 
have objective progression of 
disease together with elevated 
prostate specific antigen 
levels. 
 
 Meijerman I, Beijnen JH, Schellens JHM. Herb-drug 
interactions in oncology: focus on mechanisms of 
induction. Oncologist. 2006;11(7):742-752. 
 Piscitelli SC, Burstein AH, Welden N, Gallicano 
KD, Falloon J. The effect of garlic supplements on 
the pharmacokinetics of saquinavir. Clin Infect Dis. 
2002;34(2):234-238. 
 Foster BC, Foster MS, Vandenhoek S, et al. An in 
vitro evaluation of human cytochrome P450 3A4 and 
P-glycoprotein inhibition by garlic. J Pharm Pharm 
Sci. 2001;4(2):176-184. 
 Kuang YH, Shen T, Chen X, et al. Lapatinib and 
erlotinib are potent reversal agents for MRP7 
(ABCC10)-mediated multidrug resistance. Biochem 
Pharmacol. 2010;79(2):154-161. 
 Azzariti A, Porcelli L, Simone GM, et al. Tyrosine 
kinase inhibitors and multidrug resistance proteins: 
interactions and biological consequences. Cancer 
Chemother Pharmacol. 2010;65(2):335-346. 
 Colabufo NA, Pagliarulo V, Berardi F, et al. 
Bicalutamide failure in prostate cancer treatment: 
involvement of Multi Drug Resistance proteins. Eur 
J Pharmacol. 2008;601(1-3):38-42. 
 AstraZeneca Pharmaceuticals LP. Casodex 
(bicalutamide) oral tablets [product information]. 















 Increased risk of 
hypoglycaemia due to additive 
effects on glycaemic control. 
 
Caution is advised. Patients 
should be monitored for signs 
and symptoms of rituximab-
induced hypoglycaemia (e.g. 
fatigue, sweating, and 
restlessness). 
 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 
Drug Information Handbook with International 
Trade Names Index. 15th ed. Hudson, OH: Lexi-
comp Inc.; 2007-2008. 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Hussain BM, Geetha N, Lali V, Pandey M. 
Rituximab induced hypoglycemia in non-Hodgkin's 
lymphoma. World J Surg Oncol. 2006;4:89. 
 Cicero AF, Derosa G, Gaddi A. What do herbalists 
suggest to diabetic patients in order to improve 
glycemic control? Evaluation of scientific evidence 






Ginger Increased risk of bleeding due 
to additive haematological 
effects. 
 
Concurrent use of ginger and 
these ACDS is not 
recommended. Patients should 
be monitored closely for signs 
and symptoms of bleeding, as 
well as haematological 
complications if concomitant 
administration cannot be 
avoided. 
 
 Shalansky S, Lynd L, Richardson K, Ingaszewski A, 
Kerr C. Risk of warfarin-related bleeding events and 
supratherapeutic international normalized ratios 
associated with complementary and alternative 
medicine: a longitudinal analysis. Pharmacotherapy. 
2007;27(9):1237-1247. 
 Heck AM, DeWitt BA, Lukes AL. Potential 
interactions between alternative therapies and 





 Increased risk of 
hypoglycaemia due to additive 
effects on glycaemic control. 
 
Caution is advised. Patients 
should be monitored for signs 
and symptoms of rituximab-
induced hypoglycaemia (e.g. 
fatigue, sweating, and 
restlessness). 
 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 
Drug Information Handbook with International 
Trade Names Index. 15th ed. Hudson, OH: Lexi-
comp Inc.; 2007-2008. 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Hussain BM, Geetha N, Lali V, Pandey M. 
Rituximab induced hypoglycemia in non-Hodgkin's 
lymphoma. World J Surg Oncol. 2006;4:89. 
 Cicero AF, Derosa G, Gaddi A. What do herbalists 
suggest to diabetic patients in order to improve 
glycemic control? Evaluation of scientific evidence 
and potential risks. Acta Diabetol. 2004;41(3):91-98. 
 















 are CYP2C19 substrates may 
be decreased due to induction 
of the same isozyme by 
ginkgo. 
 
levels and clinical efficacy of 
the ACDs should be closely 
monitored in patients 
concurrently on ginkgo and 
these drugs. 
 
MS. Pharmacogenetics and herb-drug interactions: 






 Plasma levels of ACDs that 
are CYP2B substrates may be 
decreased due to induction of 
the same isozyme by ginkgo. 
 
Caution is advised. Plasma 
levels and clinical efficacy of 
the ACDs should be closely 
monitored in patients 
concurrently on ginkgo and 
these drugs. 
 
 Taki Y, Yamazaki Y, Shimura F, Yamada S, 
Umegaki K. Time-dependent induction of hepatic 
cytochrome P450 enzyme activity and mRNA 








 Plasma levels of ACDs that 
are CYP2C9 substrates may 
increase due to inhibition of 
the same isozyme by ginkgo. 
 
Caution is advised during 
concurrent use of ginkgo with 
drugs that are CYP2C9 
substrates. Plasma levels of 
ACDs should be closely 
monitored in patients 
concurrently on ginkgo and 
these drugs. 
 
 Yale SH, Glurich I. Analysis of the inhibitory 
potential of Ginkgo biloba, Echinacea purpurea, and 
Serenoa repens on the metabolic activity of 
cytochrome P450 3A4, 2D6, and 2C9. J Altern 


















Hormone agonists / 
antagonists 
 Contradictory evidence exists. 
Some in-vitro studies have 
indicated that ginkgo extracts 
moderately inhibit CYP3A4, 
while others have suggested 
that the terpenoids and 
flavonoids of ginkgo extracts 
exhibit differential induction 
potentials. Plasma levels of 
ACDs that are CYP3A4 
substrates may be altered due 
to inhibition or induction of 
the CYP3A4 isozyme by 
ginkgo. 
 
Caution is advised during 
concurrent use of ginkgo with 
drugs that are CYP3A4 
substrates. Plasma levels and 
clinical efficacy of ACDs 
should be closely monitored in 
patients concurrently on 
ginkgo and these drugs.  
 
The manufacturer 
recommends that a dose 
reduction to 12.5 mg/week or 
a dose increase to 50 mg/week 
be considered if temsirolimus 
is co-administered with strong 
CYP3A4 inhibitors or 
inducers respectively. The 
temsirolimus dose should be 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Yale SH, Glurich I. Analysis of the inhibitory 
potential of Ginkgo biloba, Echinacea purpurea, and 
Serenoa repens on the metabolic activity of 
cytochrome P450 3A4, 2D6, and 2C9. J Altern 
Complement Med. 2005;11(3):433-439. 
 Li L, Stanton JD, Tolson AH, Luo Y, Wang H. 
Bioactive terpenoids and flavonoids from Ginkgo 
biloba extract induce the expression of hepatic drug-
metabolizing enzymes through pregnane X receptor, 
constitutive androstane receptor, and aryl 








































adjusted back upon 
discontinuation of the 
inhibitor or inducer, and a 
washout period of 
approximately 1 week should 





 The monoamine oxidase 
inhibiting effect of 
procarbazine may be 
potentiated. 
 
Concomitant use of 
procarbazine and ginkgo is not 
recommended. If concurrent 
use is unavoidable, patients 
should be monitored for signs 
and symptoms of central 




 Fehske CJ, Leuner K, Müller WE. Ginkgo biloba 
extract (EGb761) influences monoaminergic 
neurotransmission via inhibition of NE uptake, but 
not MAO activity after chronic treatment. Pharmacol 
Res. 2009;60(1):68-73. 
 Sigma-Tau Pharmaceuticals Inc. Matulane 
(procarbazine hydrochloride) capsules [product 








Increased risk of 
hypoglycaemia due to additive 
effects on glycaemic control. 
 
Caution is advised. Patients 
should be monitored for signs 
and symptoms of rituximab-
induced hypoglycaemia (e.g. 
 Lacy CF, Armstrong LL, Goldman MP, Lance LL. 
Drug Information Handbook with International 
Trade Names Index. 15th ed. Hudson, OH: Lexi-












fatigue, sweating, and 
restlessness). 
 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Hussain BM, Geetha N, Lali V, Pandey M. 
Rituximab induced hypoglycemia in non-Hodgkin's 
lymphoma. World J Surg Oncol. 2006;4:89. 
 Cicero AF, Derosa G, Gaddi A. What do herbalists 
suggest to diabetic patients in order to improve 
glycemic control? Evaluation of scientific evidence 
and potential risks. Acta Diabetol. 2004;41(3):91-98. 
 Xie JT, Mehendale SR, Li X, et al. Anti-diabetic 
effect of ginsenoside Re in ob/ob mice. Biochim 




 The monoamine oxidase 
inhibiting effect of 
procarbazine may be 
potentiated. Mechanism of 
interaction is unknown, but 
has been linked to the central 
nervous system-stimulating 
and psychoactive properties of 
ginseng. 
 
Concurrent use of 
procarbazine and ginseng is 
not recommended. A 
minimum of 14 days should 
elapse between 
discontinuation of agents that 
possess monoamine oxidase 
inhibition activity (e.g. 
procarbazine) and initiation of 
treatment with agents that may 
interact with monoamine 
oxidase inhibitors (e.g. 
ginseng). 
 
 Miller LG. Herbal medicinals: Selected clinical 
considerations focusing on known or potential drug-
herb interactions. Arch Intern Med. 
1998;158(20):2200-2211. 
 Shader RI, Greenblatt DJ. Phenelzine and the dream 
machine - ramblings and reflections. J Clin 
Psychopharmacol. 1985;5(2):65. 
 Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs 
revisited. J Clin Psychopharmacol. 1988;8(4):235. 
 Jones BD, Runikis AM. Interaction of ginseng with 
phenelzine. J Clin Psychopharmacol. 1987;7(3):201-
202. 
 Bahrke MS. Comments on "Manic episode and 












Asian ginseng exhibits 
immunostimulatory properties 
associated with enhanced 
antibody formation, increased 
phagocytosis and natural killer 
cell activity, and other 
modulatory effects on humoral 
and cell-mediated immune 
responses. The 
immunostimulatory effects of 
Asian ginseng may interfere 
Caution is advised during 
concurrent use of Asian 
ginseng with corticosteroids. 
Monitoring for altered 
efficacy and safety of 
corticosteroid therapy is 
recommended. 
 
 Shin HR, Kim JY, Yun TK, Morgan G, Vainio H. 
The cancer-preventive potential of Panax ginseng: a 
review of human and experimental evidence. Cancer 













with the immunosuppressive 










































Contradictory evidence exists. 
Siberian ginseng has been 
suggested to inhibit CYP1A2, 
2C9 and 3A4 in some studies, 
but others have indicated that 
the eleutherosides found in 
Siberian ginseng are not likely 
to inhibit these isozymes in-
vitro. Plasma levels of ACDs 
that are substrates of 
CYP1A2, 2C9 and 3A4 may 
be increased due to inhibition 
of the same isozymes by 
Siberian ginseng. 
 
Caution is advised during 
concurrent use of Siberian 
ginseng with drugs which are 
CYP1A2, 2C9 and/or 3A4 
substrates. Plasma levels of 
ACDs and clinical monitoring 
of patients should be carried 
out in patients co-administered 
with these agents.  
 
The manufacturer 
recommends that a dose 
reduction to 12.5 mg/week be 
considered if temsirolimus is 
co-administered with strong 
CYP3A4 inhibitors, and a 
washout period of 
approximately 1 week be 
allowed before the 
temsirolimus dose be adjusted 
back upon discontinuation of 
the inhibitor. 
 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Yarbro CH, Goodman M, Frogge MH, Frogge MH, 
eds. Cancer Nursing: Principles And Practice. 6th 
ed. Portland, OR: Jones & Bartlett Publishers, Inc.; 
2005. 
 Henderson GL, Harkey MR, Gershwin ME, 
Hackman RM, Stern JS, Stresser DM. Effects of 
ginseng components on c-DNA-expressed 




















































Increased risk of 
hepatotoxicity possibly due to 
apoptosis promotion and cell 
membrane alteration by the 
active components of the herb. 
 
Co-administration of gotu kola 
and ACDs that are potentially 
hepatotoxic is not 
recommended. However, if 
concurrent use is unavoidable, 
periodic monitoring of the 
patient’s liver function and 
signs and symptoms of 
hepatotoxicity (fever, rash, 
anorexia, nausea, vomiting, 
fatigue, dark urine, upper right 
quadrant pain, and jaundice) is 
advised.  
 
In addition, trabectedin should 
not be administered in patients 
who have elevated bilirubin 
levels. Patients must receive 
20 mg of dexamethasone 
intravenously 30 minutes prior 
to trabectedin administration 
due to its hepatoprotective 
effects. The dose of 
trabectedin must be reduced to 
1.2 mg/m2 or 1 mg/m2 for 
subsequent treatment cycles if 
the baseline criteria defined by 
the manufacturer is not 
fulfilled or if toxicities 
reappear. Treatment 
discontinuation should be 
 Guo JJ, Wigle PR, Lammers K, Vu O. Comparison 
of potentially hepatotoxic drugs among major US 
drug compendia. Res Social Adm Pharm. 
2005;1(3):460-479. 
 Donald S, Verschoyle RD, Greaves P, et al. 
Complete protection by high-dose dexamethasone 
against the hepatotoxicity of the novel antitumor 
drug Yondelis (ET-743) in the rat. Cancer Res. 
2003;63(18):5902-5908. 
 Pharma Mar S.A. Yondelis (trabectedin) 0.25mg and 
1mg powder for concentrate for solution for infusion 
[summary of product characteristics]. Madrid, Spain; 
2009. 
 Jorge OA, Jorge AD. Hepatotoxicity associated with 














considered if further dose 




 Increased risk of sedation and 
other central nervous system-
depressant effects due to an 
interaction with the alcohol 
content in the paclitaxel 
formulation. However, 
contradictory information 
exists. Gotu kola increases 
pentobarbitone-induced 
sleeping time in animals and is 
a dietary supplement for sleep 
disorders. However, in another 
study, its active component 
(asiaticoside) did not affect 
locomotor activity in rats. 
 
Caution is advised. Patients 
who are on concomitant 
paclitaxel and gotu kola 
should be monitored for 
sedation and other signs and 
symptoms of central nervous 
system depression. 
 
 Solimando DAJ. Drug Information Handbook for 
Oncology. 6th ed. Hudson, OH: Lexi-comp; 2007. 
 Brinkhaus B, Lindner M, Schuppan D, Hahn EG. 
Chemical, pharmacological and clinical profile of the 
East Asian medical plant Centella asiatica. 
Phytomedicine. 2000;7(5):427-448. 
 Sakina MR, Dandiya PC. A psycho-
neuropharmacological profile of Centella asiatica 
extract. Fitoterapia. 1990;61(4):291-296. 
 Cauffield JS, Forbes HJ. Dietary supplements used in 
the treatment of depression, anxiety, and sleep 
disorders. Lippincotts Prim Care Pract. 
1999;3(3):290-304. 
 Wijeweera P, Arnason JT, Koszycki D, Merali Z. 
Evaluation of anxiolytic properties of Gotukola - 
(Centella asiatica) extracts and asiaticoside in rat 
behavioral models. Phytomedicine. 2006;13(9-
10):668-676. 
 AIDSinfo. Paclitaxel. Available at: 
http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailT
.aspx?MenuItem=Drugs&int_id=190&Search=Off&
ClassID=0&TypeID=0. Updated 26 December 2007. 

















Plasma levels of ACDs that 
are substrates of CYP1A and 
2C sub-families, 2D6, 2E1 and 
3A4 may be altered by green 
tea. 
 
Caution is advised during 
concurrent use of green tea 
and ACDs that are substrates 
of these isozymes. Plasma 
drug levels should be 
monitored in patients taking 
these agents together. 
 
 Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, 
Drewe J. Induction of CYP1A by green tea extract in 
human intestinal cell lines. Planta Med. 
2006;72(6):514-520. 
 Yang SP, Raner GM. Cytochrome P450 expression 
and activities in human tongue cells and their 
modulation by green tea extract. Toxicol Appl 
Pharmacol. 2005;202(2):140-150. 
 Chen L, Bondoc FY, Lee MJ, Hussin AH, Thomas 
PE, Yang CS. Caffeine induces cytochrome 
P4501A2: induction of CYP1A2 by tea in rats. Drug 
Metab Dispos. 1996;24(5):529-533. 


















































Inhibition by green tea catechins of metabolic 
activation of procarcinogens by human cytochrome 
P450. Mutat Res. 2001;479(1-2):197-206. 
 Chow HH, Hakim IA, Vining DR, et al. Effects of 
repeated green tea catechin administration on human 
cytochrome P450 activity. Cancer Epidemiol 
Biomarkers Prev. 2006;15(12):2473-2476. 
 Donovan JL, Chavin KD, Devane CL, et al. Green 
tea (Camellia sinensis) extract does not alter 
cytochrome p450 3A4 or 2D6 activity in healthy 




 The activity of bortezomib 
may be antagonised, resulting 
Concurrent use of green tea 
and bortezomib should be 
 Golden EB, Lam PY, Kardosh A, et al. Green tea 












in a decreased therapeutic 
efficacy. Various constituents 
of green tea, such as 
epigallocatechin gallate and 
other polyphenols, prevented 
tumour cell death induced by 





bortezomib and other boronic acid-based proteasome 






 Increased risk of 
haematological effects when 
used concurrently with ACDs 
that have a potential bleeding 
risk. The vitamin K in green 
tea may antagonise the 
anticoagulant effects of 
warfarin. Green tea has also 
shown to exhibit anti-platelet 
activity comparable to that of 
aspirin, possibly by inhibition 
of cytoplasmic calcium 
increase and the arachidonic 
acid pathway. 
 
Concurrent use of green tea 
and ACDS with bleeding risks 
is not recommended. Patients 
should be closely monitored 
for signs and symptoms of 
bleeding, as well as 
haematological complications 
if concomitant administration 
cannot be avoided. 
 
 Taylor JR, Wilt VM. Probable antagonism of 
warfarin by green tea. Ann Pharmacother. 
1999;33(4):426-428. 
 Kang WS, Chung KH, Chung JH, et al. Antiplatelet 
activity of green tea catechins is mediated by 
inhibition of cytoplasmic calcium increase. J 
Cardiovasc Pharmacol. 2001;38(6):875-884. 
 Sagesaka-Mitane Y, Miwa M, Okada S. Platelet 
aggregation inhibitors in hot water extract of green 
tea. Chem Pharm Bull (Tokyo). 1990;38(3):790-793. 
 Son DJ, Cho MR, Jin YR, et al. Antiplatelet effect of 
green tea catechins: a possible mechanism through 
arachidonic acid pathway. Prostaglandins Leukot 


















 Increased risk of 
hepatotoxicity due to additive 
adverse effects of green tea 
and ACDs, possibly due to 
epigallocatechin gallate or its 
metabolites which can induce 
oxidative stress in the liver. 
 
Concurrent use of green tea 
and hepatotoxic ACDs is not 
recommended. If concurrent 
use is unavoidable, periodic 
monitoring of the patient’s 
liver function and signs and 
symptoms of hepatotoxicity 
(fever, rash, anorexia, nausea, 
vomiting, fatigue, dark urine, 
upper right quadrant pain, and 
jaundice) is advised.  
 
In addition, trabectedin should 
not be administered in patients 
who have elevated bilirubin 
levels. Patients must receive 
 Guo JJ, Wigle PR, Lammers K, Vu O. Comparison 
of potentially hepatotoxic drugs among major US 
drug compendia. Res Social Adm Pharm. 
2005;1(3):460-479. 
 Donald S, Verschoyle RD, Greaves P, et al. 
Complete protection by high-dose dexamethasone 
against the hepatotoxicity of the novel antitumor 
drug Yondelis (ET-743) in the rat. Cancer Res. 
2003;63(18):5902-5908. 
 Pharma Mar S.A. Yondelis (trabectedin) 0.25mg and 
1mg powder for concentrate for solution for infusion 
[summary of product characteristics]. Madrid, Spain; 
2009. 
 Mazzanti G, Menniti-Ippolito F, Moro PA, et al. 
Hepatotoxicity from green tea: a review of the 























20 mg of dexamethasone 
intravenously 30 minutes prior 
to trabectedin administration 
due to its hepatoprotective 
effects. The dose of 
trabectedin must be reduced to 
1.2 mg/m2 or 1 mg/m2 for 
subsequent treatment cycles if 
the baseline criteria defined by 
the manufacturer is not 
fulfilled or if toxicities 
reappear. Treatment 
discontinuation should be 
considered if further dose 






 Increased risk of hypertensive 
crisis (increased blood 
pressure, confusion and 
restlessness) due to the high 
caffeine content in green tea. 
 
Concurrent use of 
procarbazine and green tea is 
not recommended. 
 
 American Society of Health-System Pharmacists. 
AHFS Drug Information. 2007 ed. Bethesda, MD: 







Increased risk of hypertensive 
crisis (increased blood 
pressure, confusion and 
restlessness) due to the high 
caffeine content in guarana. 
 
Concurrent use of 
procarbazine and guarana is 
not recommended. 
 
 American Society of Health-System Pharmacists. 
AHFS Drug Information. 2007 ed. Bethesda, MD: 







The therapeutic efficacy of 
cisplatin may be reduced by 
licorice. 
 
Caution is advised. Clinical 
monitoring of the therapeutic 
efficacy of cisplatin should be 




 Lee CK, Park KK, Lim SS, Park JHY, Chung WY. 
Effects of the licorice extract against tumour growth 
and cisplatin-induced toxicity in a mouse xenograft 








 Licorice inhibits 11-
betadehydrogenase and 
prevents the inactivation of 
cortisol. The duration of 
corticosteroid activity may be 
Concurrent use of 
corticosteroids and licorice is 
not recommended. 
 
 Walker BR, Edwards CR. Licorice-induced 
hypertension and syndromes of apparent 
mineralocorticoid excess. Endocrinol Metab Clin 
North Am. 1994;23(2):359-377. 














theoretically increased. An 
increased risk of potassium 




potassium depletion and severe myopathy due to 





 Glabridin, a major isoflavan in 
licorice root, competitively 
binds to estrogen receptors in-
vitro in a concentration-
dependent manner. The 
therapeutic effects of 
tamoxifen may be altered 
during concomitant 
administration with licorice. 
 
Caution is advised. Clinical 
efficacy of tamoxifen should 
be monitored in patients 
concurrently taking these 
agents. 
 
 Tamir S, Eizenberg M, Somjen D, et al. Estrogenic 
and antiproliferative properties of glabridin from 






 Plasma levels of ACDs that 
are CYP2B6 substrates may 
be increased due to inhibition 
of the CYP2B6 isozyme by 
gladribin, an isoflavan in 
licorice. 
 
Caution is advised during 
concurrent use of licorice with 
drugs which are CYP2B6 
substrates. Plasma levels of 
ACDs should be closely 
monitored during co-
administration of these agents. 
 
 Kent UM, Aviram M, Rosenblat M, Hollenberg PF. 
The licorice root derived isoflavan glabridin inhibits 
the activities of human cytochrome P450S 3A4, 2B6, 


















 Licorice inhibits CYP2C9 and 
3A4 in-vitro, but induces these 
same isozymes in animals. 
Plasma levels of ACDs that 
are CYP2C9 and 3A4 
substrates may be altered due 
to inhibition or induction of 
these isozymes by licorice. 
 
Caution is advised during 
concurrent use of licorice with 
drugs which are CYP2C9 and 
3A4 substrates. Plasma levels 
and clinical efficacy of ACDs 
should be closely monitored in 
patients co-administered with 
these agents.  
 
The manufacturer 
recommends that a dose 
reduction to 12.5 mg/week or 
a dose increase to 50 mg/week 
be considered if temsirolimus 
is co-administered with strong 
CYP3A4 inhibitors or 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Kent UM, Aviram M, Rosenblat M, Hollenberg PF. 
The licorice root derived isoflavan glabridin inhibits 
the activities of human cytochrome P450S 3A4, 2B6, 
and 2C9. Drug Metab Dispos. 2002;30(6):709-715. 
 Mu Y, Zhang J, Zhang S, et al. Traditional Chinese 
medicines Wu Wei Zi (Schisandra chinensis Baill) 
and Gan Cao (Glycyrrhiza uralensis Fisch) activate 
pregnane X receptor and increase warfarin clearance 
in rats. J Pharmacol Exp Ther. 2006;316(3):1369-
1377. 
 Paolini M, Barillari J, Broccoli M, Pozzetti L, 
Perocco P, Cantelli-Forti G. Effect of liquorice and 









































inducers respectively. The 
temsirolimus dose should be 
adjusted back upon 
discontinuation of the 
inhibitor or inducer, and a 
washout period of 
approximately 1 week should 
be allowed if a strong inhibitor 
is discontinued. 
 
enzymes. Cancer Lett. 1999;145(1-2):35-42. 
 Paolini M, Pozzetti L, Sapone A, Cantelli-Forti G. 
Effect of licorice and glycyrrhizin on murine liver 
CYP-dependent monooxygenases. Life Sci. 
1998;62(6):571-582. 
 Shon JH, Park JY, Kim KA, Cha IJ, Chun BH, Shin 
JG. Effect of licorice (radix glycyrrhizae) on the 
pharmacokinetics (PK) and pharmacodynamics (PD) 







Increased risk of hypertensive 
crisis (increased blood 
pressure, confusion and 
restlessness) due to the high 
caffeine content in maté. 
 
Concurrent use of 
procarbazine and maté is not 
recommended. 
 
 American Society of Health-System Pharmacists. 
AHFS Drug Information. 2007 ed. Bethesda, MD: 










Plasma levels of ACDs that 
are substrates of CYP2C9 and 
3A4 may be increased due to 
inhibition of these isozymes 
by milk thistle. 
Caution is advised during 
concurrent use of milk thistle 
with drugs that are CYP2C9 
and 3A4 substrates. Plasma 
levels of ACDs should be 
 Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo 
assessment of botanical supplementation on human 
cytochrome P450 phenotypes: Citrus aurantium, 
Echinacea purpurea, milk thistle, and saw palmetto. 




















































 closely monitored in patients 




recommends that a dose 
reduction to 12.5 mg/week be 
considered if temsirolimus is 
co-administered with strong 
CYP3A4 inhibitors, and a 
washout period of 
approximately 1 week be 
allowed before the 
temsirolimus dose be adjusted 
back upon discontinuation of 
the inhibitor. 
 
 Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, 
et al. Inhibitory effects of silibinin on cytochrome P-
























































Plasma levels of ACDs that 
are substrates of CYP1A2, 
2C9, 2C19 and 3A4 may be 
increased due to inhibition of 
these isozymes by peppermint. 
 
Caution is advised during 
concurrent use of peppermint 
with drugs which are 
CYP1A2, 2C9, 2C19 and 3A4 
substrates. Plasma levels of 
ACDs should be closely 
monitored in patients co-




recommends that a dose 
reduction to 12.5 mg/week be 
considered if temsirolimus is 
co-administered with strong 
CYP3A4 inhibitors, and a 
washout period of 
approximately 1 week be 
allowed before the 
temsirolimus dose be adjusted 
back upon discontinuation of 
the inhibitor. 
 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Unger M, Frank A. Simultaneous determination of 
the inhibitory potency of herbal extracts on the 
activity of six major cytochrome P450 enzymes 
using liquid chromatography/mass spectrometry and 
automated online extraction. Rapid Commun Mass 
Spectrom. 2004;18(19):2273-2281. 
 Dresser GK, Wacher V, Wong S, Wong HT, Bailey 
DG. Evaluation of peppermint oil and ascorbyl 
palmitate as inhibitors of cytochrome P4503A4 


























Fermented soy products 
contain tyramine which is 
involved in blood pressure 
regulation. Monoamine 
oxidase inhibitors decrease the 
breakdown of tyramine. Thus, 
an increased risk of 
hypertensive crisis exists, due 
to increased levels of 
tyramine. The risk of 
hypertensive crisis increases if 
more than 6 mg of tyramine is 
co-administered with 
monoamine oxidase inhibitors. 
 
Concomitant administration of 
procarbazine and soy products 
(e.g. soybean, soy sauce, tofu) 
is not recommended. Patients 
on drugs with monoamine 
oxidase inhibition activity 
(e.g. procarbazine) should be 
advised to avoid soy products 
and products which contain 
high amounts of tyramine. 
 
 Shulman KI, Walker SE. Refining the MAOI diet: 





 The therapeutic effects of 
tamoxifen may be altered 
during concomitant 
administration with soy 
products. In-vitro studies have 
demonstrated that low 
concentrations of soy 
isoflavones (e.g. genistein) 
may antagonise the 
therapeutic effects of 
tamoxifen, but high 
concentrations may enhance 
the effects of tamoxifen and 
inhibit tumour growth. 
 
Caution is advised. Patients on 
tamoxifen should be advised 
regarding the risks of potential 
tumour growth and to avoid 
soy products. 
 
 de Lemos ML. Effects of soy phytoestrogens 
genistein and daidzein on breast cancer growth. Ann 
Pharmacother. 2001;35(9):1118-1121. 
 Jones JL, Daley BJ, Enderson BL, Zhou J-R, 
Karlstad MD. Genistein inhibits tamoxifen effects on 
cell proliferation and cell cycle arrest in T47D breast 
cancer cells. Am Surg. 2002;68(6):575-577. 
 Ju YH, Doerge DR, Allred KF, Allred CD, Helferich 
WG. Dietary genistein negates the inhibitory effect 
of tamoxifen on growth of estrogen-dependent 
human breast cancer (MCF-7) cells implanted in 




St. John’s wort 
 
Increased risk of serotonin 
syndrome and associated 
Concurrent use of 
procarbazine and St. John’s 
 Müller WE, Singer A, Wonnemann M, Hafner U, 












adverse effects (e.g. 
hypertension, hyperthermia, 
agitation, confusion, coma), 
possibly due to monoamine 
oxidase inhibitory effects on 
serotonin metabolism. 
Mechanism of inhibition is 
postulated to be associated 
with elevated intracellular 
sodium ions. 
 
wort is not recommended. At 
least 14 days should elapse 
between use of monoamine 
oxidase inhibitors and St. 
John’s wort, and a 7 to 14 day 
washout period is 
recommended when switching 
to a monoamine oxidase 
inhibitor. 
 
neurotransmitter reuptake inhibiting constituent of 
hypericum extract. Pharmacopsychiatry. 
1998;31(Suppl 1):16-21. 
 Singer A, Wonnemann M, Müller WE. Hyperforin, a 
major antidepressant constituent of St. John's Wort, 
inhibits serotonin uptake by elevating free 










 Plasma levels of the tyrosine 
kinase inhibitors may be 
decreased due to induction of 
CYP3A4 by St. John’s wort. 
 
Caution is advised. Alternative 
herbs without CYP3A4-
inducing activity should be 
considered. However, if 
concurrent use cannot be 
avoided, pharmacologic 
responses to ACDs should be 
monitored. Increases in doses 
of ACDs may be required to 
maintain clinical efficacy 
during concomitant use with 
St. John’s wort. Manufacturer 
information recommends the 
following:  
(a) Erlotinib dose should be 
increased as tolerated at 2-
week intervals to a maximum 
of 450 mg, and the dose 
reduced upon inducer 
discontinuation. 
(b) Gefitinib dosage may be 
increased to 500 mg/day in the 
absence of severe adverse 
reactions, and decreased 
accordingly when the inducer 
is discontinued. 
(c) Lapatinib dose should be 
titrated gradually from 1250 
mg/day to 4500 mg/day 
 Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, 
Egorin MJ. Effect of St John's Wort on imatinib 
mesylate pharmacokinetics. Clin Pharmacol Ther. 
2004;76(4):323-329. 
 OSI Pharmaceuticals Inc., Genentech Inc. Tarceva 
(erlotinib) tablets [product information]. Melville, 
NY and South San Francisco, CA; 2004. 
 AstraZeneca Pharmaceuticals LP. Iressa (gefitinib) 
tablets [product information]. Wilmington, DE; 
2005. 
 GlaxoSmithKline. Tykerb (lapatinib) tablets [product 













depending on patient 
tolerability, and the dose be 
reduced upon inducer 
discontinuation. 
Data on dose adjustments of 
other tyrosine kinase 





 Plasma levels of the active 
metabolite of irinotecan (SN-
38) may be decreased due to 
CYP3A4 induction by St. 
John’s wort. 
 
Caution is advised. Patients on 
irinotecan should refrain from 
taking St. John’s wort 
concurrently. Plasma levels of 
irinotecan should be closely 
monitored if co-administration 
is unavoidable. Increased 
doses may be required to 
achieve therapeutic efficacy. 
 
 Mathijssen RHJ, Verweij J, Bruijn Pd, Loos WJ, 
Sparreboom A. Effects of St. John's wort on 





 Plasma levels of ixabepilone 
may be decreased due to 
induction of CYP3A4 by St. 
John’s wort. 
 
Concurrent administration of 
ixabepilone and St. John’s 
wort should be avoided. 
Alternative herbs with low 
enzyme induction potential 
should be considered. 
 
 Bristol-Myers Squibb. Ixempra (ixabepilone) kit for 





 Plasma levels of 
medroxyprogesterone and 
megestrol may be decreased 
due to induction of CYP3A4 
by St. John’s wort. 
 
Caution is advised. Patients 
should be closely monitored 
for pharmacological response 
to medroxyprogesterone and 
megestrol, and the doses 
adjusted as necessary. Patients 
should also be monitored 
closely for inadequate control 
of symptoms associated with 
oestrogen deficiency (e.g. 
nocturnal sweating, vasomotor 
disturbances, atrophic 
vaginitis) or changes in their 
uterine bleeding profile, and 
 Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S. 
Influence of aminoglutethimide on the metabolism of 
medroxyprogesterone acetate and megestrol acetate 
in postmenopausal patients with advanced breast 
cancer. Cancer Chemother Pharmacol. 
1990;27(2):101-105. 
 Kobayashi K, Mimura N, Fujii H, et al. Role of 
human cytochrome P450 3A4 in metabolism of 
medroxyprogesterone acetate. Clin Cancer Res. 
2000;6(8):3297-3303. 
 Halpenny O, Bye A, Cranny A, Feely J, Daly PA. 
Influence of aminoglutethimide on plasma levels of 













the dosages of megestrol be 
adjusted as necessary. 
 
 Faculty of Family Planning and Reproductive Health 
Care Clinical Effectiveness Unit. FFPRHC Guidance 
(April 2005). Drug interactions with hormonal 
contraception. J Fam Plann Reprod Health Care. 
2005;31(2):139-151. 
 Pfrunder A, Schiesser M, Gerber S, Haschke M, 
Bitzer J, Drewe J. Interaction of St John's wort with 
low-dose oral contraceptive therapy: a randomized 
controlled trial. Br J Clin Pharmacol. 
2003;56(6):683-690. 
 Schwarz UI, Buschel B, Kirch W. Unwanted 
pregnancy on self-medication with St John's wort 
despite hormonal contraception. Br J Clin 
Pharmacol. 2003;55(1):112-113. 
 Wilbur K, Ensom MH. Pharmacokinetic drug 
interactions between oral contraceptives and second-
generation anticonvulsants. Clin Pharmacokinet. 
2000;38(4):355-365. 
 Hall SD, Wang Z, Huang SM, et al. The interaction 
between St John's wort and an oral contraceptive. 




















 Plasma levels of CYP3A4 
substrates may be decreased 
due to induction of CYP3A4 
by St. John’s wort. 
 
Caution is advised. Patients on 
drugs which are CYP3A4 
substrates should refrain from 
taking St. John’s wort 
concurrently. Plasma levels of 
ACDs should be closely 
monitored if co-administration 
is unavoidable. Increased 
doses may be required to 
achieve therapeutic efficacy.  
 
The manufacturer 
recommends that a dose 
increase from 25 mg/week up 
to 50 mg/week be considered 
if temsirolimus is co-
administered with strong 
CYP3A4 inducers, and the 
 Mathijssen RHJ, Verweij J, Bruijn Pd, Loos WJ, 
Sparreboom A. Effects of St. John's wort on 
irinotecan metabolism. J Natl Cancer Inst. 
2002;94(16):1247-1249. 
 Roby CA, Anderson GD, Kantor E, Dryer DA, 
Burstein AH. St John's Wort: effect on CYP3A4 
activity. Clin Pharmacol Ther. 2000;67(5):451-457. 
 Chang SM, Kuhn JG, Rizzo J, et al. Phase I study of 
paclitaxel in patients with recurrent malignant 
glioma: a North American Brain Tumor Consortium 
report. J Clin Oncol. 1998;16(6):2188-2194. 
 Zamboni WC, Gajjar AJ, Heideman RL, et al. 
Phenytoin alters the disposition of topotecan and N-
desmethyl topotecan in a patient with 
medulloblastoma. Clin Cancer Res. 1998;4(3):783-
789. 
 Friedman HS, Petros WP, Friedman AH, et al. 



























dose be adjusted back upon 
discontinuation of the inducer. 
 








 Plasma levels of CYP2C9 
substrates may be decreased 
due to induction of CYP2C9 
by St. John’s wort. 
 
Caution is advised during 
concurrent use of St. John’s 
wort with drugs which are 
CY2C9 substrates. Plasma 
levels and clinical efficacy of 
ACDs should be closely 
monitored in patients co-
administered with these 
agents. Increased doses may 
be required to achieve 
therapeutic efficacy. 
 
 Xu H, Williams KM, Liauw WS, Murray M, Day 
RO, McLachlan AJ. Effects of St John's wort and 
CYP2C9 genotype on the pharmacokinetics and 














Hormone agonists / 
antagonists 
 Pharmacological effects of 
ACDs that are substrates of p-
glycoprotein may be 
decreased due to induction of 
p-glycoprotein. 
 
Caution is advised. 
Pharmacological effects of 
ACDs should be monitored in 
patients concurrently on these 
agents.  
 
In addition, regular monitoring 
of prostate specific antigen is 
recommended by the 
manufacturer of bicalutamide 
as part of the patients’ clinical 
response. If prostate specific 
antigen levels rise, patients 
 Meijerman I, Beijnen JH, Schellens JHM. Herb-drug 
interactions in oncology: focus on mechanisms of 
induction. Oncologist. 2006;11(7):742-752. 
 Kuang YH, Shen T, Chen X, et al. Lapatinib and 
erlotinib are potent reversal agents for MRP7 
(ABCC10)-mediated multidrug resistance. Biochem 
Pharmacol. 2010;79(2):154-161. 
 Azzariti A, Porcelli L, Simone GM, et al. Tyrosine 
kinase inhibitors and multidrug resistance proteins: 
interactions and biological consequences. Cancer 
Chemother Pharmacol. 2010;65(2):335-346. 
 Colabufo NA, Pagliarulo V, Berardi F, et al. 
































should be monitored for 
clinical progression. A 
treatment-free period of anti-
androgen while continuing 
bicalutamide may be 
considered in patients who 
have objective progression of 
disease together with elevated 
prostate specific antigen 
levels. 
 
involvement of Multi Drug Resistance proteins. Eur 
J Pharmacol. 2008;601(1-3):38-42. 
 AstraZeneca Pharmaceuticals LP. Casodex 
(bicalutamide) tablets [product information]. 
Wilmington, DE; 2003. 
 Schwarz UI, Hanso H, Oertel R, et al. Induction of 
intestinal P-glycoprotein by St John's wort reduces 
the oral bioavailability of talinolol. Clin Pharmacol 
Ther. 2007;81(5):669-678. 
 Dürr D, Stieger B, Kullak-Ublick GA, et al. St John's 
Wort induces intestinal P-glycoprotein/MDR1 and 





 Increased risk of central 
nervous system-related 
adverse effects, particularly in 
elderly or debilitated patients. 
 
Caution is advised during 
concurrent use of St. John’s 
wort and thalidomide. Patients 
should be closely monitored 
for signs and symptoms of 
neuropathy, paraesthesias, and 
other central nervous system-
related adverse effects when 
co-administered with these 
agents. 
 
 Bove GM. Acute neuropathy after exposure to sun in 
a patient treated with St John's Wort. Lancet. 
1998;352(9134):1121-1122. 
 Ernst E, Rand JI, Barnes J, Stevinson C. Adverse 
effects profile of the herbal antidepressant St. John's 
wort (Hypericum perforatum L.). Eur J Clin 
Pharmacol. 1998;54(8):589-594. 
 Celgene Corporation. Thalomid (thalidomide) 







 Increased risks of skin 
reactions, including 
photosensitivity and sunburn. 
 
Caution is advised. Patients on 
retinoids and photosensitising 
agents should avoid 
concomitant administration of 
St. John’s wort. Patients 
should also be advised to keep 
out of the sun, wear protective 
clothing outdoors and use a 
sunscreen if co-administration 
 Holme SA, Roberts DL. Erythroderma associated 
with St John's wort. Br J Dermatol. 
2000;143(5):1127-1128. 
 Golsch S, Vocks E, Rakoski J, Brockow K, Ring J. 
Reversible increase in photosensitivity to UV-B 
caused by St. John's wort extract. Hautarzt. 
1997;48(4):249-252 (abstract). 
 Lane-Brown MM. Photosensitivity associated with 












of these agents is unavoidable. 
 
perforatum). Med J Aust. 2000;172(6):302. 
 Gulick RM, McAuliffe V, Holden-Wiltse J, et al. 
Phase I studies of hypericin, the active compound in 
St. John's Wort, as an antiretroviral agent in HIV-
infected adults. AIDS Clinical Trials Group 
Protocols 150 and 258. Ann Intern Med. 
1999;130(6):510-514. 
 Jacobson JM, Feinman L, Liebes L, et al. 
Pharmacokinetics, safety, and antiviral effects of 
hypericin, a derivative of St. John's wort plant, in 
patients with chronic hepatitis C virus infection. 
Antimicrob Agents Chemother. 2001;45(2):517-524. 
 Brockmöller J, Reum T, Bauer S, Kerb R, Hubner 
WD, Roots I. Hypericin and pseudohypericin: 
pharmacokinetics and effects on photosensitivity in 
humans. Pharmacopsychiatry. 1997;30(Suppl 2):94-
101. 
 Schempp CM. Single-dose and steady-state 
administration of Hypericum perforatum extract (St 
John's wort) does not influence skin sensitivity to 
UV radiation, visible light, and solar-simulated 
radiation. Arch Dermatol. 2001;137(4):512-513. 
 Schempp CM, Pelz K, Wittmer A, Schopf E, Simon 
JC. Antibacterial activity of hyperforin from St 
John's wort, against multiresistant Staphylococcus 
aureus and gram-positive bacteria. Lancet. 
1999;353(9170):2129. 
 Bernd A, Simon S, Ramirez Bosca A, et al. 
Phototoxic effects of Hypericum extract in cultures 
of human keratinocytes compared with those of 
psoralen. Photochem Photobiol. 1999;69(2):218-221. 
 Biolitec Pharma Ltd. Foscan (temoporfin) 4mg/ml 
solution for injection [product information]. Dublin, 
Ireland; 2005. 
 Axcan Scandipharm Inc. Photofrin (porfimer 
sodium) injection powder for solution [product 
information]. Birmingham, AL; 2005. 
 Ligand Pharmaceuticals Inc. Panretin (alitretinoin) 













 Roche Laboratories Inc. Vesanoid (tretinoin) 10mg 






 Increased risk of bleeding due 
to additive haematological 
effects. 
 
Concurrent use of St. John’s 
wort and these ACDS is not 
recommended. Patients should 
be monitored closely for signs 
and symptoms of bleeding, as 
well as haematological 
complications if concomitant 
administration cannot be 
avoided. 
 
 Shalansky S, Lynd L, Richardson K, Ingaszewski A, 
Kerr C. Risk of warfarin-related bleeding events and 
supratherapeutic international normalized ratios 
associated with complementary and alternative 
medicine: a longitudinal analysis. Pharmacotherapy. 
2007;27(9):1237-1247. 
 Heck AM, DeWitt BA, Lukes AL. Potential 
interactions between alternative therapies and 































Plasma level of CYP3A4 
substrates may be increased 
due to inhibition of CYP3A4 
by valerian. 
 
Caution is advised during 
concurrent use of valerian 
with drugs that are CYP3A4 
substrates. Plasma levels of 
ACDs should be closely 
monitored in patients co-




recommends that a dose 
reduction to 12.5 mg/week be 
considered if temsirolimus is 
co-administered with strong 
CYP3A4 inhibitors, and a 
washout period of 
approximately 1 week be 
allowed before the 
temsirolimus dose be adjusted 
back upon discontinuation of 
the inhibitor. 
 
 Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) 
injection kit [product information]. Philadelphia, PA; 
2008. 
 Lefebvre T, Foster BC, Drouin CE, Krantis A, 
Livesey JF, Jordan SA. In vitro activity of 
commercial valerian root extracts against human 
cytochrome P450 3A4. J Pharm Pharm Sci. 
2004;7(2):265-273. 
 Donovan JL, DeVane CL, Chavin KD, et al. 
Multiple night-time doses of valerian (Valeriana 
officinalis) had minimal effects on CYP3A4 activity 
and no effect on CYP2D6 activity in healthy 






































Willow bark has antiplatelet 
effects in-vivo and is 
associated with an increased 
risk of self-reported bleeding. 
Therefore, an increased risk of 
bleeding, due to additive 
haematological effects exists. 
 
Concurrent use of willow bark 
and these ACDS is not 
recommended. Patients should 
be monitored closely for signs 
and symptoms of bleeding, as 
well as haematological 
complications if concomitant 
administration cannot be 
avoided. 
 
 Shalansky S, Lynd L, Richardson K, Ingaszewski A, 
Kerr C. Risk of warfarin-related bleeding events and 
supratherapeutic international normalized ratios 
associated with complementary and alternative 
medicine: a longitudinal analysis. Pharmacotherapy. 
2007;27(9):1237-1247. 
 Heck AM, DeWitt BA, Lukes AL. Potential 
interactions between alternative therapies and 
warfarin. Am J Health Syst Pharm. 
2000;57(13):1221-1227. 
 Krivoy N, Pavlotzky E, Chrubasik S, Eisenberg E, 
Brook G. Effect of salicis cortex extract on human 
platelet aggregation. Planta Med. 2001;67(3):209-
212. 
 Clauson KA, Santamarina ML, Buettner CM, 
Cauffield JS. Evaluation of presence of aspirin-
related warnings with willow bark. Ann 
Pharmacother. 2005;39(7-8):1234-1237. 
 
AED: antiepileptic drug, CAM: complementary and alternative medicine, CYP: cytochrome P450, SSRI: selective serotonin reuptake inhibitor, TCA: tricyclic 
antidepressant, TNF: tumour necrosis factor, UGT: uridine glucuronyl transferase 
 
